<SEC-DOCUMENT>0001731122-24-000760.txt : 20240509
<SEC-HEADER>0001731122-24-000760.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509163555
ACCESSION NUMBER:		0001731122-24-000760
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				980608404
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		24931371

	BUSINESS ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111
		BUSINESS PHONE:		844-689-3939

	MAIL ADDRESS:	
		STREET 1:		630 5TH AVENUE
		STREET 2:		20TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e5644_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:avxl="http://anavex.com/20240331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2023%2D(with%2DECD)_currency_rempres -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_avxl_anavex.com_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20231001_20240331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000007" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-03-31" id="xdx2ixbrl0077" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-09-30" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0246" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2023-10-01to2024-03-31" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:CommitmentSharesValue" contextRef="From2022-10-012023-03-31" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="avxl-20240331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-10-01to2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ShareProceedsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_MichaelJFoxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_AnavexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-02</xbrli:startDate>
        <xbrli:endDate>2023-02-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-03_custom_ThirdPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">avxl:ThirdPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20231001__20240331_zeSyFOdetpA2"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000013" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_90D_edei--DocumentQuarterlyReport_c20231001__20240331_zDHvK9pl4nx7"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></b></span><b>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_906_edei--DocumentPeriodEndDate_c20231001__20240331_zNJkWIzoxF9a"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate">March 31, 2024</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_908_edei--DocumentTransitionReport_c20231001__20240331_zjJjAT1MgHPb"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span><b>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from _____to _____</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <span style="text-decoration: underline"><span id="xdx_904_edei--EntityFileNumber_c20231001__20240331_zaSwDz1sV359"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000017" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityRegistrantName_c20231001__20240331_z5YGlj2V673j"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000018" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20231001__20240331_zOhXW6FdVHbl"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20231001__20240331_zdZOlPBosLo3"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000020" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityAddressAddressLine1_c20231001__20240331_z7woCXiFK557"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000021" name="dei:EntityAddressAddressLine1">630 5th Avenue</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20231001__20240331_z8jsHSR90cmj"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000022" name="dei:EntityAddressAddressLine2">20th Floor</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20231001__20240331_zwCGC6Qpjici"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000023" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20231001__20240331_zQUJapFzFzkb"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000024" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressCountry_c20231001__20240331_z30lkXrgdjBc"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000025" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A
<span id="xdx_90A_edei--EntityAddressPostalZipCode_c20231001__20240331_zrEyrTnwuqwb"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">10111</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;(Address of principal executive offices) (Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">1-<span id="xdx_902_edei--CityAreaCode_c20231001__20240331_zFA5XuQSnAn5"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000027" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90C_edei--LocalPhoneNumber_c20231001__20240331_zxAiUeZOvUd3"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000028" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b>(Registrant&#8217;s telephone number,
including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities Registered Pursuant to Section&#160;12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Title of Each Class</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Trading Symbol</span></td>
    <td style="vertical-align: top; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Name of Each Exchange on Which Registered</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20231001__20240331_zT2KqZPq7Xfd"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000029" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 32%; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20231001__20240331_z6M2wi8WBzfa"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000030" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 34%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20231001__20240331_zPdhCp6djCi4"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>&#160;<b><span id="xdx_900_edei--EntityCurrentReportingStatus_c20231001__20240331_zhjDsUP6T6Fd"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
No</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of
this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
<b><span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20231001__20240331_z9hqz77zPe1g"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span> No</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 26%; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20231001__20240331_zttLmFAuoZyh"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</span></td>
    <td style="width: 44%; text-align: justify">&#160;</td>
    <td style="width: 26%; text-align: justify"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="width: 2%; text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Non-accelerated filer</span></td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_906_edei--EntitySmallBusiness_c20231001__20240331_zHkFvVQLvQW1"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Emerging growth company</span></td>
    <td style="text-align: justify"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20231001__20240331_zYoPpMlaDDoa"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.</p>

<p style="font: 10pt Segoe UI Symbol,sans-serif; margin: 0; text-align: right"><b>&#9744;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is
a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90F_edei--EntityShellCompany_dbF_c20231001__20240331_zj4ZVgOzW8Pa" title="Entity Shell Company"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span> No</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate the number of shares outstanding of each
of the issuer&#8217;s classes of Common Stock, as of the latest practicable date: <span id="xdx_908_edei--EntityCommonStockSharesOutstanding_iI_c20240509_zYId6mxTCZd"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-05-09" id="Fact000039" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,641,537</ix:nonFraction></span> shares of Common Stock outstanding as of
May 9, 2024. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="width: 90%; text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_001"><b>PART I &#8211; FINANCIAL INFORMATION</b></a></td>
    <td style="width: 10%; text-align: right; padding-top: 0cm; padding-bottom: 0pt">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_002"><b>ITEM 1. FINANCIAL STATEMENTS</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_003"><b>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_004"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_005"><b>ITEM 4. CONTROLS AND PROCEDURES</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">37</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_006"><b>PART II &#8211; OTHER INFORMATION</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_007"><b>ITEM 1. LEGAL PROCEEDINGS</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_008"><b>ITEM 1A. RISK FACTORS</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_009"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_010"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_011"><b>ITEM 4. MINE SAFETY DISCLOSURES</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_012"><b>ITEM 5. OTHER INFORMATION</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">38</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; text-indent: -36pt; padding-top: 0cm; padding-bottom: 0pt; padding-left: 72pt"><a href="#a_013"><b>ITEM 6. EXHIBITS</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">39</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="text-align: left; padding-top: 0cm; padding-bottom: 0pt; padding-left: 0cm"><a href="#a_014"><b>SIGNATURES</b></a></td>
    <td style="text-align: right; padding-top: 0cm; padding-bottom: 0pt">40</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Anavex Life Sciences Corp.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Condensed Consolidated Interim Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 31, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp. <br/>
Condensed Consolidated Interim Balance Sheets <br/>
(in thousands, except share and per share amounts)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_pn3n3_zElUK4e8tXud" summary="xdx: Statement - Condensed Consolidated Interim Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20240331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230930" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">(Unaudited)</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zhovbcCFB62c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zXCHM3nDeLV8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzQ5P_zB1YRqOWrqv5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">Cash and cash equivalents</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-03-31" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139,386</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" id="Fact000048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxesReceivable_i02I_maCzQ5P_zTwneQHsIdMk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2024-03-31" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,785</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2023-09-30" id="Fact000051" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,709</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzQ5P_zWpyvw6O4Ox8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and other current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,345</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">653</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_mtCzQ5P_zic6Y2YMALf5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-03-31" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144,516</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" id="Fact000057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zfbTskRuytB2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Liabilities and Stockholders' Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zTq7bPhJw1m" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_i02I_maCzHEu_z7QYHJWFe7x5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-03-31" id="Fact000065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,726</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" id="Fact000066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,322</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzHEu_zMDLj1xE2Kag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities - Note 4</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact000069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeCurrent_i02I_maCzHEu_zFMzXR7gtqDj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income - Note 3</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2024-03-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">917</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2023-09-30" id="Fact000072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">917</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i02TI_mtCzHEu_maCzZnJ_z4eCU9NLsL01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-03-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,558</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,534</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_maCzZnJ_z79Ij1Sq3qvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Commitments and Contingencies - Note 6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0077">&#8212;</span></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0078">&#8212;</span></b></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Capital stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Authorized:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20240331_zZ9E8jWKnpX" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20230930_zrkF0vNys2L9" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000080" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" id="Fact000082" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20240331_zOqQu09rUzVh" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20230930_zEYehVStG0oh" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000084" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" id="Fact000086" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--PreferredStockValue_iI_pn3n3_d0_maCzhdp_c20240331_zi3Um2rym27e" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="text-align: right"><b style="display: none"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-03-31" id="Fact000088" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PreferredStockValue_iI_pn3n3_d0_maCzhdp_c20230930_zQMqxFOrsnfg" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="text-align: right"><b style="display: none"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30" id="Fact000090" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></b></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240331_zxCajdRbOWqb" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20230930_zH9Ft5amD2X1" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000092" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" id="Fact000094" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20240331_z2N9EI2TESAa" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20230930_zVPmAfwquct3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000096" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" id="Fact000098" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Issued and outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; text-indent: -10pt"><span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pip0_c20240331_zdWp3gXPKOff" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20240331_zhsUBYxbGjwj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact000100" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact000102" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,616,218</ix:nonFraction></ix:nonFraction></span></span> common shares (September 30, 2023 - <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pip0_c20230930_z69oi8QwxKg3" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20230930_zf4twPmiXrZb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" id="Fact000104" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" id="Fact000106" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,066,511</ix:nonFraction></ix:nonFraction></span></span>)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--CommonStockValue_iI_pn3n3_maCzhdp_c20240331_z2TicIbArVPe" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)" style="text-align: right"><b><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-03-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--CommonStockValue_iI_pn3n3_maCzhdp_c20230930_zuVsdcxdtN57" title="Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" id="Fact000110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_maCzhdp_z1ZmxXLDess1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-03-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-09-30" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434,839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ShareProceedsReceivable_iI_d0_maCzhdp_zxRX8WfGYbz1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share proceeds receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="avxl:ShareProceedsReceivable" contextRef="AsOf2024-03-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ShareProceedsReceivable" contextRef="AsOf2023-09-30" id="Fact000116" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_maCzhdp_z7sMiQHlohs9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accumulated deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">312,237</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293,069</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_iTI_mtCzhdp_maCzZnJ_zW1sFzm65GAh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Stockholders' Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134,958</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,852</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzZnJ_zPmSupf7tdp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Liabilities and Stockholders' Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144,516</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp. <br/>
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in
thousands, except share and per share amounts) <br/>
(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: lightgrey"><br/></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_pn3n3_z3IH0S5AxjS9" summary="xdx: Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20240101__20240331_z06xKMuj89T1" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230101__20230331_zC5bz0MPS9Gg" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_495_20231001_20240331" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20221001_20230331" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingExpensesAbstract_iB_zq338hc5KTI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz4xr_zs7QxkunFslk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-012024-03-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,790</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-03-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,883</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-01to2024-03-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,399</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-012023-03-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz4xr_zbwL6IK5CYIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-03-31" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,729</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-03-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,307</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-03-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,413</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-012023-03-31" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_mtCz4xr_msCzEJC_z2xKcJ6ytiOl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-01-012024-03-31" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,519</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-012023-03-31" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,190</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-10-01to2024-03-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,812</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-10-012023-03-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,573</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_i01T_mtCzEJC_maCzaw3_z6fGurcyhjB2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,519</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,190</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-01to2024-03-31" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">23,812</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-012023-03-31" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29,573</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z4Jg0PwCPANh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NonOperatingIncomeFromGrants_i01_d0_maCz4qC_zOoGAJc7wokc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2024-01-012024-03-31" id="Fact000157" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-01-012023-03-31" id="Fact000158" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2023-10-01to2024-03-31" id="Fact000159" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrants" contextRef="From2022-10-012023-03-31" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCz4qC_zzZET8n4ZKn" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2024-01-012024-03-31" id="Fact000162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">472</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-01-012023-03-31" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2023-10-01to2024-03-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,064</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2022-10-012023-03-31" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestIncomeExpenseNet_i01_maCz4qC_z5yhQWKNrDj2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-012024-03-31" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,756</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-03-31" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-10-01to2024-03-31" id="Fact000169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,764</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-10-012023-03-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,733</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherFinancingExpense_i01N_di0_msCz4qC_zUdaimJAJhPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other financing expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2024-01-012024-03-31" id="Fact000172" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2023-01-012023-03-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">964</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2023-10-01to2024-03-31" id="Fact000174" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:OtherFinancingExpense" contextRef="From2022-10-012023-03-31" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">964</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCz4qC_zgWtZBcWInTj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Foreign exchange gain (loss)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-012024-03-31" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">150</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-01-012023-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-10-01to2024-03-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2022-10-012023-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">247</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_mtCz4qC_maCzaw3_zwxkeXpXCra3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total other income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-012024-03-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,078</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-03-31" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,133</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-10-01to2024-03-31" id="Fact000184" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,835</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-10-012023-03-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,524</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzaw3_maCzayL_ztuRbo4go4w1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-012024-03-31" id="Fact000187" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,441</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-03-31" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,057</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-10-01to2024-03-31" id="Fact000189" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,977</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-10-012023-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26,049</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzayL_zbP3TSnU96j1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income tax expense, current</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-012024-03-31" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-10-01to2024-03-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">191</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-10-012023-03-31" id="Fact000195" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtCzayL_zztStJbs6Ef5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss and comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,546</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,107</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-03-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareAbstract_iB_zNksTugmoKuk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Net Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pip0_c20240101__20240331_zSIHOAcoAY51" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pip0_c20240101__20240331_z0GVMfjKHXFi" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-012024-03-31" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-012024-03-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pip0_c20230101__20230331_zzcbdKDMB0ti" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pip0_c20230101__20230331_zZ2BUNXvkvdc" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-03-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pip0_c20231001__20240331_zW985L9dXhL1" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20231001__20240331_zlrfUXqD1c8c" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-10-01to2024-03-31" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-01to2024-03-31" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.23</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20221001__20230331_zghKtnRfYYo3" title="Net Loss per share, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pip0_c20221001__20230331_zFMN1kv49Fy4" title="Net Loss per share, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-10-012023-03-31" id="Fact000219" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-012023-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">0.33</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zEWgy49mVEW5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Basic and diluted</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20240101__20240331_zIakU606gAxl" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20240101__20240331_zgtWbuVqupQe" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-012024-03-31" id="Fact000228" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-012024-03-31" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,464,226</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20230101__20230331_zQhYwLRq2Alg" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20230101__20230331_zI7hghWvwyf3" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-03-31" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-03-31" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">78,304,363</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20231001__20240331_zXANVPrxvvmk" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20231001__20240331_zax6VOtOdHmk" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-10-01to2024-03-31" id="Fact000236" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-01to2024-03-31" id="Fact000238" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,269,965</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pip0_c20221001__20230331_zoMPUyDHTjei" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pip0_c20221001__20230331_zLuFjQD1xHh1" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-10-012023-03-31" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-012023-03-31" id="Fact000242" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">78,138,940</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp. <br/>
Condensed Consolidated Interim Statements of Changes in Stockholders' Equity <br/>
For the three months ended March 31,
2024 and 2023 <br/>
(in thousands, except share and per share amounts) <br/>
(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_zjPdhgaHmOjc" summary="xdx: Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zOsFrquocd11" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zclcpyqwByJg" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--ShareProceedsReceivableMember_zMQjZhrwOOo7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zuKJI3T6clPk" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_zJVQLHKFyvYl" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional Paid-in</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Share proceeds</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquity_iS_z0Nl9ZG9QaEa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">Balance, January 1, 2024</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVNsSoURSyek" title="Beginning balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,086,511</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">437,184</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0246">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">301,691</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,575</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedUnder2023PurchaseAgreement_zUssRKlyH4M1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_zd1FBAWoRaId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJPCmM6eRTOh" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2024-01-012024-03-31" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,178</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommitmentSharesValue_zkQj72kZVqtc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--CommitmentSharesShares_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8GmSK9FHl87" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zXnJCZQijb1i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zb2u977Znded" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2024-01-012024-03-31" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zuJhXtpvK5Wl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000291" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,546</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,546</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20240101__20240331_eus-gaap--StockholdersEquity_iE_zPDLGFJnXZG" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; font-weight: bold; text-indent: -10pt">Balance, March 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"/><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pip0_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKyeyWHzxEba" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,616,218</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447,345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">312,237</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134,958</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_43D_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zx14EZqwnEWd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, January 1, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pip0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMMMYYWZ2jCl" title="Beginning balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">78,032,135</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">393,582</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">258,536</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000306" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135,124</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedUnder2023PurchaseAgreement_z3RG3T799CJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--InitialCommitmentShares_iP3custom--SharesIssuedUnder2023PurchaseAgreement_z1bc6f2qe4fg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Initial commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InitialCommitmentSharesShares_iP3custom--InitialCommitmentShares_pip0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHi46SPhV0Rh" title="Initial commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000322" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2023-01-012023-03-31" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_z1xdxLSAKKok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pip0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWq7oduK42g6" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,075,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-01-012023-03-31" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommitmentSharesValue_zbmv5BGM80B4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--CommitmentSharesShares_pip0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8OU2FgMyGK" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000338" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zAx2GqiWt454" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl4qnHifQVvc" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">44,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-01-012023-03-31" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zcgL3D2qoe3g" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zm0trGGS15G" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000357" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,107</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,107</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20230101__20230331_eus-gaap--StockholdersEquity_iE_z64ek0IyPPQ4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; font-weight: bold; text-indent: -10pt">Balance, March 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"/><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pip0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTjHQjJgcVvc" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">80,235,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">416,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">271,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp. <br/>
Condensed Consolidated Interim Statements of Changes in Stockholders' Equity <br/>
For the six months ended March 31,
2024 and 2023 <br/>
(in thousands, except share and per share amounts) <br/>
(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zzcD0iCnm9xi" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zJeoSVJ4OAM7" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--ShareProceedsReceivableMember_zKO5QqUzjcZh" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zBg9XSChz9F6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B6_zU1oB6RMjIzj" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Common Stock</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Additional Paid-in</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Share proceeds</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Accumulated</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Par Value</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Receivable</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_43E_c20231001__20240331_eus-gaap--StockholdersEquity_iS_zMTxrcqJzSib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">Balance, October 1, 2023</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFDXXJWSnSEf" title="Beginning balance, shares" style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000374" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">82,066,511</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434,839</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293,069</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141,852</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedUnder2023PurchaseAgreement_zOf4nD69YZg1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_zANBFlN7NfUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIhLiYSE8m1d" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000388" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000382" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2023-10-01to2024-03-31" id="Fact000386" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,178</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommitmentSharesValue_zb7arKA1wAIi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--CommitmentSharesShares_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7AtJkgLvkP5" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_zR7g145fr951" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziXTN6oZwD3a" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">46,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2023-10-01to2024-03-31" id="Fact000402" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zSwFTCA0nZ1l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000407" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-10-01to2024-03-31" id="Fact000410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zz9OXQwHPw7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-03-31" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20231001__20240331_eus-gaap--StockholdersEquity_iE_zmwTgheLSlK3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; font-weight: bold; text-indent: -10pt">Balance, March 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pip0_c20231001__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp0X7SbbPd83" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000424" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">83,616,218</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">447,345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember" id="Fact000420" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">234</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000421" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">312,237</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000422" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134,958</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_430_c20221001__20230331_eus-gaap--StockholdersEquity_iS_zH4MvehzZXf6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Balance, October 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pip0_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFj1grK9qNA9" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000432" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">77,942,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" id="Fact000426" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" id="Fact000429" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">245,564</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">142,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedUnder2023PurchaseAgreement_zzkUzBWNVrlf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued under 2023 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InitialCommitmentShares_znrbbS42V8v9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Initial commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--InitialCommitmentSharesShares_pip0_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgIukXt8FW4g" title="Initial commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentSharesShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="Fact000446" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:InitialCommitmentShares" contextRef="From2022-10-012023-03-31" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_zfRlFzPp9jB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pip0_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCyq7RLIeose" title="Purchase shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,075,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="From2022-10-012023-03-31" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CommitmentSharesValue_zVbyooODX9vg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--CommitmentSharesShares_pip0_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeKDFpvT0kvh" title="Commitment shares, shares" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="Fact000462" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,080</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_znOdFxhjJIZf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Shares issued pursuant to exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsShares_pip0_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzn9ZCnydwab" title="Shares issued pursuant to exercise of stock options, shares" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares" contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember" id="Fact000470" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">133,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextRef="From2022-10-012023-03-31" id="Fact000468" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z6J20e4EmLwk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-10-012023-03-31" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zTEa9WYFmBV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31" id="Fact000482" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20221001__20230331_eus-gaap--StockholdersEquity_iE_zr0RLtk24JId" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; font-weight: bold; text-indent: -10pt">Balance, March 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pip0_c20221001__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9k5Fag7CoP" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000490" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">80,235,398</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">416,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000487" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">271,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000488" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp. <br/>
Condensed Consolidated Interim Statements of Cash Flows <br/>
(in thousands, except share and per share amounts) <br/>
(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_pn3n3_zUB1qATxqqKa" summary="xdx: Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49C_20231001__20240331_zoZEtDec9GE5" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20221001__20230331_zNNYVZFmTGO6" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zJ3msJnmnSv3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows used in Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maNCPBUz0XS_z24XzNvGol27" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-03-31" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,168</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-10-012023-03-31" id="Fact000496" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">26,079</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zAXhNu04Z6Fa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Adjustments to reconcile net loss to net cash used in operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NoncashFinancingRelatedCharges_i01_d0_maNCPBUz0XS_zwbBCUcIfpQh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Non-cash financing related charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2023-10-01to2024-03-31" id="Fact000501" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NoncashFinancingRelatedCharges" contextRef="From2022-10-012023-03-31" id="Fact000502" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i01_maNCPBUz0XS_zdA9aSAx7Ttc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Share-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-03-31" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-03-31" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_z8DQmRH789ml" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Changes in working capital balances related to operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msNCPBUz0XS_zaO5zm040wdj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2023-10-01to2024-03-31" id="Fact000510" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,076</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2022-10-012023-03-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,545</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUz0XS_zRk6VWgtwF3l" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-01to2024-03-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">692</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-012023-03-31" id="Fact000514" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUz0XS_zs8OyPc2ZJT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-01to2024-03-31" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">596</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-012023-03-31" id="Fact000517" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maNCPBUz0XS_zgg5EU2EuTMd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Accrued liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-01to2024-03-31" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,380</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-012023-03-31" id="Fact000520" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">878</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInDeferredGrantIncome_i02_d0_maNCPBUz0XS_zJUtZL4GTC61" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Deferred grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2023-10-01to2024-03-31" id="Fact000522" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:IncreaseDecreaseInDeferredGrantIncome" contextRef="From2022-10-012023-03-31" id="Fact000523" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUz0XS_maCCERCzNnA_zOePhH49tdn7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash used in operating activities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-01to2024-03-31" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,974</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-012023-03-31" id="Fact000526" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,283</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zUDVpWP9dX58" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash Flows provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzsHE_z0Il5vlxnJIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-03-31" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,178</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-012023-03-31" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,153</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzsHE_ztRKONTNm1Y1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Proceeds from exercise of stock options</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-10-01to2024-03-31" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-10-012023-03-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUzsHE_maCCERCzNnA_zjh5MGIl18c3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-01to2024-03-31" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,336</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-012023-03-31" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzNnA_zA1Vju9SWxRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Increase (decrease) in cash and cash equivalents
    during the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-01to2024-03-31" id="Fact000540" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,638</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-012023-03-31" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,309</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zPNFnsqcVqu1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash and cash equivalents, beginning of period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151,024</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zxikp7e9Yfui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 2.5pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Cash and cash equivalents, end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">153,467</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zY0uBwFtSeJg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Supplemental Cash Flow Information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zsG1bNvZbNQ6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt">Cash paid for state and local minimum income taxes</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2023-10-01to2024-03-31" id="Fact000552" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextRef="From2022-10-012023-03-31" id="Fact000553" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Accompanying Notes to Condensed Consolidated Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anavex
Life Sciences Corp.</b> <br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000555" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zVquyOVOCMle" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 <span id="xdx_827_zKA3th0VVxZe">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000557" name="us-gaap:BasisOfAccounting"><p id="xdx_808_eus-gaap--BasisOfAccounting_zV3AqSQEUKT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 <span id="xdx_82F_zgsJzL5IulI5">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000559" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zknPsUIJItp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_866_zbqgpltKOaMa">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2023 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023 filed with the SEC on November 27, 2023.
The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the six months ended March 31,
2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000561" name="avxl:LliquidityPolicyTextBlock"><p id="xdx_845_ecustom--LliquidityPolicyTextBlock_zFI9bTi0SREa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zJ6zC46Uj13i">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23A_zXZfjaLccUY7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_234_zMEuCRCRNsTl" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_239_zcW5e6Kj9jdj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zdNxLJ5ICO81" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zUSfXcxVs0Ej" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zHzk8H8Vu6G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000567" name="us-gaap:UseOfEstimates"><p id="xdx_84B_eus-gaap--UseOfEstimates_zfYWLHu7rmYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_867_zGiShBljRHFi">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000569" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zM8b8w3vfKTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zWNRr0rCht8a">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000571" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGfnrupflT7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_86E_zmgNY1Eiqs2e">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23E_zT8p7rV9Nz91" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div id="xdx_23C_zTcldNxPPWX" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zzt1GMEcMCJd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zHlxJJuCmZga" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zloqnx8Y8ME2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zXNfOn7Ogm77" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024 and September 30, 2023, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000577" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_z9PrflCYqYf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_86A_zVkpoaKUryQa">Basic
and Diluted Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240331_zmV3jqXp2BU8" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-03-31" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,755,114</ix:nonFraction></span>
(March 31, 2023: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_zMzVmxJcFosj" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-012023-03-31" id="Fact000581" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,001,613</ix:nonFraction></span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000583" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3VLPMGUVod6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_861_zOOQVnB9Xcnf">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable
Segment Disclosures.&#8221; This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30,
2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000585" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_80F_ecustom--OtherIncomeDisclosureTextBlock_zvmiBt2Zlx2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3 <span id="xdx_821_z4Y8u21B1Jze">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of March 31, 2024, the
Company had received a $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn6n6_c20231001__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_zsmz6Bl0U3oi" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-03-31_custom_MichaelJFoxMember" id="Fact000587" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span>.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__dei--LegalEntityAxis__custom--AnavexMember_zRZcbkW30ybd" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-09-30_custom_AnavexMember" id="Fact000589" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year ended September 30, 2023 and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_zKF1xeSKuROa" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012021-09-30_custom_AnavexMember" id="Fact000591" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2024, the Company recognized $<span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20240101__20240331_zm0vCSbixRlb" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2024-01-012024-03-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90C_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230101__20230331_zilKPRJs5am2" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-01-012023-03-31" id="Fact000595" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively (2023: $<span id="xdx_903_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20231001__20240331_zj4ml7dPpc14" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2023-10-01to2024-03-31" id="Fact000597" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20230331_zNxL1TSSSlTf" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2022-10-012023-03-31" id="Fact000599" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>, respectively) of
this grant on its statements of operations as grant income. At March 31, 2024, an amount of $<span id="xdx_90F_ecustom--DeferredGrantIncome_iI_pn5n6_c20240331_zS9bCKblcLnd" title="Grant income, amount"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2024-03-31" id="Fact000601" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million (September 30, 2023: $<span id="xdx_900_ecustom--DeferredGrantIncome_iI_pn5n6_c20230930_zWmqrVziV2Fl" title="Grant income, amount"><ix:nonFraction name="avxl:DeferredGrantIncome" contextRef="AsOf2023-09-30" id="Fact000603" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million)
of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been recognized to other income.
The Company will recognize this income on its statement of operations as the relating expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<ix:exclude><p id="xdx_233_zBbMEZZ9Yha7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div id="xdx_239_znaRzGx0SYt1" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zkxf5GsZSNC7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zaK4jOopGCAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z0HiTpfTwIYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zFoByzilgH2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and six
months ended March 31, 2024 the Company recorded research and development incentive income of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331_zsebmwizv1O9" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-01-012024-03-31" id="Fact000609" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million (AUD <span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331__srt--CurrencyAxis__currency--AUD_zJZVATdDd8K8" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2024-01-012024-03-31_currency_AUD" id="Fact000611" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million) and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331_zjbVDKCe0PG7" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-01to2024-03-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span>
million (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331__srt--CurrencyAxis__currency--AUD_zEk8YwYeUUT6" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-10-012024-03-31_currency_AUD" id="Fact000615" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million), respectively (2023: $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20230101__20230331_zWbCpJDkCst7" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-01-012023-03-31" id="Fact000617" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million (AUD <span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20230101__20230331__srt--CurrencyAxis__currency--AUD_zDKAtpjC7tWg" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2023-01-012023-03-31_currency_AUD" id="Fact000619" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million) and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230331_zYeKdO54Nf54" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-03-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230331__srt--CurrencyAxis__currency--AUD_zfKLNjxF0Alk" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2022-10-012023-03-31_currency_AUD" id="Fact000623" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million), respectively) in respect
of the Australia R&amp;D credit for eligible research and development expenses incurred during the period. This amount is included within
Other income on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At March 31, 2024, Incentive
and tax receivables includes $<span id="xdx_900_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20240331_z0d5HKF0mQLj" title="Incentive and tax receivables"><ix:nonFraction name="avxl:IncentiveAndTaxReceivables" contextRef="AsOf2024-03-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million (AUD <span id="xdx_905_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20240331__srt--CurrencyAxis__currency--AUD_z0z1LyJnfe3c" title="Incentive and tax receivables"><ix:nonFraction name="avxl:IncentiveAndTaxReceivables" contextRef="AsOf2024-03-31_currency_AUD" id="Fact000627" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.6</ix:nonFraction></span> million) (September 30, 2023: $<span id="xdx_902_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20230930_zocYaQ40iKN9" title="Incentive and tax receivables"><ix:nonFraction name="avxl:IncentiveAndTaxReceivables" contextRef="AsOf2023-09-30" id="Fact000629" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million (AUD <span id="xdx_903_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20230930__srt--CurrencyAxis__currency--AUD_z7eQB3U7epX3" title="Incentive and tax receivables"><ix:nonFraction name="avxl:IncentiveAndTaxReceivables" contextRef="AsOf2023-09-30_currency_AUD" id="Fact000631" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.9</ix:nonFraction></span> million)) relating to Australia
R&amp;D credits earned during the year that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the Australian Tax Office
(ATO) has the right to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review
were to occur, the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s
assessments and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims
already received. Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO
could also assess penalties and interest on such adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2023 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000633" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z25cOZabHba5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4 <span id="xdx_82F_zNErAYmm0mE9">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000635" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zSGkyYREISz3" summary="xdx: Disclosure - Accrued liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_znUspmfuqmK8" style="display: none">Schedule of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240331_zH4vQ2fKHKya" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20230930_z5BB6nvxccth" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40B_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_zZZ4U4JI5Dq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2024-03-31" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,209</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="avxl:AccruedClinicalSiteAndPatientVisitsCosts" contextRef="AsOf2023-09-30" id="Fact000638" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,006</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_zwgKvz2P2Wn" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2024-03-31" id="Fact000640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-09-30" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,360</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_d0_zDUEVfdSER3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2024-03-31" id="Fact000643" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:FixedContractAccruals" contextRef="AsOf2023-09-30" id="Fact000644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--MilestoneBasedContractAccruals_iI_zvpBTkrgDnRl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2024-03-31" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:MilestoneBasedContractAccruals" contextRef="AsOf2023-09-30" id="Fact000647" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,267</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_z6cK2UgVFNlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000649" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,531</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact000650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,624</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_zv6wgtlCC3b5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2024-03-31" id="Fact000652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,915</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-09-30" id="Fact000653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,295</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000655" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5CX69JGah6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5 <span id="xdx_82A_zniqpAzbEhib">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board&#160;has the authority to
issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zR7D5DLhzWzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div id="xdx_23D_zDRDL6yQ5ZF7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_z1fdidym45d2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zlilDstHxTJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zfXOYQMgSQSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_235_zWucOOrEN6Ue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
(&#8220;Shares&#8221;) registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written
consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents
may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales Agents will act
as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and
federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_902_ecustom--PercentageOfGrossProceedsFromSales_pip0_dp_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zj0WvIOGuUH" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" id="Fact000661" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31, 2024 and 2023,
<span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pip0_do_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zf8fqSiXeIgh" title="Number of common stock sold"><span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pip0_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zJjHSi1hAHQc" title="Number of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember" id="Fact000663" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember" id="Fact000665" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares were sold pursuant to the Offering. At March 31, 2024, an amount of $<span id="xdx_90D_ecustom--SalesOfAgreementAmount_iI_pn5n6_c20240331_z5CDZKyLNVb3" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2024-03-31" id="Fact000667" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">142.4</ix:nonFraction></span> million (September 30, 2023: $<span id="xdx_90F_ecustom--SalesOfAgreementAmount_iI_pn5n6_c20230930_zzwlZekMwnB7" title="Sales of agreement amount"><ix:nonFraction name="avxl:SalesOfAgreementAmount" contextRef="AsOf2023-09-30" id="Fact000669" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">142.4</ix:nonFraction></span> million) was
registered pursuant to an effective registration statement. The Company currently is unable to sell shares of common stock under the Sales
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0
<span id="xdx_900_ecustom--ValueOfSharesObligatedToPurchase_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zm8Wb6FXHw0b" title="Obligated to purchase" style="display: none"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000,000</ix:nonFraction></span> million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsFctYHz57Oj" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_90C_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zRJ3av2M90ae" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgw04c5tAbig" title="Proceeds from Issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000677" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">150</ix:nonFraction></span>.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_90F_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230203_z9NL5K1Nnqbg" title="Fair value of the initial commitment"><ix:nonFraction name="avxl:FairValueOfInitialCommitment" contextRef="AsOf2023-02-03" id="Fact000679" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_901_ecustom--IncurredExpenses_iI_pn5n6_c20230203__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--ThirdPartyMember_zWlzfXwTrJGl" title="Incurred expenses"><ix:nonFraction name="avxl:IncurredExpenses" contextRef="AsOf2023-02-03_custom_ThirdPartyMember" id="Fact000681" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2024, the
Company issued to Lincoln Park an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zur39g0wxaI7" title="Share issued for aggregate, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" id="Fact000683" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,503,707</ix:nonFraction></span>
shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_pip0_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zZ4kEPrn6j2h" title="Shares issued under Sales Agreement, net of shares issue costs, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></span>
shares of common stock for an aggregate purchase price of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLpsrPXdc0n9" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000687" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.4</ix:nonFraction></span>
million and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8qptIcZR6A1" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000689" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,707</ix:nonFraction></span>
commitment shares. During the six months ended March 31, 2023, the Company issued to Lincoln Park an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_ztWKjRFDF5O" title="Share issued for aggregate, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" id="Fact000691" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,159,080</ix:nonFraction></span>
shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zeubRkKj97Jb" title="Shares issued under Sales Agreement, net of shares issue costs, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000693" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,075,000</ix:nonFraction></span>
shares of common stock for an aggregate purchase price of $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsT072V4HN1e" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000695" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">18.2</ix:nonFraction></span>
million, and <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zox0kdhE8In5" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000697" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,080</ix:nonFraction></span>
commitment shares and the <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBGq1od83j7j" title="Number of shares issued for initial commitment shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000699" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">75,000</ix:nonFraction></span>
initial commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024, an amount of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsfm5ireHVoc" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember" id="Fact000701" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">114.7</ix:nonFraction></span> million remained
available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zofGSRoHOAhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div id="xdx_231_z3vhiWoqhFP5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zvzBrikGdl08" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zDNxk5fFt7T2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_ztYsbFDpXdSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zMFgAp9ziL01" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000707" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMQ2X78MFb9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 6 <span id="xdx_826_zg5Tma7oaSq5">Commitments and Contingencies</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Leases
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i style="font-style: normal; font-weight: normal">The
Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease,
the Company is required to pay its proportionate share of operating costs. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i style="font-style: normal; font-weight: normal">During
the three and six months ended March 31, 2024 and 2023, operating lease costs were as follows (in thousands):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000709" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--LeaseCostTableTextBlock_pn3n3_zqOM4eN6D917" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B5_zaj01Oaq5Qt7" style="display: none">Schedule of operating lease costs</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20240101__20240331_zE1SniLqyBm" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_496_20230101__20230331_zhMPspwmi48j" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20231001__20240331_z0qJ2X64ggg8" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_498_20221001__20230331_zA16A6W3XB05" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_zhX6UbDxgG1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-03-31" id="Fact000711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-03-31" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-10-01to2024-03-31" id="Fact000713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-10-012023-03-31" id="Fact000714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: Black">During the three and six
months ended March 31, 2024 and 2023, the Company <i style="font-style: normal; font-weight: normal">made matching contributions under the 401(k) plan as follows (in thousands):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000716" name="us-gaap:DefinedContributionPlanDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zrHn2iRJnYo6" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B7_zgww5hPqb2C6" style="display: none">Schedule of contribution plan</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20240101__20240331_z5TNiEfCDPY" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20230101__20230331_zxrisPNYSTZd" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_496_20231001__20240331_zkhkfeeHy9s6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_494_20221001__20230331_zsyisF7uzy66" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_402_eus-gaap--PensionContributions_zBm7syOCfnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2024-01-012024-03-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-01-012023-03-31" id="Fact000719" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2023-10-01to2024-03-31" id="Fact000720" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:PensionContributions" contextRef="From2022-10-012023-03-31" id="Fact000721" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; color: gray"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="color: Black"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
The complaint is captioned Blum v. Anavex Life Sciences, Corp. et al., case number 1:24-cv-01910, and names the Company and Christopher
Missling as Defendants. The complaint alleges violations of the Securities and Exchange Act of 1934 resulting from disclosures and statements
made about certain clinical trials for ANAVEX<sup>&#174;</sup>2-73. The Company believes the complaint is without merit. The Company is
vigorously pursuing its defenses and a potential dismissal of all claims asserted in the lawsuit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="color: Black"><b><i>Share Purchase Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024 and September 30, 2023, the Company
had <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20240331_zmu0kXb8hTc" title="Warrants outstanding"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20230930_zjNWFQrDzou7" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-03-31" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-09-30" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">160,000</ix:nonFraction></ix:nonFraction></span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20240331_za276aAeuKc5" title="Warrants outstanding weighted average exercise"><span id="xdx_901_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20230930_zZA5R009xQBj" title="Warrants outstanding weighted average exercise"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2024-03-31" id="Fact000727" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="avxl:WarrantsOutstandingWeightedAverageExercise" contextRef="AsOf2023-09-30" id="Fact000729" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.72</ix:nonFraction></ix:nonFraction></span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_zuE1TmiJVPD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div id="xdx_232_zxZJVqZrkF52" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zfNocD4ifR74" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zKQkVcwZPcj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zCNHJ2zgUFp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z52HaPoPVKZk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000735" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvZm3K3TZexk" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zx3ZHkyRjUcf" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zWSYRfqFOdKh" title="Number of shares outstanding" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-03-31_custom_PurchaseWarrantsMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">150,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zGSRuTAaP0ff" title="Exercise price" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_PurchaseWarrantsMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 40%"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgtDAwaSlgS7" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2024-03-31_custom_PurchaseWarrantsMember" format="ixt:datemonthdayyearen" id="Fact000741" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zElcoj0Dihmi" title="Number of shares outstanding" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-03-31_custom_PurchaseWarrants1Member" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zUe4YIaE1AX9" title="Exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_custom_PurchaseWarrants1Member" id="Fact000745" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zwFJWe3l5PA8" title="Expiry Date"><ix:nonNumeric contextRef="AsOf2024-03-31_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" id="Fact000747" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">April 21, 2026</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331_zEn37jqZ4UA3" title="Number of shares outstanding" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-03-31" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">160,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i>Stock&#8211;based
Compensation Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHLRjapMAs3l" title="Common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member" id="Fact000751" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20231001__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zg0JjM2GgeE9" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2023-10-012024-03-31_custom_StockOptionPlan2019Member" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,000,000</ix:nonFraction></span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zO46bnH4wQee" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">406,453</ix:nonFraction></span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20231001__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zMhNmYAtQYp9" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2023-10-012024-03-31_custom_StockOptionPlan2022Member" id="Fact000757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At March 31,
2024, <span id="xdx_903_ecustom--OptionIssued_c20231001__20240331_zean1FrsW2qh" title="Option issued"><ix:nonFraction name="avxl:OptionIssued" contextRef="From2023-10-01to2024-03-31" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,452,500</ix:nonFraction></span> options had been issued under the 2022 Plan and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zhhdn5dWG0Gj" title="Option available issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-03-31_custom_StockOptionPlan2022Member" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,132,202</ix:nonFraction></span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the year ended September 30, 2023 and six months ended March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<ix:exclude><p id="xdx_235_zstIXcltOQNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div id="xdx_234_zkCOmUl0z9Qb" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_z7viZddQL2O2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zIjNx1p9bdq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zN29su7Q8y57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zE6cIWlxVB7g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000767" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zdqrhYa4Z913" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B6_zuodOXuWWejh" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Grant Date Fair Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2022</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zudUh9AjlTIj" title="Number of Options Outstanding at Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,169,616</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4Lr5W19egq4" title="Weighted Average Exercise Price Outstanding at Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000771" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.61</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWhbMTK8qji8" title="Weighted Average Grant Date Fair Value at Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000773" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1scUMGyvzAd" title="Aggregate Intrinsic Value Outstanding at Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_StockOptionMember" id="Fact000775" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,267,309</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6vd6iqeiDVa" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000777" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,959,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW92rvDzJI7f" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000779" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6SLOJMNHF6k" title="Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000781" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmCBVuk8B2i" title="Number of Options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">759,753</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzHlDzpeTqBh" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000785" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsMLjQtayyJc" title="Weighted Average Grant Date Fair Value, Exercised" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000787" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFTsyDzPzgb5" title="Aggregate Intrinsic Value, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,629,026</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxn4PGvtKn7b" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">257,083</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT9j4Pj89de6" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5NKIXLSYrZk" title="Weighted Average Grant Date Fair Value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA7gZ28dyHS8" title="Number of Options Outstanding at Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,111,780</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVo7tvcbg5Nj" title="Weighted Average Exercise Price Outstanding at Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zab2kuyfpI58" title="Weighted Average Grant Date Fair Value at Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWsYgff63quk" title="Aggregate Intrinsic Value Outstanding at Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-09-30_us-gaap_StockOptionMember" id="Fact000803" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,290,069</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxIjNofDpIf7" title="Number of Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,750,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKNPTQUPuSf9" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000807" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zy3Dj2ufvAwg" title="Weighted Average Grant Date Fair Value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000809" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK7fnGAHBdV6" title="Number of Options, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0fFTEoAfV8l" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK59nm7ZftMj" title="Weighted Average Grant Date Fair Value, Exercised" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmRxtyTRQ3N4" title="Aggregate Intrinsic Value, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000817" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,170</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXgP0dfwMfs5" title="Number of Options, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">221,166</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7UDJrqOjmue" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.84</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU1Bq6dHfVDf" title="Weighted Average Grant Date Fair Value, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.06</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, March 31, 2024</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0sCPx3LQrf" title="Number of Options Outstanding at Ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,595,114</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8dL4cyfH4ci" title="Weighted Average Exercise Price Outstanding at Ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.85</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz5Hif7OJH9f" title="Aggregate Intrinsic Value Outstanding at Ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000829" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,480,916</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, March 31, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXas9bb6sXCh" title="Number of Options, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000831" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,955,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6HigpdS0Ute" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.38</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_pp0p0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zentbb8GD9Vf" title="Aggregate Intrinsic Value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000835" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,440,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AD_zQVPwiZPcXG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at March 31, 2024 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000837" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z89dJq6hkTUa" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B2_zagP1ilq69O4" style="display: none">Schedule of summarized information about stock options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></p></td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual life (in</span></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested</span></p></td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znDHNvPCxSt1" title="Range of exercise prices, lower range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000839" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTehO74UuMje" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1i890sMCEV5" title="Number of outstanding options" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,243,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTEg961l1fI2" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" id="Fact000845" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.22</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zwbcJTV4Qr9" title="Weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zi4r5sCwSmP7" title="Number of vested options" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000849" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,243,060</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNAssKYlvRs7" title="Weighted average exercise price options vested" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIRzOQARwmd7" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zkfE6UeN4yYb" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zbOpFnkyPHPh" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000857" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,167,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKGJe864X377" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" id="Fact000859" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.24</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhO09CvJojAf" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000861" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z3MocNbcufs4" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,017,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhtu2jEuHUBg" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zcYeQbB8m9Rj" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zZghSEregeG7" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zQ0jdn6lHQTc" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">6,790,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaGTU4v6tpod" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" id="Fact000873" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.62</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUwJseYVxZN1" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zT78gGUGMv8g" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">3,436,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zLJGcSSyfLt4" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member" id="Fact000879" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zklt3QYYxEPg" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000881" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">9.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zXiY0TCzby0c" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000883" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zxrVhlD46LD5" title="Number of outstanding options" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000885" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,894,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFfVC65BXJIk" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" id="Fact000887" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.85</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zK3oIuxtPuGf" title="Weighted average exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000889" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">10.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1fGjgeRm0Bl" title="Number of vested options" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">705,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZ4IKKHZoNY9" title="Weighted average exercise price options vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">11.06</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRekty1ejdIl" title="Range of exercise prices, lower range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000895" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">13.01</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zQkzNKWyTdU6" title="Range of exercise prices, upper range limit" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000897" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">25.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zI0eUAto7LPb" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000899" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,500,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zdD4YUAXKXTb" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" id="Fact000901" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.97</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_ziZbjP9be7rb" title="Weighted average exercise price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000903" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.12</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zIqHQBA0cp4e" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">552,917</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zw9eNEK5jUZ4" title="Weighted average exercise price options vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">18.28</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSbBoqJORJR" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000909" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">15,595,114</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvOy2O8iPLS2" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact000911" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.97</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjVuMsabsk1d" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000913" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUpuUf0ADDih" title="Number of vested options" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember" id="Fact000915" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,955,616</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlK1IRYcEKV8" title="Weighted average exercise price options vested" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">5.38</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zFoZmvHm8sK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested at March 31, 2024 was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zb4MFttPh8Cg" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-012024-03-31_us-gaap_OptionMember" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.07</ix:nonFraction></span> (September 30, 2023: $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zgMPztwOY1La" title="Weighted average grant date fair value of options vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-012023-09-30_us-gaap_OptionMember" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.94</ix:nonFraction></span>). At March 31, 2024, the weighted average contractual life of options outstanding
was <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zwopy4gLxEXl" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_OptionMember" format="ixt-sec:duryear" id="Fact000923" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.0</ix:nonNumeric></span> years (September 30, 2023: <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zdcJ6sVyEGpb" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2022-10-012023-09-30_us-gaap_OptionMember" format="ixt-sec:duryear" id="Fact000925" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.0</ix:nonNumeric></span> years) and for options exercisable was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zdre5HMajH2f" title="Weighted average contractual life of options exercisable"><ix:nonNumeric contextRef="From2023-10-012024-03-31_us-gaap_OptionMember" format="ixt-sec:duryear" id="Fact000927" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.5</ix:nonNumeric></span> years (September 30, 2023: <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_z8xpHfOElB82" title="Weighted average contractual life of options exercisable"><ix:nonNumeric contextRef="From2022-10-012023-09-30_us-gaap_OptionMember" format="ixt-sec:duryear" id="Fact000929" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.75</ix:nonNumeric></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March 31, 2024,
the Company recognized stock-based compensation expense of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240331_ztXnwKYdSy4d" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-03-31" id="Fact000931" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240331_z1GK3PdAaolb" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-01to2024-03-31" id="Fact000933" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span> million, respectively (2023: $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20230331_zpo6SSSDR9hl" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-03-31" id="Fact000935" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230331_zmei0KGW2tpc" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-10-012023-03-31" id="Fact000937" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.3</ix:nonFraction></span> million,
respectively) in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have
been included in general and 	administrative expenses and research and development expenses on the Company&#8217;s condensed consolidated
interim statement of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000939" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zjfULGHAAg1" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_zEyalFhs0NGe" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbQM9WQCcnqc" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000941" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">979</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsmkmRN7mck8" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000943" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoaLPorJWvth" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000945" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,905</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZmYjr638CYb" title="Total share based compensation" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact000947" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zApFxNZu1MFa" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,673</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVMKRxNA2Vr7" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000951" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,713</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGtnsPcJVGoc" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000953" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,033</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTb2U5FQMJ8h" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000955" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,317</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zWxedXQ3tb5h" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-03-31" id="Fact000957" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,652</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zz4oAfX0nB5d" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-03-31" id="Fact000959" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,970</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zTWoC4nlDv1k" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-03-31" id="Fact000961" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,938</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331_zt5KH4EvvwP6" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-012023-03-31" id="Fact000963" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,317</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A0_zzrtn8q8zyp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zzH0UE7teaJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div id="xdx_23E_zy15XhPdNPOi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zS1SviwRPOVh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zaEMp5LcFz9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zP1PDIORHEka" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex
Life Sciences Corp.
<br/>
Notes to the Condensed Consolidated Interim Financial Statements <br/>
March 31, 2024 <br/>
(Unaudited)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zQKhgVHRHCD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20240331_zLbcl4JeuA75" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-03-31" id="Fact000969" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.5</ix:nonFraction></span> million in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of each option award
granted during the three and six months ended March 31, 2024 and 2023 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" escape="true" id="Fact000971" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zFfKx8VBGcsd" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_znw7mXYVD7Hb" style="display: none">Schedule of weighted average
assumptions</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_zIdZZtnEjvgi" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-10-01to2024-03-31" id="Fact000973" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.28</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230331_zJz8uKzViwV5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-10-012023-03-31" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.69</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfBVqffNbQsi" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" format="ixt-sec:duryear" id="Fact000977" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.74</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zHhXrgY0mwO7" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2022-10-012023-03-31" format="ixt-sec:duryear" id="Fact000979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.61</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z9hrgRugBlr3" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-10-01to2024-03-31" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">84.84</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230331_z6RKz6vN7yse" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-10-012023-03-31" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.28</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zuMquOHDfWc7" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-10-01to2024-03-31" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230331_zBEZtTrN3E21" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-012023-03-31" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A9_zNyYOjBEuvH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three and six months ended March 31, 2024 and 2023 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81D_zsbJKZlq6vIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_003"></span>ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Quarterly Report on Form 10-Q includes forward-looking
statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements
regarding our anticipated future clinical and regulatory milestone events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221;
&#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221;
&#8220;potential,&#8221; &#8220;predict&#8221;, &#8220;could,&#8221; &#8220;would,&#8221; &#8220;will,&#8221; &#8220;suggest,&#8221; &#8220;plan&#8221;
and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include,
without limitation, statements regarding:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">volatility in our stock price and in the markets in general;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to successfully conduct preclinical studies and clinical trials for our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to raise additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to generate any revenue or to continue as a going concern;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to execute our research and development plan on time and on budget; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our products candidates&#8217; ability to demonstrate efficacy or an acceptable safety profile; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain the support of qualified scientific collaborators; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to identify and obtain additional product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our reliance on third parties in non-clinical studies and clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to defend against product liability claims; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to safeguard against security breaches; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to obtain and maintain sufficient intellectual property protection for our product candidates; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to comply with our intellectual property licensing agreements; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to defend against claims of intellectual property infringement; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to comply with the maintenance requirements of the government patent agencies; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to protect our intellectual property rights throughout the world; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">competition; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated start dates, durations and completion dates of our ongoing and future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the anticipated designs of our future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to attract and retain qualified employees; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the impact of Fast Track designation on receipt of actual FDA approval; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or Fast Track designations; and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our anticipated future cash position and ability to obtain funding for our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking statements largely
on our current expectations and projections about future events, including the responses we expect from regulatory authorities and financial
trends that we believe may affect our financial condition, results of operations, business strategy, preclinical studies and clinical
trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including
without limitation the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the
Securities and Exchange Commission on November 27, 2023. These risks are not exhaustive. Other sections of this Quarterly Report on Form
10-Q include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive
and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk
factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking
statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as
required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Quarterly Report on Form 10-Q, the
terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company&#8221;, and &#8220;Anavex&#8221; mean Anavex Life Sciences
Corp., unless the context clearly indicates otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Current Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage biopharmaceutical
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead product candidate, ANAVEX<sup>&#174;</sup>2-73
(blarcamesine), is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous
system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two seed programs.
Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 9pt Sans-Serif; text-align: center; margin-top: 0; margin-bottom: 0; color: Red"><img src="image_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><i>* = Orphan Drug Designation by the FDA</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying in sigma-1
receptor (SIGMAR1) binding activities. The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone protein with
important roles in cellular communication. SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope and restores
homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds to activate quantitatively
the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography (PET) imaging scan
in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) target engagement or receptor occupancy with SIGMAR1
in the brain.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_002.jpg" alt=""/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><i>Source: Reyes
S et al., Sci Rep. 2021 Aug 25; 11(1):17150</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused by chronic
homeostatic imbalances or cellular stress of brain cells. In pediatric diseases, such as Rett syndrome or infantile spasms, chronic cellular
stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such as Alzheimer&#8217;s and
Parkinson&#8217;s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic
cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons
and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy, a characteristic found in Alzheimer&#8217;s
and Parkinson&#8217;s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.
The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in
nerve cells. For example, Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, and neurofibrillary
tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation
of microglia. With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73 (blarcamesine), our approach is to
restore cellular balance (i.e. homeostasis). Therapies that correct defects in cellular homeostasis might have the potential to halt or
delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73 (blarcamesine) specific
Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of some of our clinical trials, we have incorporated
a genomic analysis to better understand potential populations for whom our clinical programs might benefit. In our clinical trials, a
full genomic analysis of Alzheimer&#8217;s disease patients treated with ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) has helped us identify
actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine)
and COMT,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73
(blarcamesine) specific biomarker hypothesis. We believe that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73
(blarcamesine), which are considered independent of Alzheimer&#8217;s disease pathology, as well as multiple endpoints and time-points,
provides support for the potential precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) by using genetic
biomarkers identified within the trial population itself to either confirm the mechanism of action of ANAVEX<sup>&#174;</sup>2-73 (blarcamesine)
or target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) treatment. We may in the future utilize
such an approach in Alzheimer&#8217;s disease as well as indications like Parkinson&#8217;s disease dementia or Rett syndrome in which
ANAVEX<sup>&#174;</sup>2-73 (blarcamesine) is currently being studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Trials Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s
patients. This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the safety
and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer&#8217;s disease. In October 2017, we presented positive pharmacokinetic (&#8220;PK&#8221;)
and pharmacodynamic (&#8220;PD&#8221;) data from the Phase 2a clinical trial, which established a concentration-effect relationship between
ANAVEX<sup>&#174;</sup>2-73 and trial measurements. These measures obtained from all patients who participated in the entire 57 weeks include
exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally, the clinical trial appeared
to show that ANAVEX<sup>&#174;</sup>2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which also targets the SIGMAR1
receptor and has a half-life approximately twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase 2a
trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX<sup>&#174;</sup>2-73, providing
an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing these Phase
2a trial extensions were granted continued access to treatment with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department
of Health &#8211; Therapeutic Goods Administration&#8217;s compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
trial of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced in August 2018. The Phase 2b/3 trial enrolled 509 patients,
which were treated with a convenient once-daily oral formulation of ANAVEX<sup>&#174;</sup>2-73 for 48 weeks, randomized 1:1:1 to two different
ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial took place at 52 sites across North America, Europe and Australia. Primary and
secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer&#8217;s Disease Assessment
Scale &#8211; Cognitive Subscale test (&#8220;ADAS-Cog&#8221;), Alzheimer&#8217;s Disease Cooperative Study &#8211; Activities of Daily
Living (&#8220;ADCS-ADL&#8221;) and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (&#8220;CDR-SB&#8221;). In
addition to the primary endpoints, the ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses
related to potential genomic precision medicine biomarkers previously identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a clinical trial.
The trial was completed in mid-2022 and, in December 2022, the Company presented positive topline results from the Phase 2b/3 clinical
trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 met the co-primary endpoints
ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB. ANAVEX<sup>&#174;</sup>2-73 treatment slowed decline of cognition and function
in patients with early Alzheimer&#8217;s disease over 48 weeks. In addition, patients treated with ANAVEX<sup>&#174;</sup>2-73 had 1.84
times higher odds, or likelihood, to improve cognitively compared to placebo, with an ADAS-Cog score threshold change of -0.5 points or
better [Odds Ratio = 1.84 (p = 0.015)]. At clinically significant levels of improvement in function (ADCS-ADL score threshold change of
+3.5 points or better), patients treated with ANAVEX<sup>&#174;</sup>2-73 had 2.67 times higher odds, or likelihood, to improve function
compared to placebo [Odds Ratio = 2.67 (p = 0.0255)]. Additionally, treatment with ANAVEX<sup>&#174;</sup>2-73 reduced cognitive decline
at end of treatment, measured with the ADAS-Cog, as compared to placebo, by 45%, representing a treatment difference in mean score change
of -1.85 points (p=0.033). Compared to placebo, ANAVEX<sup>&#174;</sup>2-73 reduced clinical decline of cognition and function by 27% with
mean score difference of -0.42 points (p=0.040) as measured by the CDR-SB. ANAVEX<sup>&#174;</sup>2-73 was generally safe and well tolerated.
All statistical analyses were performed by outside consultancy companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2023, we provided additional data demonstrating
that the clinical effect was complemented by two independent biomarkers. A significant reduction in pathological amyloid beta levels in
plasma, as well as a significant slowing in the rate of pathological brain atrophy on Magnetic Resonance Imaging (MRI) scans. Validated
biomarkers of amyloid beta pathology, plasma A&#946;42/40 ratio increased significantly (P = 0.048), demonstrating strong anti-amyloid
effects of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease patients, while MRI revealed significant reduction in brain volume
loss, including whole brain (P = 0.0005), comparing treatment to placebo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furthermore, all pre-specified clinical endpoints
were further analyzed using a mixed model for repeated measures (MMRM). Under the multiplicity control rule, a trial is successful in
meeting the co-primary endpoints if the significance of each endpoint is P &lt; 0.05, or if the significance of only one co-primary endpoint
is P &lt; 0.025. If only one primary endpoint is significant at an &#945; level of 0.025, then the secondary endpoint will be evaluated
at the same level of 0.025. The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48
weeks between the ANAVEX<sup>&#174;</sup>2-73 and placebo groups were &#8722;1.783 [95% CI, &#8722;3.314 to &#8722;0.251]; (P = 0.0226)
for ADAS-Cog13, and &#8722;0.456 [95% CI, &#8722;0.831 to &#8722;0.080]; (P = 0.0175) for CDR-SB in patients with early Alzheimer&#8217;s
disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the respective safety population, common treatment-emergent
adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred in 120 participants (35.8%)
during titration and in 76 participants (25.2%) during maintenance with ANAVEX&#174;2-73 and 10 (6.0%) during titration and 9 (5.6%) during
maintenance with placebo.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A subsequent long-term open label extension study
of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD trial was initiated for patients who have completed the 48-week Phase 2b/3 placebo-controlled
trial referenced above. This trial extension for an additional 96 weeks is currently ongoing, and provides an opportunity to evaluate
longer term safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in persons with Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The data demonstrated dose related and significant
improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes neurological symptoms
that mimic Rett syndrome. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January
2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received in quarterly instalments
which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase 2 clinical
trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. The clinical trials are being
conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 trial, (ANAVEX<sup>&#174;</sup>2-73-RS-001),
which took place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety,
tolerability, PK and efficacy trial of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome
over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The primary endpoint
of the trial was safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional PK. All secondary
efficacy endpoints of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome Behaviour Questionnaire
(&#8220;RSBQ&#8221;) response, when compared to placebo, in the intent to treat (&#8220;ITT&#8221;) cohort (all participants, p = 0.011).
66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant improvement in RSBQ response as compared to 10%
of the subjects on placebo in the ITT cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained
improvement in Clinical Global Impression Improvement (CGI-I) response throughout the 7-week clinical trial, when compared to placebo
in the ITT cohort (all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying
the common form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified efficacy
endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">The
second, international trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June
2019.</span> This trial took place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 trial for Rett
syndrome. The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73
in 33 adult patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. Based
upon the input from the successful U.S. Phase 2 Rett syndrome trial (ANAVEX<sup>&#174;</sup>2-73-RS-001), we updated the endpoints for
the AVATAR trial (ANAVEX<sup>&#174;</sup>2-73-RS-002) to appropriately assess the clinically meaningful outcome following International
Conference on Harmonization (ICH) guidelines. These updates were approved by the respective regulatory authorities in the U.K. and in
Australia, respectively, where the AVATAR trial was conducted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The data from the AVATAR trial was released in February
2022. The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy
endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, Anxiety, Depression, and Mood Scale (ADAMS) (p = 0.010) and CGI-I
(p = 0.037) response. Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome
symptoms. Convenient once daily oral liquid doses of up to 30 mg of ANAVEX<sup>&#174;</sup>2-73 were also well tolerated with good medication
compliance. All patients who participated in the trial were eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol and subsequent Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The very first trial of ANAVEX<sup>&#174;</sup>2-73
in pediatric Rett syndrome patients, the EXCELLENCE trial, completed enrollment in February 2023. This randomized, double-blind, placebo-controlled
Phase 2/3 trial in pediatric patients with Rett syndrome included trial sites in Canada, Australia, and the United Kingdom. 92 pediatric
patients with Rett syndrome between the ages of 5 through 17 years were treated daily with up to 30 mg ANAVEX<sup>&#174;</sup>2-73. Participants
were randomized 2:1 (ANAVEX<sup>&#174;</sup>2-73:placebo) for 12 weeks, followed by a week 16 safety visit and topline results from this
trial were announced in early January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After 12 weeks, the study showed improvement on the
key co-primary endpoint RSBQ, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients&#8217;
caregivers. The other co-primary endpoint, the CGI-I, which represents a less granular assessment by the site investigators using a seven-point
scoring (one=&#8220;very much improved&#8221; to seven=&#8220;very much worse&#8221;), was not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In an ad-hoc analysis, using the predefined mixed-effect
model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX<sup>&#174;</sup>2-73-treated patients improved LS Mean (SE)
-12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated patients. The LS Mean
difference (SE) of -4.61 (2.439) points between treated and placebo groups did not reach statistical significance (n=77; p=0.063). ANAVEX<sup>&#174;</sup>2-73-treated
patients demonstrated a rapid onset of action with improvements at 4 weeks after treatment with a RSBQ total score LS Mean (SE) -10.32
(2.086) points in the drug-treated group compared to a LS Mean (SE) -5.67 (2.413) points in placebo-treated patients. The LS Mean difference
of -4.65 (2.233) points between treated and placebo groups was statistically significant (n=77; p=0.041).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The key secondary endpoint, the ADAMS, trended favorably.
In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study. Collectively, the RSBQ and ADAMS
demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive behaviors,
and social avoidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preliminary review of the safety results indicates
there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile observed with ANAVEX<sup>&#174;</sup>2-73
to date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All patients who participated in the trial were eligible
to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A high enrollment rate in the OLE of over 91% and
the high level of requests for the Compassionate Use Program (93%) provide solid numerical evidence for the reported positive Real World
Evidence (RWE) from patients with Rett syndrome under Compassionate Use Authorization. Families whose children were previously on drug
or placebo in the placebo-controlled trial commented favorably on the improvement of their child&#8217;s daily life due to ANAVEX<sup>&#174;</sup>2-73
treatment in the Compassionate Use Program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive preclinical
data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of Parkinson&#8217;s disease, which demonstrated significant improvements on behavioral,
histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data announced in
October 2017 indicated that ANAVEX<sup>&#174;</sup>2-73 induced robust neurorestoration in experimental Parkinsonism. We believe the encouraging
results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 has the potential to treat Parkinson&#8217;s disease dementia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind, randomized,
placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia in Spain and Australia,
to study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 trial enrolled
approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30 mg and 50 mg, or placebo.
The ANAVEX<sup>&#174;</sup>2-73 Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50 mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (&#8220;CDR&#8221;) computerized assessment system analysis. Treatment with ANAVEX<sup>&#174;</sup>2-73
also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson&#8217;s disease symptom severity,
MDS-Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221;) total score on top of standard of care including dopaminergic
therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX<sup>&#174;</sup>2-73&#8217;s potential capability
of slowing and reversing symptoms that progress in Parkinson&#8217;s disease. In addition, the trial confirmed the precision medicine
approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73 may result in improved clinical outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A 48-week Open Label Extension (&#8220;OLE&#8221;)
ANAVEX2-73-PDD-EP-001 Phase 2 trial was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001
Phase 2 trial discussed above. The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson&#8217;s
Disease Rating Scale Parts I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Clinical Global Impression &#8211;
Improvement (CGI-I), as well as cognitive efficacy endpoint Montreal Cognitive Assessment (MoCA) over a 48-week period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, we reported the preliminary
ANAVEX2-73-PDD-EP-001 OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX<sup>&#174;</sup>2-73 on the
pre-specified primary and secondary objectives. Preliminary analysis reveals that ANAVEX<sup>&#174;</sup>2-73 was found to be
generally safe and well tolerated; and safety findings in this trial were consistent with the known safety profile of
ANAVEX<sup>&#174;</sup>2-73. In respect to efficacy, across all efficacy endpoints, patients performed better while on
ANAVEX<sup>&#174;</sup>2-73. While all patients were on drug holiday due to COVID-19 between the DB EOT and the OLE Baseline, the
respective efficacy endpoints, including the MDS-UPDRS Part II + III and CGI-I, measured at the end of trial of the double-blind
study (DB EOT) and the OLE Baseline, were worsening, as expected in a progressive disease like Parkinson&#8217;s. However, when
patients resumed daily oral ANAVEX<sup>&#174;</sup>2-73 treatment, a consistent improvement was observed during the extension phase
from OLE Baseline through OLE Week 24, and OLE Week 48, respectively. These results are consistent with the pattern observed for all
efficacy measures in the extension phase. The two endpoints, MDS-UPDRS Part II + III and CGI-I measured in this study are the
planned primary and key secondary endpoints in our forthcoming pivotal 6-month Parkinson&#8217;s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we were awarded a research grant
of $1.0 million from&#160;The Michael J. Fox Foundation for Parkinson&#8217;s Research&#160;to develop ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Parkinson&#8217;s disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target
engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Schizophrenia, Frontotemporal Dementia and Alzheimer&#8217;s
disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71. ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation for the treatment
of Frontotemporal Dementia (&#8220;FTD&#8221;) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally administered small molecule targeting
sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase 1
clinical trial was a prospective double-blind, randomized, placebo-controlled trial in Australia. A total of 36 healthy male and female
subjects were included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 were administered in order to evaluate the safety, tolerability,
and PK of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender on its PK in healthy volunteers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The trial met
its primary and secondary endpoints of safety, with no serious adverse events (&#8220;SAEs&#8221;) or dose-limiting toxicities observed.
ANAVEX<sup>&#174;</sup>3-71 was well tolerated in all cohorts receiving ANAVEX<sup>&#174;</sup>3-71 in single doses ranging from 5 mg to
200 mg daily with no SAEs and no significant lab abnormalities in any subject. In the trial, ANAVEX<sup>&#174;</sup>3-71 exhibited linear
PK. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no
effect on the bioavailability of ANAVEX<sup>&#174;</sup>3-71. The trial also met the secondary objective of characterizing the effect of
ANAVEX<sup>&#174;</sup>3-71 on electrocardiogram (&#8220;ECG&#8221;) parameters. There were no clinically significant ECG parameters throughout
the trial. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX<sup>&#174;</sup>3-71 and placebo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In October 2023
a peer-reviewed publication in the journal Neurobiology of Aging, titled &#8220;Early treatment with an M1 and sigma-1 receptor agonist
prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology&#8221;, featured the orally available
small molecule ANAVEX<sup>&#174;</sup>3-71 (AF710B). The preclinical study described the potential disease-modifying properties of ANAVEX<sup>&#174;</sup>3-71
on Alzheimer&#8217;s disease pathology as a possible drug candidate for a potential once daily oral preventive strategy for Alzheimer&#8217;s
disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In January 2024,
in another peer-reviewed publication in the journal <i>Clinical Pharmacology in Drug Development</i>, entitled, &#8216;<i>Population-Based
Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor
Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease&#8217;</i>, reported the Population-based
characterization of the PK and food effect of ANAVEX<sup>&#174;</sup>3-71 as part of the single ascending dose study in healthy participants
with the primary objective of assessing dose proportionality of ANAVEX<sup>&#174;</sup>3-71, and to characterize the effect of food on
the PK of ANAVEX<sup>&#174;</sup>3-71. The results from this PK evaluation demonstrated that ANAVEX<sup>&#174;</sup>3-71, at single ascending
doses of 5 to 200 mg, is linear, dose proportional, and time invariant. Food had no effect on the PK of ANAVEX<sup>&#174;</sup>3-71. This
data also expands the safety objectives met in this first-in-human study of ANAVEX<sup>&#174;</sup>3-71, further supporting its drug development
program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71&#8217;s pre-clinical profile, we intend to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i>Schizophrenia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In March 2024,
we commenced the U.S. FDA cleared ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, a double-blind, placebo-controlled Phase 2 trial in
schizophrenia. The trial consists of two parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day
treatment period in a larger cohort. The trial will utilize standard clinical outcome measures for schizophrenia including the Positive
and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances
in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led
ERP Biomarker Qualification Consortium. In addition to the electrophysiological biomarkers, we are also applying novel neuroinflammatory,
metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX<sup>&#174;</sup>3-71&#8217;s
novel, dual mechanism of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73
currently in three different clinical trial indications, and several other compounds in different stages of clinical and pre-clinical
development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR&#8482; Discovery Platform
produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may
be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer&#8217;s disease, as well
as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence the functioning
of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple viruses including SARS-CoV-2
(COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular processes, in order to ensure survival
and replication. Hence, it is possible that SIGMAR1 could play a role in modulating the cellular response to viral infection and ameliorate
pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe ANAVEX<sup>&#174;</sup>2-73 may offer a
disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1. ANAVEX<sup>&#174;</sup>2-73 is
being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule
formulation for diseases such as Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73
in liquid form resulted in both significant and dose-related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome
disease model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic
visual response and respiration tests in 7-month-old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated
fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased
the automatic visual response in the MECP2 Rett syndrome disease mice. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73
starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular
coordination, balance, motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease
model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted Orphan
Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In November 2019,
the FDA granted ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of Rett syndrome. The RPD designation
is intended to encourage the development of treatments for rare pediatric diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted Fast Track
designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the treatment of Rett syndrome. The FDA Fast Track program
is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of serious
and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson&#8217;s disease, data demonstrates significant
improvements and restoration of function in a disease modifying animal model of Parkinson&#8217;s disease. Significant improvements were
seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease dementia, to
study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 trial enrolled approximately
132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 Parkinson&#8217;s disease dementia trial design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a Alzheimer&#8217;s disease trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial demonstrated that ANAVEX<sup>&#174;</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results showed clinically meaningful, dose-dependent, and statistically
significant improvements in the CDR computerized assessment system analysis. We anticipate conducting further clinical trials of ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s disease dementia after submitting the results of the trial to the FDA to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer&#8217;s disease animal models, ANAVEX<sup>&#174;</sup>2-73
has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive
therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73
has shown a potential dual mechanism which may impact amyloid, tau pathology and inflammation. In a transgenic Alzheimer&#8217;s disease
animal model Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development of
oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that
is apparently amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals,
regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing, we initiated
and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73. In this Phase 1 SAD trial, the maximum
tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown to have positive effects in mouse
models of Alzheimer&#8217;s disease. There were no significant changes in laboratory or ECG parameters. ANAVEX<sup>&#174;</sup>2-73 was
well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed adverse events at doses above the maximum
tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen
with drugs that target CNS conditions, including Alzheimer&#8217;s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s disease. The open-label randomized trial was designed to
assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients with mild-to-moderate Alzheimer&#8217;s disease.
The Phase 2a trial met both primary and secondary objectives of the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated
with ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>&#174;</sup>2-73, among
them variants related to the SIGMAR1, the target for ANAVEX<sup>&#174;</sup>2-73. Results showed that trial participants with the common
SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved cognitive (MMSE)
and functional (ADCS-ADL) scores. The results from this evaluation supported the continued evaluation of genomic information in subsequent
clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX<sup>&#174;</sup>2-73
including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>&#174;</sup>2-73
data met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled trial. On July 2, 2018, the Human Research
Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety and
efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical trial sites in Canada, the
United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 trial design incorporates inclusion of genomic precision
medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe preclinical data from our studies also
supports further research into the use of ANAVEX<sup>&#174;</sup>2-73 as a potential platform drug for other neurodegenerative diseases
beyond Alzheimer&#8217;s disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X
syndrome, Angelman syndrome, multiple sclerosis, and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated
significant improvements in all of these indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a preclinical study sponsored by the Foundation
for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced seizures in mice. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73 restored hippocampal brain-derived
neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative
pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of
BDNF expression could be a contributing factor for the positive preclinical data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data to-date also indicates
that ANAVEX<sup>&#174;</sup>2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological
conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, preclinical data on ANAVEX<sup>&#174;</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination in multiple sclerosis disease. Further,
our data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 has the potential to provide protection for oligodendrocytes (&#8220;OL&#8217;s&#8221;)
and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system neurons in addition to helping repair
by increasing OPC proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73
in a genetic mouse model of tuberous sclerosis complex (&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth
of numerous benign tumors in many parts of the body with a high incidence of seizures. The preclinical data demonstrated that treatment
with ANAVEX<sup>&#174;</sup>2-73 significantly increased survival and reduced seizures in those mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>3-71 is a clinical drug candidate
with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been shown to enhance neuroprotection
and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71 is a CNS-penetrable potential disease modifying treatment
for cognitive impairments. We believe it is effective in very small doses against the major Alzheimer&#8217;s hallmarks in transgenic
(3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial
dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71
in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation
with the administration of ANAVEX<sup>&#174;</sup>3-71. In April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71
for the treatment of FTD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>&#174;</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.
In neurodegenerative diseases such as Alzheimer&#8217;s and Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional
preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 has the potential
to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to
play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase 1 clinical
trial of&#160;ANAVEX<sup>&#174;</sup>3-71. The trial took place in Australia and was a double-blind, randomized, placebo-controlled, Phase
1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX<span style="background-color: white"><sup>&#174;</sup></span>3-71
including effects of food and gender in healthy volunteers. <span style="background-color: white">The trial met its primary and secondary
endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, </span>as more fully described
above under <i>Clinical Trials Overview &#8211; Schizophrenia, Frontotemporal Dementia and Alzheimer&#8217;s disease</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Based on these
results, and ANAVEX<sup>&#174;</sup>3-71 pre-clinical profile, the Company intends to advance ANAVEX<sup>&#174;</sup>3-71 into a biomarker-driven
clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer&#8217;s disease, evaluating longitudinal effect
of treatment with ANAVEX<sup>&#174;</sup>3-71. We believe the results of this clinical trial and preclinical study could serve as a basis
for advancing into respective registration trials in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The first of
these trials, the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial, commenced in March 2024 and is</span> more fully described above under
<i>Clinical Trials Overview &#8211; Schizophrenia.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>&#174;</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1-41 is a sigma-1 agonist. Pre-clinical
tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41
prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These activities involve both muscarinic and SIGMAR1 systems through
a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that ANAVEX<sup>&#174;</sup>1-41
has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired,
are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1066</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1066, a mixed sigma-1/sigma-2
ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066 was tested in two preclinical
models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic constriction injury model of neuropathic
pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored the nociceptive threshold in the affected paw
to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In
a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and
a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned the nociceptive threshold to control levels in a dose-dependent manner.
Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and
a favorable safety profile in a battery of behavioral measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>&#174;</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is designed for the treatment
of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for SIGMAR1 at nanomolar
levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced pre-clinical studies, this compound
revealed antitumor potential. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and
also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications highlight the possibility that these
ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed in different
tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell
membrane reorganization and interactions with ion channels, we believe our drug candidates may play an important role in inhibiting the
processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of
new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>&#174;</sup>1037 is currently in the pre-clinical
and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown
in human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions with
potential strategic and commercial partners to most effectively advance our programs and increase stockholder value. Further, we may acquire
or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are developing compounds with potential application
to two broad categories and several specific indications, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Alzheimer&#8217;s disease &#8211; In 2023, an estimated 6.7 million Americans aged 65 and older suffered from Alzheimer&#8217;s disease. The Alzheimer&#8217;s Association<sup>&#174;</sup> estimates that the annual number of new cases of Alzheimer&#8217;s and other dementias is projected to double by 2050. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. We believe that there is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 28px">&#160;</td>
<td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Parkinson&#8217;s disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson&#8217;s disease currently is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people. The Parkinson&#8217;s disease market is expected to reach $11.5 billion by 2029, according to GlobalData.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 28px"><span style="font-size: 10pt">&#160;</span></td>
<td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify">Rett syndrome &#8211; Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females. &#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 28px">&#160;</td>
<td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Schizophrenia - Schizophrenia is a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including 2.8 million people in the U.S., according to the World Health Organization. It is characterized by three symptom domains: positive symptoms (hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment (deficits in memory, concentration, and decision-making). In part due to limitations with current treatments, people living with schizophrenia often struggle to maintain employment, live independently, and manage relationships. While current treatments can be effective in managing select symptoms, approximately 30% of people do not respond to therapy, with an additional 50% experiencing only a partial improvement in symptoms or unacceptable side effects, according to the World Health Organization.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
</table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 28px"/><td style="width: 24px"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Fragile X &#8211; Fragile X syndrome (FXS) is the most prevalent genetic form of intellectual disability
and autism spectrum disorder, primarily affecting boys. As with most neurodevelopmental disorders, FXS is considered a condition of synaptic
development and function. The disease has a range of clinical presentations depending on the specific genetic changes associated with
an &#8220;expansion&#8221; of the FMR1 gene. The disease is characterized by deficits in long-term potentiation and homeostatic plasticity.
FXS has been detected in all populations and ethnic groups. Researchers do not know the exact number for how many Americans could have
full mutation FXS. Studies estimate that the disease affects approximately 1:4,000 males and 1:6,000-8,000 females. Worldwide, more than
1,400,000 people could be affected by FXS.&#160;</td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Depression &#8211; Depression is a major cause of morbidity worldwide according to the World Health Organization. The global antidepressant drug market is projected to reach $21 billion by 2030 according to Allied Market Research. Pharmaceutical treatment for depression has been historically dominated by blockbuster brands. However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Epilepsy &#8211; Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with medications that are categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 28px">&#160;</td>
<td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify"><span style="font-size: 10pt">Neuropathic Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Malignant Melanoma &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for a large majority of skin cancer deaths. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Prostate Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market Research Future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 28px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pancreatic Cancer &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.7 billion by 2027.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; text-indent: -18pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights to twenty-five
(25) U.S. patents, twenty-four U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73
and certain anticholinesterase inhibitors composition and method for neuroprotection,&#8221; which claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73
directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent
is expected to expire in June 2034, absent any patent term extension for regulatory delays. We own one issued U.S. patent entitled &#8220;A2-73
crystalline polymorph compositions of matter and methods of use thereof&#8221;. It claims crystals of A2-73 freebase or its fumarate salt,
dosage forms and pharmaceutical formulations. This patent is expected to expire in July 2039, absent any patent term extension for regulatory
delays. We own four issued U.S. patents each with claims directed to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these
four patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73, dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73,
and methods of treatment for Alzheimer&#8217;s disease using them. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays. The second of these four patents claims pharmaceutical compositions containing a crystalline form of
ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to
expire in June 2036, absent any patent term extension for regulatory delays. The third of these four patents claims pharmaceutical compositions
containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s disease using the compositions.
This patent is expected to expire in June 2036, absent any patent term extension for regulatory delays. The fourth of these four patents
claims method of making certain crystalline forms ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in October 2036, absent
any patent term extension for regulatory delays. We also own three issued U.S. patents for seizure treatment. The first of these three
patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with
either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. The
second of these three patents further claims a combination seizure treatment involving administration of an anti-epilepsy drug combined
with (i) ANAVEX<sup>&#174;</sup>19-144, or (ii) ANAVEX 19-144<sup>&#174;</sup> and ANAVEX 2-73<sup>&#174;</sup>. The third of these three
patents claims a dosage form for seizure reduction, comprising (i) ANAVEX<sup>&#174;</sup>19-144, (ii) ANAVEX<sup>&#174;</sup>2-73, or (iii)
a combination of ANAVEX<sup>&#174;</sup>19-144 and ANAVEX<sup>&#174;</sup>2-73; and optionally further comprising a low-dose anti-epilepsy
drug. All three patents are expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own four
issued U.S. patents with claims directed to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental
disorder, multiple sclerosis, their related biochemical and functional abnormalities, or loss-of-function associated with a neurodevelopmental
disorder, by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41 (another sigma
receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73), or compositions thereof. All four patents are expected to expire in January 2037,
absent any patent term extension for regulatory delays. In addition, we own one issued U.S. patent with claims directed to methods of
treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected to expire in February 2030, absent any
patent term extension for regulatory delays. We also own an issued U.S. patent that claims crystalline forms of ANAVEX<sup>&#174;</sup>19-144,
dosage forms and compositions containing the crystalline forms of ANAVEX<sup>&#174;</sup>19-144, and methods of treatment for Alzheimer&#8217;s
disease. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. Further, we own one issued
U.S. patent with claims directed to methods of treating cardiac dysfunction with ANAVEX<sup>&#174;</sup>2-73. This patent is expected to
expire in July 2038, absent any patent term extension for regulatory delays. Additionally, we own two issued U.S. patent for the treatment
of insomnia, anxiety, or agitation. The first of the two patents claims methods of treating insomnia or anxiety with ANAVEX<sup>&#174;</sup>2-73,
ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in September 2038. The second of the
two patents claims a dosage form comprising any of, or any combination of ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, and/or
ANAVEX<sup>&#174;</sup>1-41. This patent is expected to expire in July 2038, absent any patent term extension for regulatory delays. Further,
we own one issued U.S. patent with claims directed to a method of treating systolic hypertension using ANAVEX<sup>&#174;</sup>2-73. This
patent is expected to expire in July 2039, absent any patent term extension for regulatory delays. Additionally, we own one issued U.S.
patent with claims directed to pharmaceutical dosage forms of (-) enantiomer of ANAVEX<sup>&#174;</sup>2-73. This patent is expected to
expire in July 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own three (3) issued U.S. patents related
to ANAVEX<sup>&#174;</sup>1066. The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX<sup>&#174;</sup>1066
isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>&#174;</sup>1066 isomer. The third patent
claims dosage forms and pharmaceutical compositions comprising (+) ANAVEX<sup>&#174;</sup>1066 isomer. All three patents are expected to
expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also have granted or pending applications in Australia, Canada, China,
Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>&#174;</sup>3-71, we own
exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>&#174;</sup>3-71 compound and methods of
treating various diseases including Alzheimer&#8217;s with the same. These patents are expected to expire in April 2030, and January 2030,
respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related patents or applications
that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected
to expire in January 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications and certain
granted foreign patents directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional
protection for one or more of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual property
rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business strategy
including the selective development, protection, and exploitation of our intellectual property rights. In addition to filings made with
intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered
processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions
for the same in contractor&#8217;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse
in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions
for which important legal principles are unresolved. For more information regarding challenges to our existing or future patents, see
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on November
27, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Overview </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion should be read in conjunction
with our condensed consolidated interim financial statements and related notes thereto contained elsewhere in this report. Past operating
results are not necessarily indicative of results that may occur in future periods. The discussion contains forward-looking statements,
which involve a number of risks and uncertainties. See &#8220;Forward Looking Statements&#8221; included elsewhere in this report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are in the development stage and have not earned
any revenue since our inception in 2004. We do not anticipate earning any revenues until we can establish an alliance with other companies
to develop, co-develop, license, acquire or market our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating costs consist primarily of research
and development activities including the cost of clinical trials and clinical supplies as well as clinical drug manufacturing and formulation.
Research and development expenses also include personnel related costs such as salaries and wages, and third-party contract research organization
(CRO) expenses in support of these clinical trials. Personnel costs include salaries and wages, benefits, and non-cash stock-based compensation
charges associated with options and other equity awards granted to employees and consultants who are directly engaged in support of our
research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses consist of personnel
costs, expenses for outside professional services and expenses associated with operating as a public company. Personnel costs consist
of salaries and wages, benefits and stock-based compensation for general and administrative personnel. Outside professional services and
public company expenses include expenses related to compliance and reporting, additional insurance expenses, audit and SOX compliance,
expenses associated with patent research, applications and filings, investor and stockholder relations activities and other administrative
expenses and professional services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of the three and six months ended March
31, 2024 and 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses for the quarter ended March
31, 2024 were $12.5 million, compared to $14.2 million for the comparable quarter ended March 31, 2023. Total operating expenses for the
six-month period ended March 31, 2024 were $23.8 million, compared to $29.6 million for the comparable six month period ended March 31,
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses for the three
months ended March 31, 2024 were $9.7 million, as compared to $11.3 million for the three months ended March 31 2023. Our research and
development expenses for the six months ended March 31, 2024 were $18.4 million, as compared to $23.4 million for the comparable six month
period ended March 31 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The decrease in research and development expenses
during the three- and six-month periods is primarily related to the following;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(i)</td><td style="text-align: justify">a decrease in stock-based compensation expense of $1.0 million in the three-month period and $3.3 million
in the six-month period, as a result of the vesting of previous option awards and the extended timeline of milestone based vesting awards.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(ii)</td><td style="text-align: justify">a decrease of approximately $1.3 million in the three-month period and $2.1 million in the six-month period
in expenditures over the comparable periods relating to our Rett syndrome program as a result of the completion of the EXCELLENCE trial
and the respective extension trial under the AVATAR trial.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"/><td style="width: 36pt">(iii)</td><td style="text-align: justify">a decrease of approximately $1.1 million in the six-month period in expenditures over the comparable period
relating to our Alzheimer&#8217;s program as a result of the completion of the Phase 2b/3 clinical trial in the comparable period.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 54pt; text-align: justify; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These decreases were partially offset by an increase
of $0.5 million in both the three- and six-month periods relating to expenditures on the ANAVEX<sup>&#174;</sup>3-71-SZ-001 clinical trial,
which trial commenced in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes our research and development
expenses for the three- and six-months ended March 31, 2024 (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended <br/>
March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended <br/>
March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Cost of external service providers</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">6,165</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">9,732</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,219</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Personnel costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,862</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,788</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,673</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,317</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other common costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total research and development costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,729</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,307</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,413</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,373</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three- and six-months ended March 31, 2024
and 2023, external service providers cost by product candidate was as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended <br/> March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended <br/> March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>2-73</span></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,510</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">7,991</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">10,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">ANAVEX<sup>&#174;</sup>3-71</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,240</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other product candidates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other external service provider costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">222</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total external service provider costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,167</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,165</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses were $2.8 million
for the three months ended March 31, 2024, as compared to $2.9 million for the same quarter of fiscal 2023. General and administrative
expenses were $5.4 million for the six months ended March 31, 2024, as compared to $6.2 million for the same period of fiscal 2023.The
primary reason for the decrease in general and administrative expenses was a reduction in stock-based compensation charges of $0.3 million
for the three month period and $1.1 million for the six month period, as a result of the vesting of previous option awards and the extended
timeline of milestone based vesting awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expect to see our research and development expenditures
increase from current levels as we advance our clinical programs, including ongoing extension trials of our Alzheimer&#8217;s and Rett
syndrome programs, advancement of ANAVEX<sup>&#174;</sup>3-71 trial in Schizophrenia, planned advancement of ANAVEX<sup>&#174;</sup>2-73
for Parkinson&#8217;s disease, planned initiation of an ANAVEX<sup>&#174;</sup>2-73 for a Fragile X clinical trial, and as we continue
to add additional staffing to manage and support these clinical initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other income (net)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net amount of other income for the three months
ended March 31, 2024 was $2.1 million as compared to $1.1 million for the comparable three months ended March 31, 2023. The net amount
of other income for the six months ended March 31, 2024 was $4.8 million as compared to $3.5 million for the comparable six month period
ended March 31, 2023. The increase in other income for the quarter is primarily related to a one-time financing charge of $0.9 million
recognized in the comparable three- and six-month periods associated with entering into the 2023 Purchase Agreement (as described below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net loss for the three months ended March 31, 2024,
was $10.5 million, or $0.13 per share, as compared to $13.1 million, or $0.17 per share in the comparative quarter of fiscal 2023. The
net loss for the six months ended March 31, 2024 was $19.2 million, or $0.23 per share, as compared to $26.1 million, or $0.33 per share
in the comparative six month period. The decrease in net loss for the quarter is primarily related to a decrease in research and development
expenditures and an increase in other income, as discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Working Capital (in thousands)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">March 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Current Assets</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">144,516</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">154,386</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Current Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,558</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,534</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Working Capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">134,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">141,852</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024, we had net current assets of $144.5
million, a decrease of $10.0 million from September 30, 2023. The decrease in net current assets primarily relates to a decrease in cash
and cash equivalents of $11.6 million due to cash utilized in operations, partially offset by $7.2 million in cash generated under the
2023 Purchase Agreement. Over the period, our net working capital position decreased by $6.9 million to $135.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first six months of fiscal 2024, we utilized
cash and cash equivalents of $19.0 million to fund our operations, compared to $14.3 million during the same period of fiscal 2023. Our
cash position was $139.4 million at March 31, 2024 compared to $151.0 million at our fiscal year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We intend to
continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73 and ANAVEX<sup>&#174;</sup>3-71, and
to perform the work necessary to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following
table summarizes cash flows during the six months ended March 31, 2024 and 2023 (in thousands): </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net cash flows used in operating activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(18,974</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(14,283</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net cash flows from financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,336</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,592</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Increase/ (decrease) in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,638</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow used in operating activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities for the six
months ended March 31, 2024 was $19.0 million, compared to $14.3 million during the comparable period ended March 31, 2023. The principal
reason for this increase in net cash used in operating activities in the current period is due to a net decrease (pay down) of $3.0 million
in accounts payable and accrued liabilities during the six-month period ended March 31, 2024, as compared to a net increase of $3.3 million
in accounts payable and accrued liabilities in the comparable six-month period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash flow provided by financing activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash provided by financing activities for the six-month
period ended March 31, 2024 was $7.3 million, compared to $18.6 million during the comparable six-month period ended March 31, 2023. Cash
provided by financing activities in both periods is primarily attributable to cash received from the issuance of common shares at various
market prices under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2023 Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150,000,000
purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant
to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0 million
in value of its shares of Common Stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On any business day and subject to certain customary
conditions, the Company may direct Lincoln Park to purchase up to 200,000 shares of Common Stock (such purchases, &#8220;Regular Purchases&#8221;).
The amount of a Regular Purchase may increase under certain circumstances based on the market price of the Common Stock; provided, however,
that Lincoln Park&#8217;s committed obligation under any Regular Purchase shall not exceed $4.0 million. The purchase price of shares
of Common Stock will be based on the then prevailing market prices of such shares at the time of sales as described in the 2023 Purchase
Agreement. There are no limits on the price per share that Lincoln Park may pay to purchase Common Stock under the 2023 Purchase Agreement.
In addition, if the Company has directed Lincoln Park to purchase the full amount of Common Stock available as a Regular Purchase on a
given day, it may direct Lincoln Park to purchase additional amounts as &#8220;accelerated purchases&#8221; and &#8220;additional accelerated
purchases,&#8221; each as set forth in the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement limits the Company&#8217;s
sale of shares of Common Stock to Lincoln Park to 15,606,426 shares of Common Stock, representing 19.99% of the shares of the Common Stock
outstanding on the date of the 2023 Purchase Agreement unless (i) stockholder approval is obtained to issue more than such amount or (ii)
the average price of all applicable sales of Common Stock to Lincoln Park under the 2023 Purchase Agreement equals or exceeds the lower
of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average
of the closing price of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 Purchase Agreement also prohibits the Company
from directing Lincoln Park to purchase any shares of Common Stock if those shares, when aggregated with all other shares of Common Stock
then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership,
at any single point in time, of more than 4.99% of the then total outstanding shares of Common Stock, as calculated pursuant to Section
13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park 75,000 shares of Common Stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
during the year ended September 30, 2023 and agreed to issue up to 75,000 shares pro rata (collectively with the initial commitment shares,
the &#8220;commitment shares&#8221;), when and if, Lincoln Park purchased, at the Company&#8217;s discretion, the $150.0 million aggregate
commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six-month period ended March 31, 2024,
the Company issued to Lincoln Park an aggregate of 1,503,707 shares of Common Stock under the 2023 Purchase Agreement, including 1,500,000
shares of Common Stock for an aggregate purchase price of $7,411,700 and 3,707 commitment shares. During the six-month period ended March
31, 2023, the Company issued to Lincoln Park an aggregate of 2,159,080 shares of Common Stock under the 2023 Purchase Agreement, including
2,075,000 shares of Common Stock for an aggregate purchase price of $18,152,000, 9,080 commitment shares as well as the 75,000 initial
commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024, an amount of $114.7 million remained
available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Controlled Equity Offering Sales Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended and Restated
Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;),
pursuant to which we may offer and sell shares of Common Stock registered under an effective registration statement from time to time
through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on our instructions
and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of Common Stock by methods deemed to
be an &#8220;at the market offering&#8221;, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to our prior written
consent. We are not obligated to make any sales of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the
At-the-Market Offering upon notice to the other party, subject to certain conditions. The Sales Agents will act as agents on a commercially
reasonable efforts basis consistent with their normal trading and sales practices, applicable state and federal law, and rules and regulations
and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have agreed to pay the Sales Agents&#8217; commissions
for their services of 3.0% of the gross proceeds from the sale of shares of Common Stock pursuant to the Sales Agreement. We have also
agreed to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shares were sold during the six months ended March
31, 2024 and 2023 under the Sales Agreement. The Company currently is unable to sell shares of Common Stock under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We prepare our condensed
consolidated interim financial statements in accordance with accounting principles generally accepted in the United States of America
and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue and expenses, and the related disclosures
of contingent liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable in the
circumstances. Actual results may differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no significant
changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K for the year ended September 30,
2023, as filed with the SEC on November 27, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Please refer to Note 2 &#8220;Recent
Accounting Pronouncements&#8221; in notes to our Condensed Consolidated Interim Financial Statements included in this Form 10-Q.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There have been no material
changes in our exposure to market risk from that disclosed in Item 7A of our Annual Report on Form 10-K for the year ended September 30,
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>ITEM 4. CONTROLS AND PROCEDURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Disclosure Controls and
Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We maintain disclosure controls
and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports
filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief executive
officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We carried out an evaluation,
under the supervision and with the participation of our management, including our principal executive officer and principal financial
officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13a-15(e) under
the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive
officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Changes in Internal
Control over Financial Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the quarter ended
March 31, 2024, there were no changes to our internal control over financial reporting identified in management&#8217;s evaluation pursuant
to Rules 13a 15(d) or 15d 15 (d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal
controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_006"></span>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>ITEM 1. LEGAL PROCEEDINGS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
The complaint is captioned Blum v. Anavex Life Sciences, Corp. et al., case number 1:24-cv-01910, and names the Company and Christopher
Missling as Defendants. The complaint alleges violations of the Securities and Exchange Act of 1934 resulting from disclosures and statements
made about certain clinical trials for ANAVEX<sup>&#174;</sup>2-73. The Company believes the complaint is without merit. The Company is
vigorously pursuing its defenses and a potential dismissal of all claims asserted in the lawsuit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">We
know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
to which our Company or our subsidiaries are a party or of which any of their property is subject. There are no other proceedings in which
any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries&#8217; interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>ITEM 1A. RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the risk factors
discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023,
filed with the SEC on November 27, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_009"></span>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period covered by this Quarterly Report
on Form 10-Q, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously
reported in a Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_010"></span>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>ITEM 4. MINE SAFETY DISCLOSURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>ITEM 5. OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Insider Trading Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended March 31, 2024, no director
or Section 16 officer <span id="xdx_90D_eecd--Rule10b51ArrAdoptedFlag_dbF_c20240101__20240331_z6LWnpulI6C1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90A_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20240101__20240331_zB5bXJ0R5Ko7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-012024-03-31" format="ixt:booleanfalse" id="Fact000988" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-01-012024-03-31" format="ixt:booleanfalse" id="Fact000989" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span>, modified, or <span id="xdx_90A_eecd--Rule10b51ArrTrmntdFlag_dbF_c20240101__20240331_zqcrNbZMxBZ9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_909_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20240101__20240331_zezxJsAwhJZb" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-01-012024-03-31" format="ixt:booleanfalse" id="Fact000990" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-01-012024-03-31" format="ixt:booleanfalse" id="Fact000991" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading
arrangement&#8221; (in each case, as defined in Item 408(a) of Regulation S-K).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>ITEM 6. EXHIBITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 11%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Exhibit <br/>
Number </b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 89%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b><br/>
Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(3) </b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Articles of Incorporation and Bylaws </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.1</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm"><span style="font-size: 10pt">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Annual Report on Form 10-K for the year ended September 30, 2021 filed on November 24, 2021)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">3.2</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm"><span style="font-size: 10pt">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on April 14, 2023)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(31) </b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Rule 13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.1*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e5644_ex31-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">31.2*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e5644_ex31-2.htm"><span style="font-size: 10pt">Certification of Sandra Boenisch</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(32) </b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>Section 1350 Certifications</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">32.1**</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e5644_ex32-1.htm"><span style="font-size: 10pt">Certification of Christopher Missling, PhD and Sandra Boenisch.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>(101)</b></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><b>XBRL</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.INS*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL INSTANCE DOCUMENT</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.SCH*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION SCHEMA</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.CAL*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.DEF*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.LAB*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">101.PRE*</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="font: normal 16pt Calibri Light; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>SIGNATURES</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: center; text-indent: -36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX LIFE SCIENCES CORP. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font-size: 10pt">/s/Christopher Missling, PhD</span></td>
<td style="width: 50%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid">&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Christopher Missling, PhD</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Chief Executive Officer</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Date: May 9, 2024</span></td>
<td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font-size: 10pt">/s/Sandra Boenisch</span></td>
<td style="width: 50%">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: black 1pt solid">&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Principal Financial Officer</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
<td>&#160;</td></tr>
<tr style="vertical-align: top">
<td><span style="font-size: 10pt">Date: May 9, 2024</span></td>
<td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e5644_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Christopher Missling, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended March 31, 2024 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: May <FONT>9</FONT>, 2024</FONT></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD</FONT></TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Chief Executive Officer, President and Secretary</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e5644_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right">&nbsp;<B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Sandra Boenisch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this Quarterly Report on Form 10-Q
for the three months ended March 31, 2024 of Anavex Life Sciences Corp. (the &ldquo;registrant&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&ndash;15(e)
and 15d&ndash;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) designed such internal control over
financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(c) evaluated the effectiveness of the
registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(d) disclosed in this report any change
in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(b) any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: May 9, 2024</FONT></TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e5644_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Quarterly Report of Anavex
Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended March 31, 2024 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, in the capacities and on the date indicated below,
hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the
best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(1) the Report fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">(2) the information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Date: May 9, 2024</FONT></TD>
<TD STYLE="border-bottom: black 1pt solid; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Christopher Missling, PhD </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Christopher Missling, PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer) </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 50%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/Sandra Boenisch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Principal Financial Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD>
<TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The foregoing certification is being furnished solely
to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic
version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $! G # 2(  A$! Q$!_\0
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MX)^8?0U-+XGM5^UB*)Y6MIA$V",<@_-GLN59<GN/3FH'U_09!APQ_=&'[O\
M <9'7V%5FU#PNRH/(*E!M5D!5@/J#G_]9H^N8?\ G7WA]5K?R/[C7L-<34+V
M:"*!@(NK%P2> > /KZU9T[4!J$4K>4\3Q2F)T<@D$8/;ZUAV^L>';61G@62/
M<,%5W;.@'W<XZ =JEM/$&A6,9CM]Z*3D\$DG '4GT 'X4?7,/_.OO#ZK6_D?
MW'1T5A_\)9I7_/1_^^:/^$LTK_GH_P#WS1]<P_\ .OO#ZK6_D?W&Y16'_P )
M9I7_ #T?_OFC_A+-*_YZ/_WS1]<P_P#.OO#ZK6_D?W&Y16'_ ,)9I7_/1_\
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MM'[?I_\ T!8O^_[TOV_3_P#H"P_^!#T>SA_.ON?^0<\OY7^'^9FT5I?;]/\
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M\Q_A1]3J]D+ZU3[LY\BS4L2 V&X56/([_C_]>HV%J)(SQMQEE!)_#/8UT?\
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M&,_B*G34M9DC61&A((SQ%'D#D9(QQT-.>^UM,9:'E]@Q%'R>/;WI)NVC=O\
M#_P0:5]4O_ O^ 5QK$0'^H(SD\/P"<YQ^)J*VU1+=0-C/AF."XP<D'./48J\
M+[6V[PCEAS%'VZ]O:JIU[4@2#+%D''^H3_"DYVLW)_\ @/\ P1J-[I17W_\
M %BUJ.+'[C<0"-Q89P3G^=,75PH7$?*L"'W8;&[)'XT[^W]1_P">L7_?A/\
M"C^W]1_YZQ?]^$_PI>V7\[_\!_X(_9/^5??_ , KR:@DEGY!B!8A29"W)8<
M_EG\ZI[AZBM3^W]1_P">L7_?A/\ "C^W]1_YZQ?]^$_PK*3IRWD_N_X)I'GC
MM%??_P  R]P]11N'J*U/[?U'_GK%_P!^$_PH_M_4?^>L7_?A/\*GEI?S/[O^
M"5>I_*OO_P" 9>X>HHW#U%:G]OZC_P ]8O\ OPG^%']OZC_SUB_[\)_A1RTO
MYG]W_!"]3^5??_P#+W#U%&X>HK4_M_4?^>L7_?A/\*/[?U'_ )ZQ?]^$_P *
M.6E_,_N_X(7J?RK[_P#@&7N'J*,CU'YUJ?V_J/\ SUB_[\)_A5G3M0OKJ:::
M:X4JF%1%1 .1R2,=?2M*=*G-V4G]W_!(G4J05W'\?^ 5?[7A("M:)LQ@@-V
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MC=_(X \[/WG4;/\ ?Y^6HV1_):38>'V;=R[C[@9^[[U7@M;1]BN_S,S997
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MY#Y:;]PD4AO93GD^U-6UF=H5P@\T9RTB@)_O<\&LW ]!1@>@I>UI_P OX_\
M '[.?\WX?\$O?9YC")/+ZOLV[EW#WQG[OO0]G.OGC:I\G'W9%.__ '.?FJC@
M>@HP/04O:4_Y?Q_X ^2?\WX?\$O?8+@RJF(_F3?N,J[1[$YX;VJ-;*X=86V
M>:VW#.H*>[<\#WJK@>@HP/04N>G_ "_C_P  ?+4_F_#_ ()Z)X;,%II B;;
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M4&6>"23S'\N/9UR2>>:\ISC>VG_@)Z:C*W7[R3S=%_Y]+[_O^O\ A1YNB?\
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M>=G/H?RKT/PI_P @"'_>;^=>EE#_ -H?H_T.',U^X^:_4VZ***^I/G HHHH
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MB1]7;R75@PD8K&=Z$.3P5'//T[4TG5%#R,PQ&ZB1F=/E8$X#'/!YZ&M_WO\
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MZ>OX5J9$]%5S?681G-U $5MC,9!@-Z'W]J<UW;(\B-<1!HEW2*7&4'J?04:
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M(52<YP.W))X]:8%HZUI_V:XGCN4E6WC\R01G)"XSTJ.#7]-F!W7"PN"RE)2
M1@9/?'2@:!8!KTB-O],!64;NQY./J3FFW7AW3;R9))( I5-@6/Y1CDC@>A)-
M #HM?TR5"XN45-VT,W&XY(X_*B/Q!I4BAEO(]NP.23C&<8!]^1Q4#^%M.D8-
M)Y[MNWL6E/S'.[)_&I!X=LE2,(TZO$24D64AER #S]!B@"W>:A%9^4"DLTDN
M=D<*[F8 9)^G^-5QX@TEH]ZWL1R,A<\],XQZ\CCW%2RZ7'/%$KS3B2(L4F5]
MK@'J,^F./P'>JC^&;%_+C'F);(KJ8%8X;<5/)Z_PB@"PFNZ6\,<HOH0CJ6!9
ML< 9.?2BXUJT@B@E027"3!BI@7=POWC^%5Y_#&FW$PED64D8./,.,@8_E5BX
MT6UN%12TT>UI&S'(5)WG+#/H<T /CUC3949TO8"JXW'>!C--EUJPCLUNA,)8
MF+ &,;ON@EOR -5[CPU83P"("2-%# *K';R2PR.X!.121>'XQ9QP3W#SL))'
MD=NKAP0PZ\<']* +5UJUK:17$DF_$$BQN O\3 $=>/XAR>*9=:Y:6EI;W$JR
M[9P-B[<'G YSC')'YT#18! \?GW)+MO:0RG<S< $GOPH&.F*8?#]E]F6 >:$
M155,/]S#!N/Q )HL \:W:&'S-LO#A-H7)R5W#H<'BK\4B2Q)+&0R. RL.X/0
MUG-H4&_S$FF$H'!9LKOVE0Y7H2 <?@*T+>!+:VB@CSLB0(N?0# H DHHHH *
M*** "BBB@ HHJI>ZE;:>T"3F0O.Y2-8XV<L0"3P!V )H MT5E0>(]+G5&%R4
M\R1(T$L;(69P2F 1T(!P?:I3K5@)(4,V/.E\E&((!DY^3Z\'\OI32;5R7))I
M-[DVI_\ (*N_^N+_ ,C7F=O:M<EB'(VMAN^!@G/Z?K7INH!#IUR)"0GE-N*C
M) QVKSHQ:-D_Z;>_]^%_^*KY[-HWJ0;ML^MNI[N6RM"25]^U^@\Z0  1<LP9
MB%95^4 9Y;GCICZTQM+VQA_-E;_95.<Y[#/3U-)Y6C?\_M[_ -^%_P#BJ/*T
M;_G]O?\ OPO_ ,57E<L.R_\  CTN:7=_^ B#36W.K2.,'"MMXQMSD\\#M4IT
M@ C]_)@L%'R\_4U'Y6C?\_M[_P!^%_\ BJ/*T?\ Y_;[_OPO_P 50HP[+_P(
M'*7=_<)'IXDD=#.RD*I56&&)8$X(SUXZ5(-(&<-=#)P!MYR<'<.O8C%,\K1O
M^?R]_P"_"_\ Q5'DZ-_S^7O_ 'X7_P"*I*,>J7_@0.4N[_\  1!IX-S+#YDN
M$V\[?4XR?85(ND C/VASP2<+[9X]>E,\K1O^?V^_[\+_ /%4>5HW_/[??]^%
M_P#BJ%&'5+_P('*7=_<.32F8*3,>5)*@9*GL#SQP0:JWMM]DF$8=FXSD\?E5
MCRM&_P"?V]_[\+_\51Y6C?\ /[??]^%_^*I2A%JRLO\ MX<9M.[O]QG9/J?S
MHR?4_G6CY6C?\_E[_P" Z_\ Q5'E:-_S^7O_ (#K_P#%5E[)]U]Z-/:KL_N,
M[)]3^=&3ZG\ZT?*T;_G\O?\ P'7_ .*H\K1O^?R]_P# =?\ XJCV3[K[T'M5
MV?W&=D^I_.C)]3^=:/E:-_S^7O\ X#K_ /%4>5HW_/Y>_P#@.O\ \51[)]U]
MZ#VJ[/[C.R?4_G1D^I_.M'RM&_Y_+W_P'7_XJCRM&_Y_+W_P'7_XJCV3[K[T
M'M5V?W&=D^I_.MSPTL92\;8=_F*"S#K\HZ54\K1O^?R]_P# =?\ XJK>DF42
M74>GL7MPZGS;E2,';R HZ]N<_A7;@J;57=;=SDQ=1.GL]^QN>6@  1<+R/E'
M'TI/+0@@HF"<D;1S5;=J)!(BM5W' 4NQ\L>I./F^@Q]:4MJ )/EVS!> H<@R
M'U!_A'3@Y^M>OR^:^\\SF\BQL3).Q<D8)QU'I1L0%<(HV]..GTJL#J/ (M#@
M9+C=AO\ 9 [?[V3]*3.HD#Y+52Y[ECY0SW_OGZ;:.3S7WAS>19\N/;CRTQG.
M-HZ^M(40[LHIW=>.OUJN6U##,(K;T";SD_[6<=/]G&?>@F_#8VVS!1DD%AYG
ML!_#]3FER/NOO'S>1/L7(.U<@8!QT'I2>6@  1< Y VCBJ__ !,"%!%J"W);
MYB$_V<?Q'WR/I2%M0()$5L-QPJER=G^T3CYN_  ^M+D?=?>/F\OP+!C0@Y1>
M>3\HY^M(47.=JY(QG';TJ#-\"3LMV"\8#$&3W!_A^AS2?Z?PI^RYQN+C=@_[
M('_LV?PI<C[K[Q\WD_N)MB#&$7Y>G'3Z4TQIC&Q,9SC:.OK4.;X@?+;*7/<L
M?*&>_P#?X]-M(6OL,PCMSC@)O.6/][..!_LXS[U/(^Z^\:EY/[B8HA+$JI+=
M>.OUI-B@@A5R!@''05$?MH;'^CL%&2PW#S/8#^'ZG/TIO^FG:#]G4MR6^8A!
MZ8_B/OD?2IY'W7WE<Z[/[B0QH !L7 .0-HX-(40@Y1?FZ\=?K41-X06V0 DX
M5"Q.W_:)[_0 ?6@F[!/$#!.P)!D^G]S\<U+@^Z^\I379_</*+G.U<XQG';TI
MFQ!C"*-O3CI]*9_IGRJ3;YQEGPV/]T#U_P!K/X4T_:B,X@4L>A)/ECU/]_\
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M)L;;"T.<8_T5.<C</TYI#J&H+$TIL[$(N,G[,G>LY136K_\ )7_F7&33V_\
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M:MICZDD02X\DQDL"%R2<=,]AZCO6C13C)Q=T3**DK,IR:9:3! \0PBA5"D@
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M1]5]W_!-/^P-2_YX)_W^3_&C^P-2_P">"?\ ?Y/\:S,#T%&!Z"ES4OY7]_\
MP M4[K[O^":?]@:E_P \$_[_ "?XT?V!J7_/!/\ O\G^-9F!Z"C ]!1S4OY7
M]_\ P M4[K[O^":?]@:E_P \$_[_ "?XT?V!J7_/!/\ O\G^-9F!Z"C ]!1S
M4OY7]_\ P M4[K[O^":?]@:E_P \$_[_ "?XT?V!J7_/!/\ O\G^-9F!Z"C
M]!1S4OY7]_\ P M4[K[O^":?]@:E_P \$_[_ "?XT?V!J7_/!/\ O\G^-9F!
MZ"C ]!1S4OY7]_\ P M4[K[O^":?]@:E_P \$_[_ "?XUU_A2SGLM/FCN$"L
M9<@!@W&!Z5Y[@>@KN_!(QI<__7;_ -E%>EECIO$KE3V?7_@'!F"G[!W?5=/^
M"=-1117U1\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% ##YN>-GZTG[[_8_6N)NO#_B&ZN-4D=T$6I_*R).0T(1U\LCMG8#T
M[FF/H'BD[")H3);7,EVKM(0)WRH48'3*JV<\?/0!W/[[_8_6C]]_L?K7$7_A
MC5ITOXU^>!)%-C&)1G:\JR2@YXXQM&>U//AS49;NP86IAM(4"7$7GA3-DMAL
M+\OR9W#USCM0!V:M(Z[E,;#U!S2_OO\ 8_6N4;PU=V-_IG]GKO$$A=KB27"@
M$$%2@Y/4'CKWX J6X\.7-U+JMQ*%2ZFLQ#&]O(R"1R"6.,G&2%'T!]: .F_?
M?['ZT?OO]C]:991O#86\4O\ K$B56YSR!S4] $?[[_8_6C]]_L?K4E% %'4G
M,>EW;S >4L+E]GWL8.<9[UY<VL>',G*:KU](_P#&O3]<_P"0!J/_ %[2?^@F
MO$M/OK6U2X6XB\T2 8  YQGC)Z=1ZUZ.$RK"XV$IUX<S6BUL<U;'5\-)1I2L
MF;G]L>'/[FJ_E'_C1_;'AO\ NZK^4?\ C6;_ &O8!P6M_..YFW.BJ5!'"@#@
MX]Z>VL6&%54<HH'#1)EASE2<]#D<]@!77_JYEW_/A_>S+^V<9_S]_!%_^V/#
M9_@U7\H_\:/[9\-_W=5_*/\ QK..N6+SAI+"(HK@KC&0N&'/KR1QTXJ5M>L'
M0'[*$?S Q 16# $G&<^GKFE_JYE__/A_^!,/[9QG_/W\"[_;'AS^YJOY1_XT
M?VOX<_N:K^4?^-9QU?2BH_XE^,QF-E!7"[L;B/ICCZ]:Q-R_WA^=:0X:RV6]
M%KYLF6=8U;5+_)'6?VQX=_N:K^4?^-']L>'?[FK?E'_C7)[E_O#\Z-R_WA^=
M7_JQEG_/O\63_;>._G_!'6?VQX=_N:M^4?\ C1_;'AW^YJWY1_XUR>Y?[P_.
MC<O]X"C_ %8RS_GW^+#^V\=_/^".L_MCP[_=U7\H_P#&C^V?#G]W5?RC_P :
MSSJ^DNNPZ>54C;E2I8 *54@^I!Y'J,]:0:UIOVE9OL*H0P^4;2 O ;TSPJX]
MRU8_ZNY?_P ^']__  33^V,9_P _?P_X!H_VSX<_NZK^4?\ C1_;/AS^[JOY
M1_XUF#6[:%&,4"23;RP>5%P01C;C)..^<]?:HVU6U$\<T</[Q(2A8JH5CSC*
M],#(Y]NE/_5S+O\ GS^+%_;.,_Y^_@C7_MCP[_=U7\H_\:/[8\._W=5_*/\
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M]:A8CU%:K+:'9_>9O%U>YZ&?B)I8_P"76\_[Y7_XJFGXCZ6/^72]_P"^5_\
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M3_A%[[_GYTS_ ,#H_P#&C_A%[[_GYTS_ ,#H_P#&M+87LB/WWF+_ ,);K/\
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M2F#P;9XCS>79VGYN4^?Z_+Q^&*M8ZDNY+PTSB6JN]=VW@FR*,/MMX"6R&RG
M]/NTC>!]/9G/VJ\ 88 W)\I]1\O\ZT6845W(>%F>>OWJN]>C_P#"!Z:60FZO
M2%&&&Y/F]S\O\J8?A[IA0 WE]G=DG<G(]/NUJLSH+O\ =_P2'@ZGD>9.*J2
M>E>JM\.=*;?_ *5?#=]WYT^7_P =_G33\-='+9-S?8QC'F+U]?NUO'-L.N_W
M?\$AX&KY%WP$X?PI!BX:;#N#N&-G/W?H/ZUTM4M)TR+1]-BL8'=XX\X9P-QR
M<\X %7:^:K34ZDI+JV>M"/+%)] HHHK(L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBHGE*MC&?QH EHJ#S_\ 9_6CS_\ 9_6@">BH//\ ]G]://\
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M]!.7_OE?\* ,;\#^5'X'\JV?^$LU[_H)R_\ ?*_X4?\ "6:]_P!!.7_OE?\
M"@#&_ _E1^!_*MG_ (2S7O\ H)R_]\K_ (4?\)9KW_03E_[Y7_"@#&_ _E7J
M?PT_Y -S_P!?)_\ 05KA?^$LU[_H)R_]\K_A7H?@+4;S4M&N);V=II%G*AF
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M3PY9S%C/+<2[R&<,X&YL8SP!VXXX_&I[+1[:QEDE1I'DDC$3-(0<J  !P!T
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MX4?V#X?_ .?"Y_\  H_X5=\M_P"X_P#WR:/+?^X__?)H I?V#X?_ .?"Y_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &? G # 2(  A$! Q$!_\0
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M&#Y^9CAOE _A/-7]8\:3V&G0ZI8Z)+?::]HMXUR;F.$;"-V%5CEGVC...W-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110!\L:K\=/&]MK%[;Q75HL45Q(B#[*IP Q
MJI_POOQW_P _EG_X"K7 Z[_R,&I?]?4O_H9JA0!Z;_POOQW_ ,_EG_X"K1_P
MOOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE
M10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\
MX"K1_P +[\=_\_EG_P" JUYE10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X
M"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE10!Z;_POOQW_
M ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_
M\_EG_P" JUYE10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\
MPOOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE10!Z;_POOQW_ ,_EG_X"K1_P
MOOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE
M10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\
MX"K1_P +[\=_\_EG_P" JUYE10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X
M"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE10!Z;_POOQW_
M ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_
M\_EG_P" JUYE10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\
MPOOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE10!Z;_POOQW_ ,_EG_X"K1_P
MOOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\ X"K1_P +[\=_\_EG_P" JUYE
M10!Z;_POOQW_ ,_EG_X"K1_POOQW_P _EG_X"K7F5% 'IO\ POOQW_S^6?\
MX"K1_P +[\=_\_EG_P" JUYE2XHL!Z9_POOQW_S^6?\ X"K1_P +[\=_\_EG
M_P" JUYGBC%-)L#TS_A??CO_ )_+/_P%6C_A??CO_G\L_P#P%6O-0A-(4Q6G
MLIVO85STO_A??CO_ )_+/_P%6C_A??CO_G\L_P#P%6O,R*2LAGIO_"^_'?\
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MYW=@.3MXKHG"C0C&>)J*">UWN>?B,PHT)<DKM]DKGCJ0,_12?I3VLY47<8V
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M]2_^AFJ% !1110 4444 %%%% !1110 4444 %%%% !1110 4"BE%-;@ K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^R?A#_R2G0/^N+?^C&KXVK[)^$/_)*= _ZXM_Z,:@#MJ*** /@[
M6O\ D/:C_P!?4G_H1KJ/^$*T@7&FZ=)XC:'5=0MH)HHY;(B$-,H9$,@<D?>
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MX9 F[<\3%MP(^Y\H/'-<W\2&C/CF]2*5Y1#%;PEG8%MR0HK!B"1N!!!YZ@T
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M *^I/_0C5&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$#_ *%R7_P(B_\ BZ/^%-_$#_H7)?\ P(B_^+H X6BNZ_X4W\0/^A<E_P#
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M%R7_ ,"(O_BZ/^%-_$#_ *%R7_P(B_\ BZ .%HKNO^%-_$#_ *%R7_P(B_\
MBZ/^%-_$#_H7)?\ P(B_^+H X6BNZ_X4W\0/^A<E_P# B+_XNC_A3?Q _P"A
M<E_\"(O_ (N@#A:*[K_A3?Q _P"A<E_\"(O_ (NC_A3?Q _Z%R7_ ,"(O_BZ
M .%HKNO^%-_$#_H7)?\ P(B_^+H_X4W\0/\ H7)?_ B+_P"+H X6BNZ_X4W\
M0/\ H7)?_ B+_P"+H_X4W\0/^A<E_P# B+_XN@#A:*[K_A3?Q _Z%R7_ ,"(
MO_BZ/^%-_$#_ *%R7_P(B_\ BZ .%HKNO^%-_$#_ *%R7_P(B_\ BZ/^%-_$
M#_H7)?\ P(B_^+H X6BNZ_X4W\0/^A<E_P# B+_XNC_A3?Q _P"A<E_\"(O_
M (N@#A:*[K_A3?Q _P"A<E_\"(O_ (NC_A3?Q _Z%R7_ ,"(O_BZ .%HKNO^
M%-_$#_H7)?\ P(B_^+H_X4W\0/\ H7)?_ B+_P"+H X6BNZ_X4W\0/\ H7)?
M_ B+_P"+H_X4W\0/^A<E_P# B+_XN@#A:*[K_A3?Q _Z%R7_ ,"(O_BZ/^%-
M_$#_ *%R7_P(B_\ BZ .%HKNO^%-_$#_ *%R7_P(B_\ BZ/^%-_$#_H7)?\
MP(B_^+H X6BNZ_X4W\0/^A<E_P# B+_XNC_A3?Q _P"A<E_\"(O_ (N@#A:*
M[K_A3?Q _P"A<E_\"(O_ (NC_A3?Q _Z%R7_ ,"(O_BZ .%HKNO^%-_$#_H7
M)?\ P(B_^+H_X4W\0/\ H7)?_ B+_P"+H X6BNZ_X4W\0/\ H7)?_ B+_P"+
MH_X4W\0/^A<E_P# B+_XN@#A:*[K_A3?Q _Z%R7_ ,"(O_BZ/^%-_$#_ *%R
M7_P(B_\ BZ .%HKNO^%-_$#_ *%R7_P(B_\ BZ/^%-_$#_H7)?\ P(B_^+H
MX6BNZ_X4W\0/^A<E_P# B+_XNC_A3?Q _P"A<E_\"(O_ (N@#A:*[K_A3?Q
M_P"A<E_\"(O_ (NC_A3?Q _Z%R7_ ,"(O_BZ .%HKNO^%-_$#_H7)?\ P(B_
M^+H_X4W\0/\ H7)?_ B+_P"+H X6BNZ_X4W\0/\ H7)?_ B+_P"+H_X4W\0/
M^A<E_P# B+_XN@#A:*[K_A3?Q _Z%R7_ ,"(O_BZ/^%-_$#_ *%R7_P(B_\
MBZ .%K[)^$/_ "2G0/\ KBW_ *,:OG#_ (4W\0/^A<E_\"(O_BZ^G/AQI%]H
M7P]T?3-2A\B\@B(ECW!MI+L<9''0B@#J:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4?RJ2HT_ULGU'\JDH **** "BBB@"-_];'^-25&_^MC_ !J2@ HHHH ****
M(YO]4?J/YU)4<W^J/U'\ZDH **** "BBB@ J.'_4K4E1P_ZE: )**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC?\ P"ZU*-.;CS7MV)GFBC^_(B_[S 5$;^T'_+S$?HP-.6TMD^[;Q#Z(*E
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M*V,.GZCKD/\ 9WV:=[Z242"WVK)$V"N' P>_&>#FNGH **** "BBB@ HHHH
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M8A8RJ(W7T^<\GTK&_P"$WO8K74V"6EY);627<$D<4L,;[G*[?GZCH0R\<]*
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MW3;O(QDYR<#L,G@=A@5H44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5P'BJ_M[+Q;)&UWHT<USI@B9-98I$8R[9V$'G)^\I SA.:[^N \77U
MZWB6W@M'O[F&%4\R#2VC>1,[PYD4G<.#&5)^7.<T =?H=NEIH&GV\5W]KCBM
MT1;C.?- 48;//!^M:%4=&6]31+%=2V_;A @GVXQOP,]..OIQ5Z@ K#A\(:%
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M44 1O_K8_P :DJ-_];'^-24 %%%% !1110!'-_JC]1_.I*CF_P!4?J/YU)0
M4444 %%%% !4</\ J5J2HX?]2M $E%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO#=E)(YPT#(\;[3&8=VS;Z<.RD=P2*Q_#OA&]TO7HKZZFB6"UMY;>W@AGD=
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaOCWcPtxJFzeZkhv2p1fUmqXyouDpSoQicJf0t2oUgJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:avxl="http://anavex.com/20240331" elementFormDefault="qualified" targetNamespace="http://anavex.com/20240331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimBalanceSheets" id="InterimBalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Interim Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" id="InterimBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" id="InterimStatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" id="InterimStatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" id="InterimStatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BusinessDescription" id="BusinessDescription">
          <link:definition>995512 - Disclosure - Business Description</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>995513 - Disclosure - Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
          <link:definition>995514 - Disclosure - Other Income</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>995515 - Disclosure - Accrued Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferings" id="EquityOfferings">
          <link:definition>995516 - Disclosure - Equity Offerings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995517 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentationPolicies" id="BasisOfPresentationPolicies">
          <link:definition>995518 - Disclosure - Basis of Presentation (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>995519 - Disclosure - Accrued Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>995520 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>995521 - Disclosure - Basis of Presentation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
          <link:definition>995522 - Disclosure - Other Income (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" id="AccruedLiabilitiesDetails">
          <link:definition>995523 - Disclosure - Accrued liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
          <link:definition>995524 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
          <link:definition>995525 - Disclosure - Commitments and Contingencies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
          <link:definition>995526 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
          <link:definition>995527 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
          <link:definition>995528 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
          <link:definition>995529 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" id="CommitmentsAndContingenciesDetails5">
          <link:definition>995530 - Disclosure - Commitments and Contingencies (Details 5)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" id="CommitmentsAndContingenciesDetails6">
          <link:definition>995531 - Disclosure - Commitments and Contingencies (Details 6)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>995532 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="avxl-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="avxl_ShareProceedsReceivableMember" name="ShareProceedsReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MichaelJFoxMember" name="MichaelJFoxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AnavexMember" name="AnavexMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement2023Member" name="PurchaseAgreement2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ThirdPartyMember" name="ThirdPartyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2022Member" name="StockOptionPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice1Member" name="OptionPrice1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice2Member" name="OptionPrice2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice3Member" name="OptionPrice3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice4Member" name="OptionPrice4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionPrice5Member" name="OptionPrice5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareProceedsReceivable" name="ShareProceedsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrants" name="NonOperatingIncomeFromGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherFinancingExpense" name="OtherFinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedUnder2023PurchaseAgreement" name="SharesIssuedUnder2023PurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentShares" name="InitialCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_InitialCommitmentSharesShares" name="InitialCommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesValue" name="CommitmentSharesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesShares" name="CommitmentSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptions" name="SharesIssuedPursuantToExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" name="SharesIssuedPursuantToExerciseOfStockOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NoncashFinancingRelatedCharges" name="NoncashFinancingRelatedCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncreaseDecreaseInDeferredGrantIncome" name="IncreaseDecreaseInDeferredGrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" name="CashPaidForStateAndLocalMinimumIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LliquidityPolicyTextBlock" name="LliquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredGrantIncome" name="DeferredGrantIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncentiveAndTaxReceivables" name="IncentiveAndTaxReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AccruedClinicalSiteAndPatientVisitsCosts" name="AccruedClinicalSiteAndPatientVisitsCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FixedContractAccruals" name="FixedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MilestoneBasedContractAccruals" name="MilestoneBasedContractAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesOfAgreementAmount" name="SalesOfAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FairValueOfInitialCommitment" name="FairValueOfInitialCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncurredExpenses" name="IncurredExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_WarrantsOutstandingWeightedAverageExercise" name="WarrantsOutstandingWeightedAverageExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionIssued" name="OptionIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheets" xlink:href="avxl-20240331.xsd#InterimBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:href="avxl-20240331.xsd#InterimBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20240331.xsd#InterimStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20240331.xsd#InterimStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:href="avxl-20240331.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20240331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20240331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20240331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20240331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20240331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20240331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20240331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20240331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20240331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20240331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20240331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Interim Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareProceedsReceivable" xlink:label="loc_avxlShareProceedsReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_avxlShareProceedsReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="995512 - Disclosure - Business Description" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="995513 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="995514 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="995515 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="995516 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="995517 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="995518 - Disclosure - Basis of Presentation (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="995519 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="995520 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="995521 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="995522 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="995523 - Disclosure - Accrued liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="995524 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="995525 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995526 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="995527 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="995528 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="995529 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="995530 - Disclosure - Commitments and Contingencies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:title="995531 - Disclosure - Commitments and Contingencies (Details 6)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995532 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheets" xlink:href="avxl-20240331.xsd#InterimBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:href="avxl-20240331.xsd#InterimBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20240331.xsd#InterimStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20240331.xsd#InterimStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:href="avxl-20240331.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20240331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20240331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20240331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20240331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20240331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20240331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20240331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20240331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20240331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20240331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20240331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Interim Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlShareProceedsReceivableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CommitmentSharesValue" xlink:label="loc_avxlCommitmentSharesValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesValue_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="995512 - Disclosure - Business Description" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="995513 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="995514 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="995515 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="995516 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="995517 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="995518 - Disclosure - Basis of Presentation (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="995519 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="995520 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="995521 - Disclosure - Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="995522 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD" xlink:label="loc_currencyAUD_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncentiveAndTaxReceivables" xlink:label="loc_avxlIncentiveAndTaxReceivables_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlIncentiveAndTaxReceivables_160" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="995523 - Disclosure - Accrued liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="995524 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ThirdPartyMember" xlink:label="loc_avxlThirdPartyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_avxlThirdPartyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1_140" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="995525 - Disclosure - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995526 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="995527 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="995528 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="995529 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="995530 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:title="995531 - Disclosure - Commitments and Contingencies (Details 6)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995532 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_140" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="avxl_ShareProceedsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareProceedsReceivableMember" xlink:to="avxl_ShareProceedsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareProceedsReceivableMember_lbl" xml:lang="en-US">Share Proceeds Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_MichaelJFoxMember" xlink:label="avxl_MichaelJFoxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxMember" xlink:to="avxl_MichaelJFoxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxMember_lbl" xml:lang="en-US">Michael J Fox [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_AnavexMember" xlink:label="avxl_AnavexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AnavexMember" xlink:to="avxl_AnavexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AnavexMember_lbl" xml:lang="en-US">Anavex [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald And Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseAgreement2023Member" xlink:label="avxl_PurchaseAgreement2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement2023Member" xlink:to="avxl_PurchaseAgreement2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement2023Member_lbl" xml:lang="en-US">Purchase Agreement 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">Purchase Agreement 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ThirdPartyMember" xlink:label="avxl_ThirdPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ThirdPartyMember" xlink:to="avxl_ThirdPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ThirdPartyMember_lbl" xml:lang="en-US">Third Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">Stock Option Plan 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">Stock Option Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2022Member" xlink:label="avxl_StockOptionPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2022Member" xlink:to="avxl_StockOptionPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2022Member_lbl" xml:lang="en-US">Stock Option Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice1Member" xlink:label="avxl_OptionPrice1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice1Member" xlink:to="avxl_OptionPrice1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice1Member_lbl" xml:lang="en-US">Option Price 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice2Member" xlink:label="avxl_OptionPrice2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice2Member" xlink:to="avxl_OptionPrice2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice2Member_lbl" xml:lang="en-US">Option Price 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice3Member" xlink:label="avxl_OptionPrice3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice3Member" xlink:to="avxl_OptionPrice3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice3Member_lbl" xml:lang="en-US">Option Price 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice4Member" xlink:label="avxl_OptionPrice4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice4Member" xlink:to="avxl_OptionPrice4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice4Member_lbl" xml:lang="en-US">Option Price 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice5Member" xlink:label="avxl_OptionPrice5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionPrice5Member" xlink:to="avxl_OptionPrice5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionPrice5Member_lbl" xml:lang="en-US">Option Price 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities - Note 4</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred grant income - Note 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 6</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareProceedsReceivable" xlink:label="avxl_ShareProceedsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareProceedsReceivable" xlink:to="avxl_ShareProceedsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareProceedsReceivable_lbl" xml:lang="en-US">Share proceeds receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="avxl_NonOperatingIncomeFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrants" xlink:to="avxl_NonOperatingIncomeFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrants_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OtherFinancingExpense" xlink:label="avxl_OtherFinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avxl_OtherFinancingExpense_lbl" xml:lang="en-US">Other financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss per share, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss per share, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:to="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedUnder2023PurchaseAgreement_lbl" xml:lang="en-US">Shares issued under 2023 Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_InitialCommitmentShares" xlink:label="avxl_InitialCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentShares" xlink:to="avxl_InitialCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentShares_lbl" xml:lang="en-US">Initial commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_InitialCommitmentSharesShares" xlink:label="avxl_InitialCommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_InitialCommitmentSharesShares" xlink:to="avxl_InitialCommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_InitialCommitmentSharesShares_lbl" xml:lang="en-US">Initial commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CommitmentSharesValue" xlink:label="avxl_CommitmentSharesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesValue" xlink:to="avxl_CommitmentSharesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesValue_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CommitmentSharesShares" xlink:label="avxl_CommitmentSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesShares" xlink:to="avxl_CommitmentSharesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesShares_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptions_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:to="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares_lbl" xml:lang="en-US">Shares issued pursuant to exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="avxl_NoncashFinancingRelatedCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NoncashFinancingRelatedCharges" xlink:to="avxl_NoncashFinancingRelatedCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NoncashFinancingRelatedCharges_lbl" xml:lang="en-US">Non-cash financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:to="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncreaseDecreaseInDeferredGrantIncome_lbl" xml:lang="en-US">Deferred grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:to="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashPaidForStateAndLocalMinimumIncomeTaxes_lbl" xml:lang="en-US">Cash paid for state and local minimum income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Award Underlying Securities Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Award Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Award Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="avxl_LliquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LliquidityPolicyTextBlock" xlink:to="avxl_LliquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LliquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:to="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of contribution plan</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summarized information about stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_DeferredGrantIncome" xlink:label="avxl_DeferredGrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredGrantIncome" xlink:to="avxl_DeferredGrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredGrantIncome_lbl" xml:lang="en-US">Grant income, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncentiveAndTaxReceivables" xlink:label="avxl_IncentiveAndTaxReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncentiveAndTaxReceivables" xlink:to="avxl_IncentiveAndTaxReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_IncentiveAndTaxReceivables_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:to="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AccruedClinicalSiteAndPatientVisitsCosts_lbl" xml:lang="en-US">Accrued clinical site and patient visits costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_FixedContractAccruals" xlink:label="avxl_FixedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FixedContractAccruals" xlink:to="avxl_FixedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FixedContractAccruals_lbl" xml:lang="en-US">Fixed contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="avxl_MilestoneBasedContractAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MilestoneBasedContractAccruals" xlink:to="avxl_MilestoneBasedContractAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MilestoneBasedContractAccruals_lbl" xml:lang="en-US">Milestone based contract accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">All other accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SalesOfAgreementAmount" xlink:label="avxl_SalesOfAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesOfAgreementAmount" xlink:to="avxl_SalesOfAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesOfAgreementAmount_lbl" xml:lang="en-US">Sales of agreement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued for initial commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="avxl_FairValueOfInitialCommitment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FairValueOfInitialCommitment" xlink:to="avxl_FairValueOfInitialCommitment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FairValueOfInitialCommitment_lbl" xml:lang="en-US">Fair value of the initial commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncurredExpenses" xlink:label="avxl_IncurredExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncurredExpenses" xlink:to="avxl_IncurredExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncurredExpenses_lbl" xml:lang="en-US">Incurred expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionContributions" xlink:label="us-gaap_PensionContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding at Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value at Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, lower range limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of exercise prices, upper range limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of outstanding options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of vested options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_WarrantsOutstandingWeightedAverageExercise" xlink:to="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_WarrantsOutstandingWeightedAverageExercise_lbl" xml:lang="en-US">Warrants outstanding weighted average exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionIssued" xlink:label="avxl_OptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionIssued" xlink:to="avxl_OptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionIssued_lbl" xml:lang="en-US">Option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Option available issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of options vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average contractual life of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherFinancingExpense" xlink:to="avxl_OtherFinancingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherFinancingExpense_2_lbl" xml:lang="en-US">OtherFinancingExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_2_lbl" xml:lang="en-US">NonOperatingIncomeFromGrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncentiveAndTaxReceivables" xlink:to="avxl_IncentiveAndTaxReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncentiveAndTaxReceivables_2_lbl" xml:lang="en-US">IncentiveAndTaxReceivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20240331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheets" xlink:href="avxl-20240331.xsd#InterimBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:href="avxl-20240331.xsd#InterimBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:href="avxl-20240331.xsd#InterimStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:href="avxl-20240331.xsd#InterimStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:href="avxl-20240331.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescription" xlink:href="avxl-20240331.xsd#BusinessDescription" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentation" xlink:href="avxl-20240331.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20240331.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilities" xlink:href="avxl-20240331.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferings" xlink:href="avxl-20240331.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationPolicies" xlink:href="avxl-20240331.xsd#BasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesTables" xlink:href="avxl-20240331.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:href="avxl-20240331.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20240331.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:href="avxl-20240331.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:href="avxl-20240331.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Interim Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareProceedsReceivable" xlink:label="loc_avxlShareProceedsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_avxlShareProceedsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NonOperatingIncomeFromGrants" xlink:label="loc_avxlNonOperatingIncomeFromGrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OtherFinancingExpense" xlink:label="loc_avxlOtherFinancingExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlOtherFinancingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareProceedsReceivableMember" xlink:label="loc_avxlShareProceedsReceivableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlShareProceedsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedUnder2023PurchaseAgreement" xlink:label="loc_avxlSharesIssuedUnder2023PurchaseAgreement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedUnder2023PurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_InitialCommitmentShares" xlink:label="loc_avxlInitialCommitmentShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_InitialCommitmentSharesShares" xlink:label="loc_avxlInitialCommitmentSharesShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlInitialCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CommitmentSharesValue" xlink:label="loc_avxlCommitmentSharesValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CommitmentSharesShares" xlink:label="loc_avxlCommitmentSharesShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptions" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:label="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToExerciseOfStockOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimStatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NoncashFinancingRelatedCharges" xlink:label="loc_avxlNoncashFinancingRelatedCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_avxlNoncashFinancingRelatedCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncreaseDecreaseInDeferredGrantIncome" xlink:label="loc_avxlIncreaseDecreaseInDeferredGrantIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_avxlIncreaseDecreaseInDeferredGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CashPaidForStateAndLocalMinimumIncomeTaxes" xlink:label="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_avxlCashPaidForStateAndLocalMinimumIncomeTaxes" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescription" xlink:title="995512 - Disclosure - Business Description">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentation" xlink:title="995513 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="995514 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilities" xlink:title="995515 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferings" xlink:title="995516 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="995517 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationPolicies" xlink:title="995518 - Disclosure - Basis of Presentation (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_LliquidityPolicyTextBlock" xlink:label="loc_avxlLliquidityPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlLliquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesTables" xlink:title="995519 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="995520 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosuresTableTextBlock" xlink:label="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanDisclosuresTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BasisOfPresentationDetailsNarrative" xlink:title="995521 - Disclosure - Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="995522 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_MichaelJFoxMember" xlink:label="loc_avxlMichaelJFoxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_AnavexMember" xlink:label="loc_avxlAnavexMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlAnavexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_DeferredGrantIncome" xlink:label="loc_avxlDeferredGrantIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlDeferredGrantIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncentiveAndTaxReceivables" xlink:label="loc_avxlIncentiveAndTaxReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlIncentiveAndTaxReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/AccruedLiabilitiesDetails" xlink:title="995523 - Disclosure - Accrued liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_AccruedClinicalSiteAndPatientVisitsCosts" xlink:label="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlAccruedClinicalSiteAndPatientVisitsCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_FixedContractAccruals" xlink:label="loc_avxlFixedContractAccruals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlFixedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_MilestoneBasedContractAccruals" xlink:label="loc_avxlMilestoneBasedContractAccruals" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_avxlMilestoneBasedContractAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingsDetailsNarrative" xlink:title="995524 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseAgreement2023Member" xlink:label="loc_avxlPurchaseAgreement2023Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesAxis" xlink:to="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ThirdPartyMember" xlink:label="loc_avxlThirdPartyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationRevenueSourcesDomain" xlink:to="loc_avxlThirdPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_SalesOfAgreementAmount" xlink:label="loc_avxlSalesOfAgreementAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlSalesOfAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_FairValueOfInitialCommitment" xlink:label="loc_avxlFairValueOfInitialCommitment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlFairValueOfInitialCommitment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_IncurredExpenses" xlink:label="loc_avxlIncurredExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlIncurredExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="995525 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="995526 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionContributions" xlink:label="loc_us-gaapPensionContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapPensionContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="995527 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="995528 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="995529 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice1Member" xlink:label="loc_avxlOptionPrice1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice2Member" xlink:label="loc_avxlOptionPrice2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice3Member" xlink:label="loc_avxlOptionPrice3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice4Member" xlink:label="loc_avxlOptionPrice4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionPrice5Member" xlink:label="loc_avxlOptionPrice5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_avxlOptionPrice5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails5" xlink:title="995530 - Disclosure - Commitments and Contingencies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails6" xlink:title="995531 - Disclosure - Commitments and Contingencies (Details 6)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995532 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_StockOptionPlan2022Member" xlink:label="loc_avxlStockOptionPlan2022Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_WarrantsOutstandingWeightedAverageExercise" xlink:label="loc_avxlWarrantsOutstandingWeightedAverageExercise" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlWarrantsOutstandingWeightedAverageExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20240331.xsd#avxl_OptionIssued" xlink:label="loc_avxlOptionIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860722975952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">630 5th Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">20th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,641,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860810579344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 139,386<span></span>
</td>
<td class="nump">$ 151,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">144,516<span></span>
</td>
<td class="nump">154,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,726<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities - Note 4</a></td>
<td class="nump">4,915<span></span>
</td>
<td class="nump">7,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred grant income - Note 3</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">9,558<span></span>
</td>
<td class="nump">12,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">447,345<span></span>
</td>
<td class="nump">434,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareProceedsReceivable', window );">Share proceeds receivable</a></td>
<td class="num">(234)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(312,237)<span></span>
</td>
<td class="num">(293,069)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">134,958<span></span>
</td>
<td class="nump">141,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 144,516<span></span>
</td>
<td class="nump">$ 154,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareProceedsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareProceedsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860816316880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">83,616,218<span></span>
</td>
<td class="nump">82,066,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">83,616,218<span></span>
</td>
<td class="nump">82,066,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860718719120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,790<span></span>
</td>
<td class="nump">$ 2,883<span></span>
</td>
<td class="nump">$ 5,399<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,729<span></span>
</td>
<td class="nump">11,307<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
<td class="nump">23,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,519<span></span>
</td>
<td class="nump">14,190<span></span>
</td>
<td class="nump">23,812<span></span>
</td>
<td class="nump">29,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(12,519)<span></span>
</td>
<td class="num">(14,190)<span></span>
</td>
<td class="num">(23,812)<span></span>
</td>
<td class="num">(29,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrants', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">3,764<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherFinancingExpense', window );">Other financing expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(964)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">4,835<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(10,441)<span></span>
</td>
<td class="num">(13,057)<span></span>
</td>
<td class="num">(18,977)<span></span>
</td>
<td class="num">(26,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (10,546)<span></span>
</td>
<td class="num">$ (13,107)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (26,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share, Basic</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share, Diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, Basic</a></td>
<td class="nump">82,464,226<span></span>
</td>
<td class="nump">78,304,363<span></span>
</td>
<td class="nump">82,269,965<span></span>
</td>
<td class="nump">78,138,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, Diluted</a></td>
<td class="nump">82,464,226<span></span>
</td>
<td class="nump">78,304,363<span></span>
</td>
<td class="nump">82,269,965<span></span>
</td>
<td class="nump">78,138,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherFinancingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherFinancingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860717009984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Share Proceeds Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 387,977<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (245,564)<span></span>
</td>
<td class="nump">$ 142,491<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2022</a></td>
<td class="nump">77,942,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">Initial commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">18,151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares, shares</a></td>
<td class="nump">2,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesValue', window );">Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">133,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,317<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,079)<span></span>
</td>
<td class="num">(26,079)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">416,728<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(271,643)<span></span>
</td>
<td class="nump">145,165<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">393,582<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(258,536)<span></span>
</td>
<td class="nump">135,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">78,032,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentShares', window );">Initial commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_InitialCommitmentSharesShares', window );">Initial commitment shares, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">18,151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares, shares</a></td>
<td class="nump">2,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesValue', window );">Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">44,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,970<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,107)<span></span>
</td>
<td class="num">(13,107)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2023</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">416,728<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(271,643)<span></span>
</td>
<td class="nump">145,165<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">80,235,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">434,839<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(293,069)<span></span>
</td>
<td class="nump">141,852<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Sep. 30, 2023</a></td>
<td class="nump">82,066,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares, shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesValue', window );">Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,938<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
<td class="num">(19,168)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">447,345<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(312,237)<span></span>
</td>
<td class="nump">134,958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="nump">83,616,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2023</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">437,184<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(301,691)<span></span>
</td>
<td class="nump">135,575<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="nump">82,086,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase shares, shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesValue', window );">Commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CommitmentSharesShares', window );">Commitment shares, shares</a></td>
<td class="nump">3,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions', window );">Shares issued pursuant to exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares', window );">Shares issued pursuant to exercise of stock options, shares</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,652<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,546)<span></span>
</td>
<td class="num">(10,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 447,345<span></span>
</td>
<td class="num">$ (234)<span></span>
</td>
<td class="num">$ (312,237)<span></span>
</td>
<td class="nump">$ 134,958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="nump">83,616,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_InitialCommitmentSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_InitialCommitmentSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860810677504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (26,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NoncashFinancingRelatedCharges', window );">Non-cash financing related charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,938<span></span>
</td>
<td class="nump">9,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(1,076)<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(596)<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(2,380)<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncreaseDecreaseInDeferredGrantIncome', window );">Deferred grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,974)<span></span>
</td>
<td class="num">(14,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">7,178<span></span>
</td>
<td class="nump">18,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,336<span></span>
</td>
<td class="nump">18,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents during the period</a></td>
<td class="num">(11,638)<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">151,024<span></span>
</td>
<td class="nump">149,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">139,386<span></span>
</td>
<td class="nump">153,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes', window );">Cash paid for state and local minimum income taxes</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashPaidForStateAndLocalMinimumIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashPaidForStateAndLocalMinimumIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncreaseDecreaseInDeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncreaseDecreaseInDeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NoncashFinancingRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NoncashFinancingRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860816426864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (10,546)<span></span>
</td>
<td class="num">$ (13,107)<span></span>
</td>
<td class="num">$ (19,168)<span></span>
</td>
<td class="num">$ (26,079)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860724876048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860719977952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description</a></td>
<td class="text"><p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zVquyOVOCMle" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>Note 1 <span id="xdx_827_zKA3th0VVxZe">Business Description</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. (&#8220;Anavex&#8221; or
the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860724441664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BasisOfAccounting_zV3AqSQEUKT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 <span id="xdx_82F_zgsJzL5IulI5">Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zknPsUIJItp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_866_zbqgpltKOaMa">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2023 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023 filed with the SEC on November 27, 2023.
The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the six months ended March 31,
2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_ecustom--LliquidityPolicyTextBlock_zFI9bTi0SREa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zJ6zC46Uj13i">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--UseOfEstimates_zfYWLHu7rmYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_867_zGiShBljRHFi">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zM8b8w3vfKTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zWNRr0rCht8a">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGfnrupflT7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_86E_zmgNY1Eiqs2e">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024 and September 30, 2023, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_z9PrflCYqYf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_86A_zVkpoaKUryQa">Basic
and Diluted Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240331_zmV3jqXp2BU8" title="Loss per share for potentially dilutive common shares">15,755,114</span>
(March 31, 2023: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_zMzVmxJcFosj" title="Loss per share for potentially dilutive common shares">15,001,613</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3VLPMGUVod6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_861_zOOQVnB9Xcnf">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable
Segment Disclosures.&#8221; This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30,
2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860818410496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_80F_ecustom--OtherIncomeDisclosureTextBlock_zvmiBt2Zlx2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 3 <span id="xdx_821_z4Y8u21B1Jze">Other Income</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Grant Income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of March 31, 2024, the
Company had received a $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn6n6_c20231001__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_zsmz6Bl0U3oi" title="Research and development incentive income">1</span>.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#8217;s Research. The grant
will be used to fund a clinical trial of the Company&#8217;s lead compound, ANAVEX<sup>&#174;</sup>2-73 related to Parkinson&#8217;s disease.
Of the total, $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__dei--LegalEntityAxis__custom--AnavexMember_zRZcbkW30ybd" title="Research and development incentive income">0.5</span> million was received during the year ended September 30, 2023 and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_zKF1xeSKuROa" title="Research and development incentive income">0.5</span> million was received during the year ended September
30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2024, the Company recognized $<span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20240101__20240331_zm0vCSbixRlb" title="Grant income">0</span> and $<span id="xdx_90C_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230101__20230331_zilKPRJs5am2" title="Grant income">0</span>, respectively (2023: $<span id="xdx_903_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20231001__20240331_zj4ml7dPpc14" title="Grant income">0</span> and $<span id="xdx_90F_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20230331_zNxL1TSSSlTf" title="Grant income">25,000</span>, respectively) of
this grant on its statements of operations as grant income. At March 31, 2024, an amount of $<span id="xdx_90F_ecustom--DeferredGrantIncome_iI_pn5n6_c20240331_zS9bCKblcLnd" title="Grant income, amount">0.9</span> million (September 30, 2023: $<span id="xdx_900_ecustom--DeferredGrantIncome_iI_pn5n6_c20230930_zWmqrVziV2Fl" title="Grant income, amount">0.9</span> million)
of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been recognized to other income.
The Company will recognize this income on its statement of operations as the relating expenditures are incurred to offset the income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Research and development
incentive income</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#8217;s annual income tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the three and six
months ended March 31, 2024 the Company recorded research and development incentive income of $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331_zsebmwizv1O9" title="Research and development incentive income">0.5</span> million (AUD <span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331__srt--CurrencyAxis__currency--AUD_zJZVATdDd8K8" title="Research and development incentive income">0.7</span> million) and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331_zjbVDKCe0PG7" title="Research and development incentive income">1.1</span>
million (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331__srt--CurrencyAxis__currency--AUD_zEk8YwYeUUT6" title="Research and development incentive income">1.6</span> million), respectively (2023: $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20230101__20230331_zWbCpJDkCst7" title="Research and development incentive income">0.7</span> million (AUD <span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20230101__20230331__srt--CurrencyAxis__currency--AUD_zDKAtpjC7tWg" title="Research and development incentive income">1.1</span> million) and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230331_zYeKdO54Nf54" title="Research and development incentive income">1.5</span> million (AUD <span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230331__srt--CurrencyAxis__currency--AUD_zfKLNjxF0Alk" title="Research and development incentive income">2.2</span> million), respectively) in respect
of the Australia R&amp;D credit for eligible research and development expenses incurred during the period. This amount is included within
Other income on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At March 31, 2024, Incentive
and tax receivables includes $<span id="xdx_900_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20240331_z0d5HKF0mQLj" title="Incentive and tax receivables">3.6</span> million (AUD <span id="xdx_905_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20240331__srt--CurrencyAxis__currency--AUD_z0z1LyJnfe3c" title="Incentive and tax receivables">5.6</span> million) (September 30, 2023: $<span id="xdx_902_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20230930_zocYaQ40iKN9" title="Incentive and tax receivables">2.5</span> million (AUD <span id="xdx_903_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20230930__srt--CurrencyAxis__currency--AUD_z7eQB3U7epX3" title="Incentive and tax receivables">3.9</span> million)) relating to Australia
R&amp;D credits earned during the year that are expected to be reimbursed upon filing of the Company&#8217;s annual claim under this program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Australia R&amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;D activities are eligible and (iii) if the individual R&amp;D expenditures have nexus to such R&amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the Australian Tax Office
(ATO) has the right to review the Company&#8217;s qualifying programs and related expenditures for a period of four years. If such a review
were to occur, the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#8217;s
assessments and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#8217; claims
already received. Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO
could also assess penalties and interest on such adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Currently, the Company&#8217;s
tax incentive claims from 2020 to 2023 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860720127264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z25cOZabHba5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 4 <span id="xdx_82F_zNErAYmm0mE9">Accrued Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The principal components of accrued liabilities consist of (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zSGkyYREISz3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_znUspmfuqmK8" style="display: none">Schedule of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240331_zH4vQ2fKHKya" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20230930_z5BB6nvxccth" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40B_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_zZZ4U4JI5Dq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,209</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,006</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_zwgKvz2P2Wn" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,360</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_d0_zDUEVfdSER3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--MilestoneBasedContractAccruals_iI_zvpBTkrgDnRl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_z6cK2UgVFNlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,531</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_zv6wgtlCC3b5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,915</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,295</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860818410496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5CX69JGah6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 5 <span id="xdx_82A_zniqpAzbEhib">Equity Offerings</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#8220;Board&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Board&#160;has the authority to
issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sales Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company may offer and sell shares of common stock
(&#8220;Shares&#8221;) registered under an effective registration statement from time to time through the Sales Agents (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon delivery of a placement notice based on the Company&#8217;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#8220;at the market&#8221; offering, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written
consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents
may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales Agents will act
as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and
federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has agreed to pay the Sales Agents commissions
for their services of up to <span id="xdx_902_ecustom--PercentageOfGrossProceedsFromSales_pip0_dp_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zj0WvIOGuUH" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31, 2024 and 2023,
<span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pip0_do_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zf8fqSiXeIgh" title="Number of common stock sold"><span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pip0_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zJjHSi1hAHQc" title="Number of common stock sold">no</span></span> shares were sold pursuant to the Offering. At March 31, 2024, an amount of $<span id="xdx_90D_ecustom--SalesOfAgreementAmount_iI_pn5n6_c20240331_z5CDZKyLNVb3" title="Sales of agreement amount">142.4</span> million (September 30, 2023: $<span id="xdx_90F_ecustom--SalesOfAgreementAmount_iI_pn5n6_c20230930_zzwlZekMwnB7" title="Sales of agreement amount">142.4</span> million) was
registered pursuant to an effective registration statement. The Company currently is unable to sell shares of common stock under the Sales
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2023 Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0
<span id="xdx_900_ecustom--ValueOfSharesObligatedToPurchase_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zm8Wb6FXHw0b" style="display: none" title="Obligated to purchase">150,000,000</span> million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsFctYHz57Oj" title="Share issued for offering, shares">75,000</span> shares of common stock as a commitment fee (the &#8220;initial commitment shares&#8221;)
and agreed to issue up to an additional <span id="xdx_90C_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zRJ3av2M90ae" title="Pro rata basic number of shares obligated to purchase">75,000</span> shares pro rata, when and if, Lincoln Park purchased, at the Company&#8217;s discretion,
the $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgw04c5tAbig" title="Proceeds from Issuance or sale of equity">150</span>.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $<span id="xdx_90F_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230203_z9NL5K1Nnqbg" title="Fair value of the initial commitment">0.8</span> million with
reference to the closing price of the Company&#8217;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $<span id="xdx_901_ecustom--IncurredExpenses_iI_pn5n6_c20230203__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--ThirdPartyMember_zWlzfXwTrJGl" title="Incurred expenses">0.1</span> million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended March 31, 2024, the
Company issued to Lincoln Park an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zur39g0wxaI7" title="Share issued for aggregate, shares">1,503,707</span>
shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_pip0_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zZ4kEPrn6j2h" title="Shares issued under Sales Agreement, net of shares issue costs, shares">1,500,000</span>
shares of common stock for an aggregate purchase price of $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLpsrPXdc0n9" title="Number of shares issued for aggregate purchase price, value">7.4</span>
million and <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8qptIcZR6A1" title="Number of shares issued for commitment">3,707</span>
commitment shares. During the six months ended March 31, 2023, the Company issued to Lincoln Park an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_ztWKjRFDF5O" title="Share issued for aggregate, shares">2,159,080</span>
shares of common stock under the 2023 Purchase Agreement, including <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zeubRkKj97Jb" title="Shares issued under Sales Agreement, net of shares issue costs, shares">2,075,000</span>
shares of common stock for an aggregate purchase price of $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsT072V4HN1e" title="Number of shares issued for aggregate purchase price, value">18.2</span>
million, and <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zox0kdhE8In5" title="Number of shares issued for commitment">9,080</span>
commitment shares and the <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBGq1od83j7j" title="Number of shares issued for initial commitment shares">75,000</span>
initial commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024, an amount of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsfm5ireHVoc" title="Amount of shares remain available">114.7</span> million remained
available under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860720128576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMQ2X78MFb9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Note 6 <span id="xdx_826_zg5Tma7oaSq5">Commitments and Contingencies</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Leases
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i style="font-style: normal; font-weight: normal">The
Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease,
the Company is required to pay its proportionate share of operating costs. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i style="font-style: normal; font-weight: normal">During
the three and six months ended March 31, 2024 and 2023, operating lease costs were as follows (in thousands):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--LeaseCostTableTextBlock_pn3n3_zqOM4eN6D917" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B5_zaj01Oaq5Qt7" style="display: none">Schedule of operating lease costs</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20240101__20240331_zE1SniLqyBm" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_496_20230101__20230331_zhMPspwmi48j" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20231001__20240331_z0qJ2X64ggg8" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_498_20221001__20230331_zA16A6W3XB05" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_zhX6UbDxgG1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">31</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Employee 401(k) Benefit Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: Black">During the three and six
months ended March 31, 2024 and 2023, the Company <i style="font-style: normal; font-weight: normal">made matching contributions under the 401(k) plan as follows (in thousands):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zrHn2iRJnYo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B7_zgww5hPqb2C6" style="display: none">Schedule of contribution plan</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20240101__20240331_z5TNiEfCDPY" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20230101__20230331_zxrisPNYSTZd" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_496_20231001__20240331_zkhkfeeHy9s6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_494_20221001__20230331_zsyisF7uzy66" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_402_eus-gaap--PensionContributions_zBm7syOCfnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; color: gray"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="font-style: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="color: Black"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#8217;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">On
March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
The complaint is captioned Blum v. Anavex Life Sciences, Corp. et al., case number 1:24-cv-01910, and names the Company and Christopher
Missling as Defendants. The complaint alleges violations of the Securities and Exchange Act of 1934 resulting from disclosures and statements
made about certain clinical trials for ANAVEX<sup>&#174;</sup>2-73. The Company believes the complaint is without merit. The Company is
vigorously pursuing its defenses and a potential dismissal of all claims asserted in the lawsuit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><span style="color: Black"><b><i>Share Purchase Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024 and September 30, 2023, the Company
had <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20240331_zmu0kXb8hTc" title="Warrants outstanding"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20230930_zjNWFQrDzou7" title="Warrants outstanding">160,000</span></span> warrants outstanding at a weighted average exercise price of $<span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20240331_za276aAeuKc5" title="Warrants outstanding weighted average exercise"><span id="xdx_901_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20230930_zZA5R009xQBj" title="Warrants outstanding weighted average exercise">3.72</span></span> as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvZm3K3TZexk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zx3ZHkyRjUcf" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zWSYRfqFOdKh" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number of shares outstanding">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zGSRuTAaP0ff" style="width: 20%; text-align: right" title="Exercise price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 40%"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgtDAwaSlgS7" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zElcoj0Dihmi" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zUe4YIaE1AX9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zwFJWe3l5PA8" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331_zEn37jqZ4UA3" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i>Stock&#8211;based
Compensation Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2015 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 18, 2015, the Company&#8217;s Board approved
a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHLRjapMAs3l" title="Common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The maximum number of our common shares reserved for
issue under the plan was <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20231001__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zg0JjM2GgeE9" title="Additional shares of common stock available for issuance">6,000,000</span> shares, subject to adjustment in the event of a change of the Company&#8217;s capitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended September 30, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zO46bnH4wQee" title="Option granted">406,453</span>
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2022 Stock Option Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20231001__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zMhNmYAtQYp9" title="Additional shares of common stock available for issuance">10,000,000</span> additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#8217;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At March 31,
2024, <span id="xdx_903_ecustom--OptionIssued_c20231001__20240331_zean1FrsW2qh" title="Option issued">5,452,500</span> options had been issued under the 2022 Plan and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zhhdn5dWG0Gj" title="Option available issuance">5,132,202</span> options were available for issue under the 2022 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock option
activity during the year ended September 30, 2023 and six months ended March 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>











<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zdqrhYa4Z913" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B6_zuodOXuWWejh" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Grant Date Fair Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2022</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zudUh9AjlTIj" style="width: 12%; text-align: right" title="Number of Options Outstanding at Beginning">13,169,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4Lr5W19egq4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning">6.61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWhbMTK8qji8" style="width: 12%; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning">4.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1scUMGyvzAd" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning">62,267,309</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6vd6iqeiDVa" style="text-align: right" title="Number of Options, Granted">1,959,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW92rvDzJI7f" style="text-align: right" title="Weighted Average Exercise Price, Granted">9.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6SLOJMNHF6k" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">6.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmCBVuk8B2i" style="text-align: right" title="Number of Options, Exercised">(759,753</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzHlDzpeTqBh" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsMLjQtayyJc" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFTsyDzPzgb5" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">4,629,026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxn4PGvtKn7b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(257,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT9j4Pj89de6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5NKIXLSYrZk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">6.74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA7gZ28dyHS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding at Beginning">14,111,780</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVo7tvcbg5Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning">7.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zab2kuyfpI58" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning">5.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWsYgff63quk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning">22,290,069</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxIjNofDpIf7" style="text-align: right" title="Number of Options, Granted">1,750,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKNPTQUPuSf9" style="text-align: right" title="Weighted Average Exercise Price, Granted">5.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zy3Dj2ufvAwg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">3.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK7fnGAHBdV6" style="text-align: right" title="Number of Options, Exercised">(46,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0fFTEoAfV8l" style="text-align: right" title="Weighted Average Exercise Price, Exercised">3.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK59nm7ZftMj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised">2.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmRxtyTRQ3N4" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">125,170</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXgP0dfwMfs5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(221,166</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7UDJrqOjmue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">13.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU1Bq6dHfVDf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">9.06</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, March 31, 2024</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0sCPx3LQrf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding at Ending">15,595,114</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8dL4cyfH4ci" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at Ending">6.85</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz5Hif7OJH9f" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding at Ending">12,480,916</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, March 31, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXas9bb6sXCh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable">9,955,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6HigpdS0Ute" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_pp0p0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zentbb8GD9Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable">12,440,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AD_zQVPwiZPcXG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes information about stock options
at March 31, 2024 by a range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z89dJq6hkTUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B2_zagP1ilq69O4" style="display: none">Schedule of summarized information about stock options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></p></td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual life (in</span></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested</span></p></td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znDHNvPCxSt1" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTehO74UuMje" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">3.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1i890sMCEV5" style="width: 11%; text-align: right" title="Number of outstanding options">3,243,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTEg961l1fI2" title="Weighted average remaining contractual life (in years)">4.22</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zwbcJTV4Qr9" style="width: 10%; text-align: right" title="Weighted average exercise price">2.38</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zi4r5sCwSmP7" style="width: 10%; text-align: right" title="Number of vested options">3,243,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNAssKYlvRs7" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.38</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIRzOQARwmd7" style="text-align: right" title="Range of exercise prices, lower range limit">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zkfE6UeN4yYb" style="text-align: right" title="Range of exercise prices, upper range limit">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zbOpFnkyPHPh" style="text-align: right" title="Number of outstanding options">2,167,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKGJe864X377" title="Weighted average remaining contractual life (in years)">4.24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhO09CvJojAf" style="text-align: right" title="Weighted average exercise price">3.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z3MocNbcufs4" style="text-align: right" title="Number of vested options">2,017,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhtu2jEuHUBg" style="text-align: right" title="Weighted average exercise price options vested">3.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zcYeQbB8m9Rj" style="text-align: right" title="Range of exercise prices, lower range limit">5.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zZghSEregeG7" style="text-align: right" title="Range of exercise prices, upper range limit">9.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zQ0jdn6lHQTc" style="text-align: right" title="Number of outstanding options">6,790,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaGTU4v6tpod" title="Weighted average remaining contractual life (in years)">6.62</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUwJseYVxZN1" style="text-align: right" title="Weighted average exercise price">6.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zT78gGUGMv8g" style="text-align: right" title="Number of vested options">3,436,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zLJGcSSyfLt4" style="text-align: right" title="Weighted average exercise price options vested">6.19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zklt3QYYxEPg" style="text-align: right" title="Range of exercise prices, lower range limit">9.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zXiY0TCzby0c" style="text-align: right" title="Range of exercise prices, upper range limit">13.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zxrVhlD46LD5" style="text-align: right" title="Number of outstanding options">1,894,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFfVC65BXJIk" title="Weighted average remaining contractual life (in years)">7.85</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zK3oIuxtPuGf" style="text-align: right" title="Weighted average exercise price">10.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1fGjgeRm0Bl" style="text-align: right" title="Number of vested options">705,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZ4IKKHZoNY9" style="text-align: right" title="Weighted average exercise price options vested">11.06</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRekty1ejdIl" style="text-align: right" title="Range of exercise prices, lower range limit">13.01</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zQkzNKWyTdU6" style="text-align: right" title="Range of exercise prices, upper range limit">25.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zI0eUAto7LPb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zdD4YUAXKXTb" title="Weighted average remaining contractual life (in years)">6.97</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_ziZbjP9be7rb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zIqHQBA0cp4e" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">552,917</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zw9eNEK5jUZ4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.28</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSbBoqJORJR" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options">15,595,114</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvOy2O8iPLS2" title="Weighted average remaining contractual life (in years)">5.97</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjVuMsabsk1d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price">6.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUpuUf0ADDih" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options">9,955,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlK1IRYcEKV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested">5.38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A7_zFoZmvHm8sK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average grant date fair value of options
vested at March 31, 2024 was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zb4MFttPh8Cg" title="Weighted average grant date fair value of options vested">4.07</span> (September 30, 2023: $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zgMPztwOY1La" title="Weighted average grant date fair value of options vested">3.94</span>). At March 31, 2024, the weighted average contractual life of options outstanding
was <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zwopy4gLxEXl" title="Weighted average contractual life of options outstanding">6.0</span> years (September 30, 2023: <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zdcJ6sVyEGpb" title="Weighted average contractual life of options outstanding">6.0</span> years) and for options exercisable was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zdre5HMajH2f" title="Weighted average contractual life of options exercisable">4.5</span> years (September 30, 2023: <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_z8xpHfOElB82" title="Weighted average contractual life of options exercisable">4.75</span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#8217;s stock for the options
that were in-the-money at March 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended March 31, 2024,
the Company recognized stock-based compensation expense of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240331_ztXnwKYdSy4d" title="Share based compensation expense">2.7</span> million and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240331_z1GK3PdAaolb" title="Share based compensation expense">4.9</span> million, respectively (2023: $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20230331_zpo6SSSDR9hl" title="Share based compensation expense">4.0</span> million and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230331_zmei0KGW2tpc" title="Share based compensation expense">9.3</span> million,
respectively) in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have
been included in general and 	administrative expenses and research and development expenses on the Company&#8217;s condensed consolidated
interim statement of 	operations as follows (in thousands):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zjfULGHAAg1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_zEyalFhs0NGe" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbQM9WQCcnqc" style="width: 10%; text-align: right" title="Total share based compensation">979</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsmkmRN7mck8" style="width: 10%; text-align: right" title="Total share based compensation">1,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoaLPorJWvth" style="width: 10%; text-align: right" title="Total share based compensation">1,905</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZmYjr638CYb" style="width: 10%; text-align: right" title="Total share based compensation">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zApFxNZu1MFa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,673</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVMKRxNA2Vr7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,713</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGtnsPcJVGoc" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,033</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTb2U5FQMJ8h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">6,317</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zWxedXQ3tb5h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,652</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zz4oAfX0nB5d" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,970</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zTWoC4nlDv1k" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">4,938</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331_zt5KH4EvvwP6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,317</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A0_zzrtn8q8zyp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An amount of approximately $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20240331_zLbcl4JeuA75" title="Remaining stock based compensation">14.5</span> million in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The fair value of each option award
granted during the three and six months ended March 31, 2024 and 2023 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zFfKx8VBGcsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_znw7mXYVD7Hb" style="display: none">Schedule of weighted average
assumptions</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_zIdZZtnEjvgi" title="Risk-free interest rate">4.28</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230331_zJz8uKzViwV5" title="Risk-free interest rate">3.69</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfBVqffNbQsi" title="Expected life of options (years)">5.74</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zHhXrgY0mwO7" title="Expected life of options (years)">5.61</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z9hrgRugBlr3" title="Annualized volatility">84.84</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230331_z6RKz6vN7yse" title="Annualized volatility">85.28</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zuMquOHDfWc7" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230331_zBEZtTrN3E21" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>



<p id="xdx_8A9_zNyYOjBEuvH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of stock compensation charges recognized
during the three and six months ended March 31, 2024 and 2023 was determined with reference to the quoted market price of the Company&#8217;s
shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860810637760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zknPsUIJItp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b><i><span id="xdx_866_zbqgpltKOaMa">Basis of Presentation</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;)
and accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2023 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023 filed with the SEC on November 27, 2023.
The Company follows the same accounting policies in the preparation of interim reports.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating results for the six months ended March 31,
2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_LliquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_845_ecustom--LliquidityPolicyTextBlock_zFI9bTi0SREa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zJ6zC46Uj13i">Liquidity</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the Company&#8217;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital
position will be sufficient to meet the Company&#8217;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--UseOfEstimates_zfYWLHu7rmYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_867_zGiShBljRHFi">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zM8b8w3vfKTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_zWNRr0rCht8a">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#8220;Anavex Australia&#8221;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGfnrupflT7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_86E_zmgNY1Eiqs2e">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2024 and September 30, 2023, the Company
did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_z9PrflCYqYf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><span style="color: Black"><b><i><span id="xdx_86A_zVkpoaKUryQa">Basic
and Diluted Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2024 loss per share excludes <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240331_zmV3jqXp2BU8" title="Loss per share for potentially dilutive common shares">15,755,114</span>
(March 31, 2023: <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_zMzVmxJcFosj" title="Loss per share for potentially dilutive common shares">15,001,613</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3VLPMGUVod6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_861_zOOQVnB9Xcnf">Recently Adopted Accounting
Pronouncements</span> </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2023, the Financial
Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &#8220;Segment Reporting: Improvements to Reportable
Segment Disclosures.&#8221; This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30,
2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In December 2023, the FASB
issued ASU No. 2023-09, &#8220;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#8221; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_LliquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_LliquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860810515904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zSGkyYREISz3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_znUspmfuqmK8" style="display: none">Schedule of accrued liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240331_zH4vQ2fKHKya" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20230930_z5BB6nvxccth" style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40B_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_zZZ4U4JI5Dq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Accrued clinical site and patient visits costs</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,209</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,006</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_zwgKvz2P2Wn" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued compensation and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">630</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,360</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FixedContractAccruals_iI_d0_zDUEVfdSER3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--MilestoneBasedContractAccruals_iI_zvpBTkrgDnRl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Milestone based contract accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_z6cK2UgVFNlb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">All other accrued liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,531</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,624</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_zv6wgtlCC3b5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total accrued liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,915</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,295</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860816258368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--LeaseCostTableTextBlock_pn3n3_zqOM4eN6D917" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B5_zaj01Oaq5Qt7" style="display: none">Schedule of operating lease costs</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20240101__20240331_zE1SniLqyBm" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_496_20230101__20230331_zhMPspwmi48j" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20231001__20240331_z0qJ2X64ggg8" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_498_20221001__20230331_zA16A6W3XB05" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_zhX6UbDxgG1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Operating lease costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">31</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock', window );">Schedule of contribution plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zrHn2iRJnYo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"><span id="xdx_8B7_zgww5hPqb2C6" style="display: none">Schedule of contribution plan</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49E_20240101__20240331_z5TNiEfCDPY" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49A_20230101__20230331_zxrisPNYSTZd" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_496_20231001__20240331_zkhkfeeHy9s6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_494_20221001__20230331_zsyisF7uzy66" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_402_eus-gaap--PensionContributions_zBm7syOCfnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">Contributions to 401(k) plan</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">56</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">100</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvZm3K3TZexk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zx3ZHkyRjUcf" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zWSYRfqFOdKh" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number of shares outstanding">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zGSRuTAaP0ff" style="width: 20%; text-align: right" title="Exercise price">3.17</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="text-align: right; width: 40%"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgtDAwaSlgS7" title="Expiry Date">May 6, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zElcoj0Dihmi" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zUe4YIaE1AX9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zwFJWe3l5PA8" title="Expiry Date">April 21, 2026</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331_zEn37jqZ4UA3" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding">160,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zdqrhYa4Z913" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B6_zuodOXuWWejh" style="display: none">Schedule of outstanding stock purchase options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Exercise Price</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Grant Date Fair Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Aggregate intrinsic value</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2022</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zudUh9AjlTIj" style="width: 12%; text-align: right" title="Number of Options Outstanding at Beginning">13,169,616</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4Lr5W19egq4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning">6.61</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWhbMTK8qji8" style="width: 12%; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning">4.96</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1scUMGyvzAd" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning">62,267,309</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6vd6iqeiDVa" style="text-align: right" title="Number of Options, Granted">1,959,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW92rvDzJI7f" style="text-align: right" title="Weighted Average Exercise Price, Granted">9.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6SLOJMNHF6k" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">6.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmCBVuk8B2i" style="text-align: right" title="Number of Options, Exercised">(759,753</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzHlDzpeTqBh" style="text-align: right" title="Weighted Average Exercise Price, Exercised">2.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsMLjQtayyJc" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFTsyDzPzgb5" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">4,629,026</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxn4PGvtKn7b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(257,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT9j4Pj89de6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">12.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5NKIXLSYrZk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">6.74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, September 30, 2023</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA7gZ28dyHS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding at Beginning">14,111,780</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVo7tvcbg5Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning">7.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zab2kuyfpI58" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning">5.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWsYgff63quk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning">22,290,069</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxIjNofDpIf7" style="text-align: right" title="Number of Options, Granted">1,750,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKNPTQUPuSf9" style="text-align: right" title="Weighted Average Exercise Price, Granted">5.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zy3Dj2ufvAwg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">3.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK7fnGAHBdV6" style="text-align: right" title="Number of Options, Exercised">(46,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0fFTEoAfV8l" style="text-align: right" title="Weighted Average Exercise Price, Exercised">3.43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK59nm7ZftMj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised">2.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmRxtyTRQ3N4" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">125,170</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXgP0dfwMfs5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited">(221,166</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7UDJrqOjmue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">13.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU1Bq6dHfVDf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">9.06</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, March 31, 2024</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0sCPx3LQrf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding at Ending">15,595,114</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8dL4cyfH4ci" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at Ending">6.85</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz5Hif7OJH9f" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding at Ending">12,480,916</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, March 31, 2024</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXas9bb6sXCh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable">9,955,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6HigpdS0Ute" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">5.38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_pp0p0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zentbb8GD9Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable">12,440,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summarized information about stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z89dJq6hkTUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center"><span id="xdx_8B2_zagP1ilq69O4" style="display: none">Schedule of summarized information about stock options</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercises prices</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">outstanding</span></p></td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contractual life (in</span></p></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">vested</span></p></td><td style="font-size: 11pt">&#160;</td>
    <td colspan="3" style="font-size: 11pt; text-align: center"><p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted</span></p> <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">average</span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">From</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">To</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">exercise price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znDHNvPCxSt1" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit">0.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTehO74UuMje" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit">3.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1i890sMCEV5" style="width: 11%; text-align: right" title="Number of outstanding options">3,243,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTEg961l1fI2" title="Weighted average remaining contractual life (in years)">4.22</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zwbcJTV4Qr9" style="width: 10%; text-align: right" title="Weighted average exercise price">2.38</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zi4r5sCwSmP7" style="width: 10%; text-align: right" title="Number of vested options">3,243,060</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNAssKYlvRs7" style="width: 10%; text-align: right" title="Weighted average exercise price options vested">2.38</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIRzOQARwmd7" style="text-align: right" title="Range of exercise prices, lower range limit">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zkfE6UeN4yYb" style="text-align: right" title="Range of exercise prices, upper range limit">5.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zbOpFnkyPHPh" style="text-align: right" title="Number of outstanding options">2,167,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKGJe864X377" title="Weighted average remaining contractual life (in years)">4.24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhO09CvJojAf" style="text-align: right" title="Weighted average exercise price">3.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z3MocNbcufs4" style="text-align: right" title="Number of vested options">2,017,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhtu2jEuHUBg" style="text-align: right" title="Weighted average exercise price options vested">3.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zcYeQbB8m9Rj" style="text-align: right" title="Range of exercise prices, lower range limit">5.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zZghSEregeG7" style="text-align: right" title="Range of exercise prices, upper range limit">9.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zQ0jdn6lHQTc" style="text-align: right" title="Number of outstanding options">6,790,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaGTU4v6tpod" title="Weighted average remaining contractual life (in years)">6.62</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUwJseYVxZN1" style="text-align: right" title="Weighted average exercise price">6.58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zT78gGUGMv8g" style="text-align: right" title="Number of vested options">3,436,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zLJGcSSyfLt4" style="text-align: right" title="Weighted average exercise price options vested">6.19</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zklt3QYYxEPg" style="text-align: right" title="Range of exercise prices, lower range limit">9.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zXiY0TCzby0c" style="text-align: right" title="Range of exercise prices, upper range limit">13.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zxrVhlD46LD5" style="text-align: right" title="Number of outstanding options">1,894,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFfVC65BXJIk" title="Weighted average remaining contractual life (in years)">7.85</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zK3oIuxtPuGf" style="text-align: right" title="Weighted average exercise price">10.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1fGjgeRm0Bl" style="text-align: right" title="Number of vested options">705,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZ4IKKHZoNY9" style="text-align: right" title="Weighted average exercise price options vested">11.06</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRekty1ejdIl" style="text-align: right" title="Range of exercise prices, lower range limit">13.01</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zQkzNKWyTdU6" style="text-align: right" title="Range of exercise prices, upper range limit">25.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zI0eUAto7LPb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options">1,500,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zdD4YUAXKXTb" title="Weighted average remaining contractual life (in years)">6.97</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_ziZbjP9be7rb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price">18.12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zIqHQBA0cp4e" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options">552,917</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zw9eNEK5jUZ4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested">18.28</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSbBoqJORJR" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options">15,595,114</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvOy2O8iPLS2" title="Weighted average remaining contractual life (in years)">5.97</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjVuMsabsk1d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price">6.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUpuUf0ADDih" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options">9,955,616</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlK1IRYcEKV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested">5.38</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zjfULGHAAg1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)">
  <tr style="vertical-align: bottom">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_zEyalFhs0NGe" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three months ended March 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six months ended March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbQM9WQCcnqc" style="width: 10%; text-align: right" title="Total share based compensation">979</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsmkmRN7mck8" style="width: 10%; text-align: right" title="Total share based compensation">1,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoaLPorJWvth" style="width: 10%; text-align: right" title="Total share based compensation">1,905</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZmYjr638CYb" style="width: 10%; text-align: right" title="Total share based compensation">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zApFxNZu1MFa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">1,673</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVMKRxNA2Vr7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,713</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGtnsPcJVGoc" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,033</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTb2U5FQMJ8h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">6,317</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total stock-based compensation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zWxedXQ3tb5h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,652</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zz4oAfX0nB5d" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,970</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zTWoC4nlDv1k" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">4,938</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331_zt5KH4EvvwP6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">9,317</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zFfKx8VBGcsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BD_znw7mXYVD7Hb" style="display: none">Schedule of weighted average
assumptions</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_zIdZZtnEjvgi" title="Risk-free interest rate">4.28</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230331_zJz8uKzViwV5" title="Risk-free interest rate">3.69</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected life of options (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfBVqffNbQsi" title="Expected life of options (years)">5.74</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zHhXrgY0mwO7" title="Expected life of options (years)">5.61</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z9hrgRugBlr3" title="Annualized volatility">84.84</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230331_z6RKz6vN7yse" title="Annualized volatility">85.28</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zuMquOHDfWc7" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230331_zBEZtTrN3E21" title="Dividend rate">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860724470176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">15,755,114<span></span>
</td>
<td class="nump">15,001,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860723001040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_DeferredGrantIncome', window );">Grant income, amount</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncentiveAndTaxReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncentiveAndTaxReceivables', window );">Incentive and tax receivables</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=avxl_AnavexMember', window );">Anavex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember', window );">Michael J Fox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncentiveAndTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncentiveAndTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_AnavexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_AnavexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860816395760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts', window );">Accrued clinical site and patient visits costs</a></td>
<td class="nump">$ 1,209<span></span>
</td>
<td class="nump">$ 2,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FixedContractAccruals', window );">Fixed contract accruals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_MilestoneBasedContractAccruals', window );">Milestone based contract accruals</a></td>
<td class="nump">1,545<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">All other accrued liabilities</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,915<span></span>
</td>
<td class="nump">$ 7,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AccruedClinicalSiteAndPatientVisitsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AccruedClinicalSiteAndPatientVisitsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FixedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FixedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_MilestoneBasedContractAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_MilestoneBasedContractAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860717832080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_SalesOfAgreementAmount', window );">Sales of agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_FairValueOfInitialCommitment', window );">Fair value of the initial commitment</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=avxl_ThirdPartyMember', window );">Third Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_IncurredExpenses', window );">Incurred expenses</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald And Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued for initial commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503,707<span></span>
</td>
<td class="nump">2,159,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member', window );">Purchase Agreement 2023 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Obligated to purchase</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">Purchase Agreement 1 [Member] | Lincoln Park Capital Fund L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued for initial commitment shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or sale of equity</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues1', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues1', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
<td class="nump">9,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FairValueOfInitialCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FairValueOfInitialCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncurredExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncurredExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SalesOfAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SalesOfAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=avxl_ThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=avxl_ThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860810850768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860724883600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contributions to 401(k) plan</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860810686896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember', window );">Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Apr. 21,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860722804368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - Equity Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding at Beginning</a></td>
<td class="nump">14,111,780<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at Beginning</a></td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value at Beginning</a></td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding at Beginning</a></td>
<td class="nump">$ 22,290,069<span></span>
</td>
<td class="nump">$ 62,267,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,750,500<span></span>
</td>
<td class="nump">1,959,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 5.53<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(46,000)<span></span>
</td>
<td class="num">(759,753)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 3.43<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value, Exercised</a></td>
<td class="nump">$ 2.60<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="nump">$ 125,170<span></span>
</td>
<td class="nump">$ 4,629,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(221,166)<span></span>
</td>
<td class="num">(257,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 13.84<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="nump">$ 9.06<span></span>
</td>
<td class="nump">$ 6.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding at Ending</a></td>
<td class="nump">15,595,114<span></span>
</td>
<td class="nump">14,111,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at Ending</a></td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding at Ending</a></td>
<td class="nump">$ 12,480,916<span></span>
</td>
<td class="nump">$ 22,290,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">9,955,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 12,440,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860714538512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4) - Equity Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">15,595,114<span></span>
</td>
<td class="nump">14,111,780<span></span>
</td>
<td class="nump">13,169,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="nump">$ 7.12<span></span>
</td>
<td class="nump">$ 6.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">9,955,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">3,243,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,243,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">2,167,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">4 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">2,017,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">6,790,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">3,436,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,894,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 10.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">705,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 11.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Option Price 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices, lower range limit</a></td>
<td class="nump">13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of exercise prices, upper range limit</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of outstanding options</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 18.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of vested options</a></td>
<td class="nump">552,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options vested</a></td>
<td class="nump">$ 18.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avxl_OptionPrice5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860717834320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 5) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 2,652<span></span>
</td>
<td class="nump">$ 3,970<span></span>
</td>
<td class="nump">$ 4,938<span></span>
</td>
<td class="nump">$ 9,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total share based compensation</a></td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="nump">$ 2,713<span></span>
</td>
<td class="nump">$ 3,033<span></span>
</td>
<td class="nump">$ 6,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860718694192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 6)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.28%<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 8 months 26 days<span></span>
</td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">84.84%<span></span>
</td>
<td class="nump">85.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139860712605184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_WarrantsOutstandingWeightedAverageExercise', window );">Warrants outstanding weighted average exercise</a></td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avxl_OptionIssued', window );">Option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,452,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contractual life of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">Stock Option Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">Stock Option Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member', window );">Stock Option Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Option available issuance</a></td>
<td class="nump">5,132,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,132,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_WarrantsOutstandingWeightedAverageExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_WarrantsOutstandingWeightedAverageExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,,S2#L-ZM7>NDN#!2?BM^A[-$D2/ZF55V8[BD-^K-/!-G0F!^$$*J98I9<'
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M]8\#.+V1T$ELN.W]+0S&;9_-64+,-IG#<?K\T-G!$5A(XBDQ.\0>2%@4)6=
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M=#$Q+GAM;)U7VW+;-A!]UU?L*)E,,^/J:CMI?)FQG5[\D#KCN.TS1*Y$-"3
M *!D]>M[%B!UB1TUT_'(!$'LV;-7 .<KZS[[@CG08U4:?]$O0JC?#8<^*[A2
M?F!K-O@RMZY2 :]N,?2U8Y5'H:H<3D:CTV&EM.E?GL>YC^[RW#:AU(8_.O)-
M52FWON;2KB[ZXWXW<:\719")X>5YK1;\B<,?]4>'M^$&)=<5&Z^M(<?SB_[5
M^-WUL:R/"_[4O/([8Q)+9M9^EI?;_*(_$D)<<A8$0>&QY!LN2P$"C2\M9G^C
M4@1WQQWZ+]%VV#)3GF]L^9?.0W'1?]NGG.>J*<.]7?W&K3TG@I?9TL?_M$IK
MQ],^98T/MFJ%P:#2)CW58^N''8&WHV\(3%J!2>2=%$66[U50E^?.KLC):J#)
M()H:I4%.&PG*I^#P54,N7-Z%@AW=FLQ6?#X,0)3Y8=9*7R?IR3>D3^F#-:'P
M]+/).=^7'X+)ALZDHW,].0CX0;D!3<='-!E-C@_@33?F32/>]'^:EZ2/GY>6
M@GCG:Y7Q11\9[]DMN7_YZL7X='1V@-OQAMOQ(?3_Y'90^GENO]O -*5=9/K5
M*1.ZERM/=D[P<E9LW'Q$6-Z[L56MS)H*E:/8,D:MY*3H)8T)%K\Y/J/1X"3^
M'@JF1035";10GF;,IH=J8.<@MRK8[*"8G+0LT69!JK(NZ'\P'2S92+2% 0I>
M(5:JP$+"<^0IXCDOT3]J=(- _(B.E.O08 4IQR+?B-H!O6\<=/0$)A2..<IZ
M_4A52E.6-'W.?.K,!VF[,)'?2QK%O\G)T6B$P>"G^+O_!J\>:. !BSN#OG^E
MXQA#$Y(+VED(&_"8K>G*J"4_TA7Z@5.E5A)$6;B=N'^EJOKL/67P@PX#! D>
MSY0O:$>9W\9DMNY]#7I$38T^.=>EQ D:%&6ETA40*+/&M'UTI4/QA-"K%V\G
MXS=GB(<QC2H["X)ZA$I$RG2QH2>QZ1V(S9/0N/Q09CSQ*XQXV>;M&QH/QOB=
M[HQ/:#*8T%5XDA&W'5!/5"0KQ'%J5B+G %XV.08O:0J\$_PFP)HB.1X.!*57
M.XNZJ20.BK QS7]4WK/WU'U V3A&N'>MKH!&[3J-_.!2+_0,,0IK) A8K^$+
MJ:6< SOL$$P_Z->D4X*(%5BH.[F2>S_H[6=?<Z;G.MLPC9ND#KJMK$XH>AJ"
M6TF-"ESJ7&+=R>[598'\(,./C1=NO@'1ISH&O8<=2WFIR@:E_]3.!JGA4N8@
M%-LH=WY3L:M%;\Q4J?"=THDF!US<M'-"Y@I 9>'.V"Z0+V(5V@T4HRBQ5I%:
M*EU*E =/:T[")KZ /2B'H$V3QK%&!+LS<)\D#DY"L+32_,0VJ)33DM_W;@?I
M>\",'6W[_;M:(1B7H;#-HMC+GQE0( '80@71+MT:Q5%C.D_%K,JRZ[S1%<(%
MH"CVY-=G(]'Y/IH'@)J=MKE/[N#\:+\_&7J 4^[FR#5DX-7#W>O((VJ5<Y,X
MTO%23G$[Y#==Y0OR3,_7TC]:O;X+7MPK]E(O,FKY"/^YA2^E2N"BVWG*1=5J
MZZU0<7$GRN#QEO3#'4Y8ZY3"N9YC3TO-!?6%-AW4QC,9NX!([GG(\9=&(\+2
MS*.^#C+77BW0]UJG/V-F+Y5Y%(WFI:Z73/3-S ,ZIFU=LRK]D40SLTV9=TI)
MY7_#XS$U8%/R4*W6<4+XMGD/!]5BOT5U1L>T#%+PP*.4\_UZLUL@M?*4$(CT
M^JCK 5V*K1#)QG2UD3,:NH0=I2=N5M[*MS4:RJ*)BVKK(Q@*Y3/."1C$F"3E
MFQCTDFDPU';]#T%696I.<J20@##*N0/86C^@FV2JL'W.T_LEFC33W-E*-H"1
MF('G-/9 N?_(1(VS%9:CX;6)VC9J4/W:/[$^VOP3:<G(5DC+]H%SDC8Z<$]O
MT\,WTHR#L%!-/J#=SBBE8FR0W$?/Y9084&57L=?%A,=,=,*6YM8=<*HOHC>A
M;9UR779UT3UOI&H&]-R!=KASKZC8+>+M2;I'8T*Z8FQF-Q>TJW0OV2Y/MSOL
ML OI>27/(8HM^*2?*K][";:.MY29#;CSQ&&!)&0G"_!];F%8^R(*-M?6RW\!
M4$L#!!0    ( 'F$J5C%J\95WP(  &$&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;(U576_:,!1]SZ^PTJK:)-1\0BD%)-A6;=(ZH=)M#],>G.1"
MK#IV9CNE_?>[=FC*I(#V$G_=<WRNKWTRW4GUJ$L 0YXK+O3,+XVI)T&@\Q(J
MJB]E#0)7-E)5U.!0;0-=*Z"% U4\B,-P%%24"7\^=7,K-9_*QG F8*6(;JJ*
MJI<E<+F;^9'_.G'/MJ6Q$\%\6M,MK,%\KU<*1T''4K *A&92$ 6;F;^()LO4
MQKN 'PQV^J!/;":9E(]V\*68^:$5!!QR8QDH-D_P 3BW1"CCSY[3[[:TP,/^
M*_NMRQUSR:B&#Y+_9(4I9_[8)P5L:,/-O=Q]AGT^0\N72Z[=E^S:V"3Q2=YH
M(ZL]&!543+0M?=Z?PP%@'!X!Q'M ['2W&SF5'ZFA\ZF2.Z)L-++9CDO5H5$<
M$[8H:Z-PE2'.S!=YKAHHR%=&,\:98:"G@4%BNQSD>Y)E2Q(?(1F1.RE,J<DG
M44#Q+SY 09VJ^%75,CY)>$?5)4FB 8G#.#W!EW19)HXO.<*WHB\TXZ )%05Q
M*5.NR:]%IHW">_&[+^66,>UGM&]EHFN:P\S'QZ!!/8$_OSB+1N'-";UIIS<]
MQ?Z_53E)TB_QFS1 4M*S 7DH@=2*B9S5E)-<5K44((PF<H./IXWG!_&YQ*>I
MC5U^QP0QI6PTGJ]^/_'6Z!U%P^$(U,/ZYJ4K\!IJ U4&BB3AP+/EMC5/O%>!
M.6;%<M2C&0JWY:LI4@A#GAA.614:O^<D&L3A-;;Q .WH#8Y9H(/0U@$0G8&
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M12VKQA7*6BT1)E2;0JF2@=^M9">DJ>P68MK@#8@0K.V-9;OGO47J4,&[Z&$
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M965T,34N>&ULM5I;<]LV%G[GK\"X,QU[1I8E.T[27#SCW-I,T]83Q]V'G7V
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M56A06_#2B[-P'-R>T)MT>I-3[.D*B[!H.!"YQ@?<IHJ_I:I/[DG"?KG_\3+
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M_4Z" @  ^04  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK53;;M-
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M&".X1H0'L.L;C.GK"1=H=K?F_P-02P,$%     @ >82I6#X,-WW@ @  90@
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MD5VJ/O&'WVEU0P.#E_!4%G_10S4VZ*!D)Q7/*F,]@XSEY7_RK0K$GD'8?\(
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M*>_T Q92V;:1=J)%;>OD0FBLNG988.<%:0QP?RF$WDZ,0-_+D[]02P,$%
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MVT"1]N-W=D*::B%5JT[E [$=WW//O>5NM!7R5B4 FMSQ-%-C)]$Z/W%=%2?
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MT:,.7CL/OZ]:;R7#WOKD=[)^_/4(A_KV1VZ$NTHR1&KO;H<\6I,ESS59=IN
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M5&WC;8O:#B3;FA[LD4G5T9G'2K7UP#5 O5\S)I\'VD#_1T'Z#5!+ P04
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M$)A*+E6@3;49*UV(U+\<W'4]*,1&IV1"*IO;97#?DV;X#K#J@4'&>6NP%[K
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M   3    6T-O;G1E;G1?5'EP97-=+GAM;,V8RT[#,!!%?R7*MFI<&R@/M=T
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'F$J5@/@:HZ^ 4  (L@   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !YA*E8*C85)*<$  #>$   &               @($\#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ >82I6 P16_7' @  GP@
M !@              ("!&1,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M 0(4 Q0    ( 'F$J5A,GYJXW04  &P<   8              " @186  !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !YA*E85 DH0N8)
M   Y6   &               @($I'   >&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L! A0#%     @ >82I6(']FA)F!0  C!0  !@              ("!
M128  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( 'F$J5BW
MH:\,G (  .('   8              " @>$K  !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"% ,4    " !YA*E85* 3L4("  "0!@  &
M    @(&S+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M>82I6#6F8&1- P  &@<  !@              ("!*S$  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( 'F$J5A< K$?MPT  .LD   9
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M970Q-"YX;6Q02P$"% ,4    " !YA*E8+=H=XD$.  "N*   &0
M    @(&?7P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M 'F$J5C:M!"9N@(  ! &   9              " @1=N  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ >82I6*M2I=,Y!@  O!$  !D
M             ("!"'$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !YA*E8MUC]3H("  #Y!0  &0              @(%X=P  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( 'F$J5@^-%H7/ 0
M .D:   9              " @3%Z  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ >82I6#X,-WW@ @  90@  !D              ("!
MI'X  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !YA*E8
MP*"-PQT&  #?*P  &0              @(&[@0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( 'F$J5A=65L4D0(  -<'   9
M      " @0^(  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ >82I6!$3R0V= @  X@<  !D              ("!UXH  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !YA*E8_K!/;_4"  "F"@
M&0              @(&KC0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( 'F$J5C,+HI[N00  ((4   9              " @=>0  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ >82I6-$;]E'/
M!P   $(  !D              ("!QY4  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !YA*E8Y-),%'\#   T$   &0
M@('-G0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'F$
MJ5CA_[1^T (  .8'   9              " @8.A  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ >82I6#;,C,&'!@  _C0  !D
M         ("!BJ0  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !YA*E8"S<9WCL#  #L$P  #0              @ %(JP  >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( 'F$J5B7BKL<P    !,"   +
M  "  :ZN  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'F$J5BA;RQ&] (   <4
M   /              "  9>O  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !YA*E8VK %;5(!  #^$0  &@              @ &XL@  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !YA*E85@Q15'\!  ##$@
M$P              @ %"M   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..)0 E /H)  #RM0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>103</ContextCount>
  <ElementCount>184</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Interim Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimBalanceSheets</Role>
      <ShortName>Condensed Consolidated Interim Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Interim Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995512 - Disclosure - Business Description</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescription</Role>
      <ShortName>Business Description</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995513 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995514 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995516 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995518 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995519 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/AccruedLiabilities</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995520 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995521 - Disclosure - Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BasisOfPresentationPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995522 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995523 - Disclosure - Accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995524 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferings</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995526 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995528 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995529 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995530 - Disclosure - Commitments and Contingencies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails5</Role>
      <ShortName>Commitments and Contingencies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995531 - Disclosure - Commitments and Contingencies (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails6</Role>
      <ShortName>Commitments and Contingencies (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e5644_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995532 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avxl-20240331.xsd</File>
    <File>avxl-20240331_cal.xml</File>
    <File>avxl-20240331_def.xml</File>
    <File>avxl-20240331_lab.xml</File>
    <File>avxl-20240331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="e5644_10q.htm">e5644_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="404">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e5644_10q.htm": {
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "avxl-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avxl-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "e5644_10q.htm"
     ]
    }
   },
   "keyStandard": 150,
   "keyCustom": 34,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 8,
   "memberCustom": 19,
   "hidden": {
    "total": 78,
    "http://anavex.com/20240331": 36,
    "http://fasb.org/us-gaap/2023": 37,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 103,
   "entityCount": 1,
   "segmentCount": 27,
   "elementCount": 374,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 404,
    "http://xbrl.sec.gov/dei/2023": 31,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://anavex.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://anavex.com/role/InterimBalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Interim Balance Sheets",
     "shortName": "Condensed Consolidated Interim Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://anavex.com/role/InterimBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Interim Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://anavex.com/role/InterimStatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "avxl:NoncashFinancingRelatedCharges",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://anavex.com/role/BusinessDescription",
     "longName": "995512 - Disclosure - Business Description",
     "shortName": "Business Description",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://anavex.com/role/BasisOfPresentation",
     "longName": "995513 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://anavex.com/role/OtherIncome",
     "longName": "995514 - Disclosure - Other Income",
     "shortName": "Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://anavex.com/role/AccruedLiabilities",
     "longName": "995515 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://anavex.com/role/EquityOfferings",
     "longName": "995516 - Disclosure - Equity Offerings",
     "shortName": "Equity Offerings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "longName": "995517 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://anavex.com/role/BasisOfPresentationPolicies",
     "longName": "995518 - Disclosure - Basis of Presentation (Policies)",
     "shortName": "Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://anavex.com/role/AccruedLiabilitiesTables",
     "longName": "995519 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "longName": "995520 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://anavex.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "995521 - Disclosure - Basis of Presentation (Details Narrative)",
     "shortName": "Basis of Presentation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfAccounting",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "longName": "995522 - Disclosure - Other Income (Details Narrative)",
     "shortName": "Other Income (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://anavex.com/role/AccruedLiabilitiesDetails",
     "longName": "995523 - Disclosure - Accrued liabilities (Details)",
     "shortName": "Accrued liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "avxl:AccruedClinicalSiteAndPatientVisitsCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://anavex.com/role/EquityOfferingsDetailsNarrative",
     "longName": "995524 - Disclosure - Equity Offerings (Details Narrative)",
     "shortName": "Equity Offerings (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "avxl:SalesOfAgreementAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "avxl:SalesOfAgreementAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "longName": "995525 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "995526 - Disclosure - Commitments and Contingencies (Details 1)",
     "shortName": "Commitments and Contingencies (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:PensionContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DefinedContributionPlanDisclosuresTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "longName": "995527 - Disclosure - Commitments and Contingencies (Details 2)",
     "shortName": "Commitments and Contingencies (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "longName": "995528 - Disclosure - Commitments and Contingencies (Details 3)",
     "shortName": "Commitments and Contingencies (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "longName": "995529 - Disclosure - Commitments and Contingencies (Details 4)",
     "shortName": "Commitments and Contingencies (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012024-03-31_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
     "longName": "995530 - Disclosure - Commitments and Contingencies (Details 5)",
     "shortName": "Commitments and Contingencies (Details 5)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails6",
     "longName": "995531 - Disclosure - Commitments and Contingencies (Details 6)",
     "shortName": "Commitments and Contingencies (Details 6)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995532 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightOutstanding",
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e5644_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "currency_AUD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AUD",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r402"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "avxl_AccruedClinicalSiteAndPatientVisitsCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "AccruedClinicalSiteAndPatientVisitsCosts",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical site and patient visits costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities - Note 4",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r329",
      "r515",
      "r516",
      "r517",
      "r556",
      "r566"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r194"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r443",
      "r453",
      "r478"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r446",
      "r456",
      "r481"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r467"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r474"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r438",
      "r447",
      "r457",
      "r474",
      "r482",
      "r486",
      "r494"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r226"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_AnavexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "AnavexMember",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anavex [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share for potentially dilutive common shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r78",
      "r88",
      "r112",
      "r114",
      "r116",
      "r148",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r234",
      "r236",
      "r249",
      "r309",
      "r353",
      "r402",
      "r412",
      "r526",
      "r527",
      "r562"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "CantorFitzgeraldAndCoMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cantor Fitzgerald And Co [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r77",
      "r394"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r53",
      "r86"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents during the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r53"
     ]
    },
    "avxl_CashPaidForStateAndLocalMinimumIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "CashPaidForStateAndLocalMinimumIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for state and local minimum income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "avxl_CommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "CommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_CommitmentSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "CommitmentSharesValue",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies - Note 6",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r36",
      "r310",
      "r340"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r161",
      "r162",
      "r393",
      "r523"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r515",
      "r516",
      "r556",
      "r565",
      "r566"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r341"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r40",
      "r341",
      "r359",
      "r566",
      "r567"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 82,086,511 common shares (September 30, 2023 - 82,066,511)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r312",
      "r402"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r396"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense, current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r229",
      "r232",
      "r514"
     ]
    },
    "avxl_DeferredGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "DeferredGrantIncome",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income - Note 3",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosuresTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of contribution plan",
        "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r386",
      "r388",
      "r389",
      "r390",
      "r403",
      "r405"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r33",
      "r331",
      "r332",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r386",
      "r388",
      "r389",
      "r390",
      "r395",
      "r403",
      "r405"
     ]
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "DisclosureOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r426",
      "r439"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r104",
      "r106",
      "r107",
      "r108",
      "r110",
      "r247",
      "r248",
      "r307",
      "r318",
      "r397"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r104",
      "r106",
      "r107",
      "r108",
      "r110",
      "r247",
      "r248",
      "r307",
      "r318",
      "r397"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining stock based compensation",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r75",
      "r81",
      "r82",
      "r83",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r111",
      "r149",
      "r150",
      "r191",
      "r223",
      "r224",
      "r225",
      "r230",
      "r231",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r319",
      "r320",
      "r321",
      "r329",
      "r380"
     ]
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "EquityOfferingSalesAgreementMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r443",
      "r453",
      "r478"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r428",
      "r440",
      "r450",
      "r475"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_FairValueOfInitialCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "FairValueOfInitialCommitment",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the initial commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r176",
      "r189",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r317",
      "r400",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "avxl_FixedContractAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "FixedContractAccruals",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed contract accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r377"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r435",
      "r447",
      "r457",
      "r482"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r435",
      "r447",
      "r457",
      "r482"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r435",
      "r447",
      "r457",
      "r482"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r435",
      "r447",
      "r457",
      "r482"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r435",
      "r447",
      "r457",
      "r482"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r363"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "avxl_IncentiveAndTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "IncentiveAndTaxReceivables",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Incentive and tax receivables",
        "label": "IncentiveAndTaxReceivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r48",
      "r68",
      "r112",
      "r113",
      "r115",
      "r117",
      "r308",
      "r315",
      "r399"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r364"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r364"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive and tax receivables",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r511"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "avxl_IncreaseDecreaseInDeferredGrantIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "IncreaseDecreaseInDeferredGrantIncome",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred grant income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Incentive and tax receivables",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in working capital balances related to operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and deposits",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "avxl_IncurredExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "IncurredExpenses",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r438",
      "r447",
      "r457",
      "r474",
      "r482",
      "r486",
      "r494"
     ]
    },
    "avxl_InitialCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "InitialCommitmentShares",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_InitialCommitmentSharesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "InitialCommitmentSharesShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial commitment shares, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r427",
      "r498"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r427",
      "r498"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r427",
      "r498"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r88",
      "r148",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r235",
      "r236",
      "r237",
      "r249",
      "r339",
      "r398",
      "r412",
      "r526",
      "r562",
      "r563"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r67",
      "r314",
      "r402",
      "r513",
      "r522",
      "r558"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "LincolnParkCapitalFundLLCMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Capital Fund L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_LliquidityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "LliquidityPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r524",
      "r525"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r524",
      "r525"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "avxl_MichaelJFoxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "MichaelJFoxMember",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_MilestoneBasedContractAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "MilestoneBasedContractAccruals",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone based contract accruals"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows",
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r55",
      "r69",
      "r76",
      "r79",
      "r80",
      "r83",
      "r88",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r100",
      "r101",
      "r105",
      "r112",
      "r113",
      "r115",
      "r117",
      "r148",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r248",
      "r249",
      "r316",
      "r361",
      "r378",
      "r379",
      "r399",
      "r411",
      "r526"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "NonOperatingIncomeFromGrant",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Grant income",
        "label": "NonOperatingIncomeFromGrant"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NonOperatingIncomeFromGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "NonOperatingIncomeFromGrants",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "avxl_NoncashFinancingRelatedCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "NoncashFinancingRelatedCharges",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash financing related charges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r117",
      "r399"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r401"
     ]
    },
    "avxl_OptionIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OptionIssued",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r349",
      "r354",
      "r367",
      "r373",
      "r386",
      "r387",
      "r388",
      "r403",
      "r404"
     ]
    },
    "avxl_OptionPrice1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OptionPrice1Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OptionPrice2Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OptionPrice3Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OptionPrice4Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OptionPrice5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OptionPrice5Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Price 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/BusinessDescription"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r64",
      "r324",
      "r325"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "avxl_OtherFinancingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OtherFinancingExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other financing expense",
        "label": "OtherFinancingExpense"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "OtherIncomeDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Income",
        "label": "OtherIncomeDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r445",
      "r455",
      "r480"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r436",
      "r448",
      "r458",
      "r483"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r436",
      "r448",
      "r458",
      "r483"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_PensionContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionContributions",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions to 401(k) plan",
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "PercentageOfGrossProceedsFromSales",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r178"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r341"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r311",
      "r402"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r327"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "avxl_PurchaseAgreement1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "PurchaseAgreement1Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "PurchaseAgreement2023Member",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseWarrants1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "PurchaseWarrants1Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_PurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "PurchaseWarrantsMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r428",
      "r440",
      "r450",
      "r475"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r262",
      "r263",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r358",
      "r360",
      "r385"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r262",
      "r263",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r358",
      "r360",
      "r385",
      "r561"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development incentive income",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r227",
      "r564"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r441",
      "r451",
      "r476"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r430",
      "r442",
      "r452",
      "r477"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r437",
      "r449",
      "r459",
      "r484"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r60",
      "r313",
      "r322",
      "r323",
      "r328",
      "r342",
      "r402"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r149",
      "r150",
      "r223",
      "r224",
      "r225",
      "r230",
      "r231",
      "r238",
      "r240",
      "r241",
      "r243",
      "r246",
      "r319",
      "r321",
      "r329",
      "r566"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SalesOfAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "SalesOfAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales of agreement amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://anavex.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of general and administrative expenses and research and development expenses",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarized information about stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of outstanding stock purchase options",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://anavex.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails5",
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "verboseLabel": "Total share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value at Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value of options vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annualized volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional shares of common stock available for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option available issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding at Beginning",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding at Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Outstanding at Beginning",
        "periodEndLabel": "Number of Options Outstanding at Ending",
        "label": "Number of outstanding options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at Beginning",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at Ending",
        "label": "Weighted average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price options vested",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, lower range limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices, upper range limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "avxl_ShareProceedsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ShareProceedsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share proceeds receivable"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_ShareProceedsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ShareProceedsReceivableMember",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Proceeds Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual life of options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life (in years)",
        "verboseLabel": "Weighted average contractual life of options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of vested options",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedPursuantToExerciseOfStockOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "SharesIssuedPursuantToExerciseOfStockOptionsShares",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_SharesIssuedUnder2023PurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "SharesIssuedUnder2023PurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2023 Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r14",
      "r75",
      "r81",
      "r82",
      "r83",
      "r89",
      "r90",
      "r91",
      "r93",
      "r99",
      "r101",
      "r111",
      "r149",
      "r150",
      "r191",
      "r223",
      "r224",
      "r225",
      "r230",
      "r231",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r246",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r319",
      "r320",
      "r321",
      "r329",
      "r380"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r111",
      "r294",
      "r326",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r380",
      "r406"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r111",
      "r294",
      "r326",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r380",
      "r406"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r432",
      "r444",
      "r454",
      "r479"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for initial commitment shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r40",
      "r60",
      "r327",
      "r380",
      "r391"
     ]
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesNewIssues1",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, net of shares issue costs, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares, shares",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r40",
      "r60",
      "r204"
     ]
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of shares remain available"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares",
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "avxl_StockOptionPlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "StockOptionPlan2015Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2015 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "StockOptionPlan2019Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2019 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avxl_StockOptionPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "StockOptionPlan2022Member",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://anavex.com/role/InterimBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://anavex.com/role/InterimBalanceSheets",
      "http://anavex.com/role/InterimStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders' Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r57",
      "r343",
      "r359",
      "r381",
      "r382",
      "r402",
      "r412",
      "r513",
      "r522",
      "r558",
      "r566"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://anavex.com/role/EquityOfferings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r87",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r245",
      "r383",
      "r384",
      "r392"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "avxl_ThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ThirdPartyMember",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Party [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r176",
      "r189",
      "r244",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r317",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://anavex.com/role/BasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r71",
      "r72",
      "r73",
      "r74"
     ]
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "ValueOfSharesObligatedToPurchase",
     "crdr": "debit",
     "presentation": [
      "http://anavex.com/role/EquityOfferingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligated to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiry Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "avxl_WarrantsOutstandingWeightedAverageExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://anavex.com/20240331",
     "localname": "WarrantsOutstandingWeightedAverageExercise",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding weighted average exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r108"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://anavex.com/role/InterimStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r108"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "70",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001731122-24-000760-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-24-000760-xbrl.zip
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MO)!/!P>OKZ\??+0 KPA_)Q]L-)<;\#$ 04B6HQV^'2;_B[O_XKG^]T_L/\^
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M,& W94.ZP])==WWAY\93J #7"$^13SO8['*D%-II@)@[4G=@[\(@NGZDC.D
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M:/:K:\\ ]/YUC=Z$.8.E=IIR: 7ZCFK0*C59:1FS ]UX0=!_K-8!_6%\ Z?
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M]A01OW&9G?/O ?Z>E+9>A[YS<W,AY'1-K]Y]'@EVRT#F.C3:BG+_"8$7S"X
MAG=X"GSWSZ3.> ']$#XBZA; FL>IY4?8XAVY,2\DKD?,4X2Z1/ F8^@)\S06
M4'/YFIO3WZ^(C?1(^E:#7AV:IYF+XSQ[X=Y:;#;^J.?8VF(QH1HJ>)S^V'7
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M1N/)\*OBY%?Z9XJHZ^-E9Q]^FBZ.*,VQ"PAV ]F+P2=DUK=0;QW:-'S&$G6
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M\8"\58P/OU3=&8B)LLZ:OM@ZLB@M41W5HN#H.*Q#>FI'[E\JX0PK+BMZ53]
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MG'2?X3=A<8'+@OR1O\)<C;&,XY/Q2<M]"RGR=&P:T1!W3^#R"V$T>EV^[3S
M=XF"?JK!.7V;/L!LG4.V;AX<#AK#D.^3@->3D=$%ZQV-.&M'P]W1D(>L;1.@
M<]&D.=/-(SK3O203$'A25K43+[72/DEH@2PR3B,:#;W,^$Q<*LD(GC#;E],T
M0$H2"<^F4SBGCQG1/6B,[M=LT4:*(,1.=Z+9^&1\\F_?0HK$')M&-(S=$[B)
MRJF0%J"/8T^T0[RSY7S^3*KE@72=7Q,:%J"NA#=QC21]8EK>]I>?6MQN^WG?
MA()S]A#H3<2M:()@U:0(OC5)@G*79G"++!2?NGE<L?LFU4V9Y^<E9D])C9N/
M.J829E(ZJHCJF:E3$L&9_33<QGF%\#)X1=/<\9O'9@L_R1CTZ(\$6R:^/"56
MQ2RMT0;5V[$LWSOA0,1_8D5H^L*>J<;8/9Y6%.,HL%XN$XS^( L[5,Q+O&PN
MV=Z3KM1TH?AZSMERE9=;"&\AWJ 4JJMGEC,8[,XC?8)]4=!27D.,RHPN6BKW
M#G7P_,+TLXFJ3=W]#IQ9A+URFA*:.NL"%F3=G+,-\21;H@)1-S_2\R& CS3+
MYD8+]5<AU?/ _I+!#<S+%8L;UDI%U)=WU7:=;"E(]K2,:-OH61.ORXI8*_[;
MWB/B4S()/3H^O8)L(^7^.438/P]8+%.G_ ;1XH'NZ"<;TCD7$"2[Q(+WLUE1
MHXP>G1$;L8L<=_:8YNL,9N>$<M18K=O8 ,-3.O[2FZ:F#Y2VUUMCAZR.WF6Q
M0R0<31\Z9&DD_[GV )?O/]"'=U=E37HG2O)\"]IL05HNEV0BRJ3"]Z.;9D2=
M%=GI;CP50G*R+<4DK>]*4@MT'DV6L.P:727.!FA-P4Q3ZP?.PV>_FJ1ZQ/YU
MT QB\U*>HG#R^;-F2H@*>C!->QR:,A##9V(HVD,??HF?FA'V@*!JW],H[FT3
MV@%TM\]LD(V%;XXXA]3AKSQ.RHY3.(<80_[^)$>EPJX4\Q>S10]R%ZE%E@D^
MJEN F9K[""0'>>M7T^P7K>TAEN\N>:0^,FC# C.HBF"2]D8".^2."WK1J R"
M%:8<[[(=,>A84B>/ .]T)F)*X[]R0B11FN2WJ*9PKXD5(U!^016J*[:;HBJ@
MNZXW%HTM3L<I5\4XC,Y(M+HH$FFC#X@")]V*)P$V+(U(W$<:N!_+8EW!JHF4
MH5MAJ64]1U#1PQT$0I$%@Q/,!9V64,*LF?'I'A9PCI[.(8WU.D>/C=,)F<2W
MX894'48CZ,TN&8%V1D@I%9P05FC2108JR_UWB##W;R32$W'@$R*C8UT6[1&!
MG0PV#6^L<(/>T<,L'@=/G#!*SP.W2N">:AV>.D^/,TPW!61?7_-89%/R&@/8
MJ0"]B+Y&C>!L&P53&J_R')0L[F&,SM?:TI YWF?2U"X3(*MR@!F18X$44R2+
M9C1D' 57>G6LK.D1=(2$W!W]G90Y@5'RLW%A([5J"JCY?$?^5!&#WIT#6L\8
M#Y=1F,/E0U>4^H#Y4+E$TX$F*YH<'T?0[[T#R2*7"G_G\7'KAZ0 ?:7?6/HQ
M1()Z<DU=:MX,FR8+O^$/#E\Y_7 )ATL_FEXX0:&FZ'^7AWL"3;.VO(:8;LDF
M"V*0?L9EQ1XP@C"KZ-'.;:+93W?1\K;&="]"M\ZTJP1GZCB<4BR03I$Y_V'F
M.='H EIWH$H.L.7^]'E7TOGP?UXO[R%N?*^JBZHB<\2+0NAQN@%U5!)>YTI[
M%*XW"QJA'YRO3P MO6'-]/@-.>[)PYS)JS)_\L/5NAMRM#-<S6<+#)E)5CJO
M&27]W6XS0MW=75.*!6>)'9OD+YDT 8V25GS:@V46GJ;E[-5]CN@CN-E=V=Z?
M4Q7(KN.-'J[P.Z+8%.*@C"-*Z>6/5A+497>?*_R@1\T9-X>G:QHYFOOT\\)]
MAM_8)]U"Q579>]QPYP))0<.MFL$YN!=<_;#&/5,!8@DQ/U94(.K%R@8\'M3V
M0.ZK.I^ZWM"LZ%!DHDD6(0F+HJ3T!1N7@#^_NWT*MO/$&Z,=G)5[0Y8C!Y:
MRM##*92"8DC4,DHS*JZ%:,=+"#.N,)]_\M#\FE[LHNCU727G@O2>5[)J!2?H
M:*@*8@I+UE85$(-)EZ^4H9"I3^5\T<8[O)I?< .]"SJN="$PROMSQ7" O?/(
M, @')Y K0F6@R0T+-$DX4C] Q0 [G6,J/0/+SIK[DJH2R3(^G5"5\$37TYY
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MQ4>0/EW$[&L; 33Z=D'CQT5*$Y*F9R0-.9U+^=I(,W3IA*(@I8+;6TY2P7<
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MPJA-0ROKZ.OF)Y(($F,QV\;1C";Y"X.RW$=)L%Y$UH[81P,[]LR-H8%([$[
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MD7K2J&\G-'4QG\<Y<D&\1NXRF3 ^"U0/#BNNP*$#H-</;:$CCNCX2F:3QF!
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M95\VFCUP$U5:+MP0$/HV1J?3K.1![QZHM<%-4P&!R+3$HZ"\)D!8N:N4IK8
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M+#(Y'<:T654[(.I>'&HM%AL5DX@+S@.?)1EPO:FV!:+NQ6'6>KEI,HN[VMC
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MHB=3B &YGD(H[&IS<1'@2))<V%T\MZ&\%G87R"TI;G #L^?-I(W6U&89JBW
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M/W8N_K0G4=8HF?HO#"HUL&%U=4[S4B1FC=.^^ N>\#923I:0?XV%&ZUBV8
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MG6M-LIV+H2Z.>\^1[G3?P>G<V6:@@FL6/Y_N"CC!Z</K2(Y'M'3(DL.;6_=
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M-0VAG7&_]-UY"WV#Z/;S.R2(#VET(+RDK;Z])]0 DW--<DP9Y/9LYB=T X8
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M4T 4A_VA@MP]TGP,>P'#/M?%8A)GZ1ZZ#P6"]L'7$8%@UL<"UKJ@4[@8\3#
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M)%%5!*+<IRJR"B,8=!Q[&B 94S4?E1@$Z>H:RA[DO]-I"#50I!.J+G3A$FJ
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MOL$IC9Z@=E&/#I5ZU_079.Y%"WRG+M68VG_H0B8>XV82Q*R4("M0:0HCX+H
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M3%#N= #*1B"KX;(41>;A>5AH/([NHFS1[\!2.,A17R0;O:\H!8^-!RKCPS^
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M*UEFWO[R*R4;E$")"G3\4(@$0R:HI]NR-N@)T($3P1#'=)3M'%! [<('\)E
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MJ*NBH:G>KZS[LZ!B1(*I*&-*0Y*Y3-X<\J>.9-4N.Z!T) '3+RACB(3"H.Z
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MMV\T[3(-UN C*!\6EA["0Q3K!1?K,PMC_8=$UK "L'*%H!RH\B8E !3/9O>
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MCF3M*>T<;G0>.(%&<% XJ:;WM3U6A($!X.03,^@D#PU>K-LXW$3R3]>:2-K
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M,+XLU"VG^KTV*E<_6QSPO@\'E<[)#^WM?J_:V^H6!Y6)[%I?OP%/>ELW($Y
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MEIRN]N=N)X[??)W!<.8^>\H\8S%7!><75=#NJI&%?K.P:B=EA)K+;SU+/>'
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M3<,#X:U.0+ZP#.3#VLE8/#HK7LL-R=#:FP!YIH/8QE38)XUFQL&^E(MJDAR
M?18HQ$*_N?JB:"/AZQ2'T<%2E^&209%>QM"HM%JMYDV]KVW&97 R*$9>1=)
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M>B#.M*I] >,HZL6'\6/W[OSHN-'H < L9P#7,B+[^%MHJE9',RP'^,4NHM)
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MXK.N6'L,BHC-A['5/CW[K3U77DXZ*T:1Y8X*_*,---#^)P6PA=>*2P*L!I,
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M1:T.JN0CZJE4E:?*O^7K@!_82@(W6 !044!Y%P 0QMRF$ !JL9Q.!PBLZVC
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MR9&X^0D*$!@%4!@#*,  5:T^P7+2I@U3*%!@["JT.(QH,RA ^NJ0JT"QDH"
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MRP9UBZ0/D8-BZ=L0@&3(I"X+/R/CZ @[:C@]@! &>_-9C^9XAP9:J&0QH&2
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M41B^&)HS4#(:6,G^4O)7   /#_ 3Y?/EG2R3O<03YDI63RIN,8L_=$ST(@Z
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M;MK6)S =*FW305'O)C!%98=X>2\9-^0[ Q>B>R)-;YA#M8:0685<&QMC\@@
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M)@/LDN@9/^P'&F&_F(PC2O?_8 S=<D[A-;X"8_R=R)B7H)B-)QV,=(258:;
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M-M?JF@MZ%J,J) 9Q ;)H$7VYOD(]DRR=/8I(;%FF<K0-Y6@]6#F6UH20;E'
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M1AP^,38K!G]>XWMDB:I--%!SXXW-"!.4H!<R.J(9KKSH DB,.?!8/[#[4X=
M(JXZFC)D-$^4^/MQ-2>L96K4V!:4/HBF8?4D1K'&._)64PT032#7 TO,#M,V
M85RD,Z50(9](2_LLHI^]\" H7A]V)&N#3PQS 2QB--'X.Z2,$[FO@+N\80!1
M1#TE*@149><6+44X4IA_,FHG4 /@*7<ZGZ9@P%JZ'1C!4YAN UXUY20<6,DB
M@^U$>!U@R[,.F,TNL<C2H;WS*%4!EB!V9\%!93\$6;!%E2]^J!\XWZT ]'';
M.5XS2<>)KH%=_\:.;[F'J! -1F/*IDQTK6@A)OX+GK@ER(G;8>" /*-L@Z(7
M,7G9HU$61MNQ+HX*IO"=NC:M6Q+Q4)0$G8N2H!:7!(D^!-%WDK0)>6]TEX\=
M3!3_[X_R'_3O,9HLXM\/'L.=UYT,\*/E__R!\;S_3D+Y$) 9HLJ4XP(C\ \1
M\IMTY8?$]ZM[XWL]X$DW]W/;^+E86A;'6HR\SRX/&)^RO[.[_[=*;&<\;7FR
M-_74?*BWS*2"\5<M5T4B2;'N[)1VD3!KB#9/8X0075"W#$K=J7-6C)1]-"5C
MM<N&UA(NL/2O&U$4=)A1)&5FJ-%$AA7@^ZCB-?H0KY".(R%,"T#/$FY!\$&X
M(CYR* GS(@2^0I.Z6JZ72_:9JZD%!&LBP3E@!$'7F;-#R8QZQ%0F&TPOXD(3
M?5[ MA%!.IJ,!E:3JT%=9^"FF^!-QZ@FIGPAPMP8$H.7@^TEV+=IV)>]'+A9
M S9I(&>2TFI9C/\=) 7J90+GU9AU?2 ]RIT0*S7/E]QFW1:D9,HM_$](IVJ+
MCN\_7Z<FZ/]J%+3/9!^A'WH4@7IF%RM[\9#]]](A2S7(*MKCVVF.K],:^=PC
M4FOD?X+B)TIR-?Y7.EF)$E,Z6ER#&&*.."KH/DWHLG45?C$:!G<%8@5!BAR4
M928'45$;H4O@:<P#&0,$" _/B2BLZ/<1@!E+8Y/):<N80F>NQTLD"J#^B!X)
MD8!C@O27%BR"X1HEN,R<7@^,EPFC8(C%KE)6FG;L!EB);!":@=\O2?"];G?H
M%DD%<[-ZT+_P<_Z.Z/V0.R"AP7 T]V.E^N#X=@;VGY5*J6ZWQ1A(#U;W8<T[
MG8 9*^"3SX=!VQD>.1,GXZ2K<_[[H"\XZ,L.,4\D^PP_LC:(][>29SS^4UU.
M_*X([O:M05(88Z%+-&7G/+U@,:.^T2+*CV?KSID;)U!\*T;0*FJ5V-WKA-[8
M+('#(0TG9'ZPPX@C)(0BYH$8MTE. "FA<#I6?$%< X%9(9A:P&$DJ4<P&09G
MCYY*$R[$U%DV$($GR$ W*J!@G:;2,J/IQ#'+<KA1&RY@R3YPZ0MP$(9NQ.:!
M8[:B'V"4EUAZL1.YI"X@@ZOGTI>0<GV.*;! 6Q=R<T270_E^W$"52.-%=X@@
M'A8;MB-"?LU((GQ&, PT.S"3#@HB1"9APFXSSQHQ2W7FX.LC1PH/A0;!)=BN
M_$ A(4K)S3$J 0MFN)C?XE+U'[?^4ZUS!MZPJY0<!MO^E@\3>Q)B(_JN(V.:
MKA?&[*VQZ]R"&#G#6U:F#H;WAZX[%D('B@29LE39.'T(*^(2AAMB#0B>!1*$
MC4P2G>(D3;'9?,>NT K2K"IE9# M5NI$9"J6L&0;-D&^AEV*]S-QA\MQ)OM/
M&6>RO[XXDSPQ^+DOPY_1ZHUABNUB'&,L[%HD(X\FTMEBZG%0_TY[R'TM2/>
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M:,@J"@-,ZIGOK&:^5XYDP>=64[^KCS/K73\D1W/DJM(>J1V-'Y'=R1PW'"9
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M2K &]ACP'?J(0;W:N&E<-Z[XQ[_E]SO*[[<1X*52::\NE592*-, M <)YN4
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MZ.CT)$2!L&B/NY !0I(H<H5K;='&Q$KRS>+GU!)]6PX(ZT$<$.M:\/I6=L%
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MAZCQ-[Q-+B ?!$/20]@'>X85JGC9HG[DNY;OZ%' 1]-GQ2#/0&ACVW@+7^>
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MMVF$K#ST>YR,C_<ZEFIF'QZPRF%;A8@)X1'M.)QP,B]DIJB42'%N)#8&RG_
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M;1ELLKV]/RA0\[\_8-+/<B;\N"/8-T>0O^I__./P/_Z[%1O,/^E_"V^-_BB
M=]FE-!/YDGF[;;[T.ASYDR4[_:D3GK<_G-T??-A_3&'<SQ;&54;H?KY_&37N
M!B\_M-=$%O?+>;*HY_NX Z@L$$5S#*KZ^('"2$:[]#$)KP /+U9T]:\N))-N
M)\BL^ (\M9CQ)2OC2]A9D @X,42;!$J0][I=WMMP*%UZI8J%[5;QU3HS#:R0
M@]Q[RCG(O=\YR,<U;VMQ\W:G9#??O3@Y./EF^/ULJU8W432;)B:;*C[XK4:G
MQ 4=%9<U400A27>HXJ<]L]O)IEORG=CZ3;8@"KG!8+VT2RV(Y(^Q_9#\:2+
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MRE_D!DW^A!NS3X=SN^-,(Z)5(C8V2D8RN9L@B\.R7.S8X@Z<88]KLT1?,_Y
M03:-A6_1 YWI9! 0>]LZ:_?V/US6#L;!<1,\YI/F^6&S91]>7%V6[.]8RO"C
MH6Q+M8FA2<1#ZZB(%IME6]%6;@0W9ECF/%TND3K]#QGF8O,S]G#\VI>];%E
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M(:TTUZ.=.\J;8C@@(4C=A0#-O(EJ^&$^9F#\8>DN?&KS 8-JWQU1I&>)WJ7
MT#+0L2_WQ'U,J0%=&Q_&+W%Y^18Q\3)$[:JR[&'[XOY &K>5,YI=R^@=V:UA
MV#03I*H>?W@C**IAOF#_#LD^QZE86S=B3B6&?F8*="N#_8TS(Q'J?U^@J#M8
M=%':9VI]\;7MT1;U]LW%9YJ)9K*-!7BTUDT;P1!>R7-LE351W?G4/!NT7YV"
M9+%[88[3AQ*?MK#;)RPN*I_/0N=2XMWT=Q[K[?/)3P3"U]/JO=6_:ML+$Y!>
MMYXFDWW04KDEY;*JVI[HV)J=;5):6>AOQAWF,[FPA7+-=<JQFP+#Z*%:VC!(
M#._C@X450Z\7+<DFT0!,?'<$)$AGT7(NBJWW,9<\H=P/*:.$J#X^4\4\\ML_
M396*X74M#MS;N@@S=-^9O:SK2RS.DA/^:HQ(L==A;E<.5'Q_,*U\NWSR0G ?
M2V) JR!+V['.YJ*W^H5OC09<$_)B]THS^%"L77N1MCTHZ%GVH!JI^)WA:,T?
M67DM?'0G,Q-WV2^A]UQ5JQA:\9CVI_5I(O>^B]VY[N'@I5)IL*7%_TJT92N$
M,@7LS[KV-83N(]//5%R^_CNKT'3E$'CM]^F%M:?/&'HY<_1-\ 3D7H[J]-7>
M&W2$3A$[3!U]3.F*?$M*HY&:7\CG3W>HDK@DE!).^0O,4,%O*?3'05G\UDZQ
MSF5S;_$SMRBW,#+V6BJOQMW[3>U>AAO$!KQ%MAU'W$D[+#*RD)WN%-Y ,+\H
M,II_B)E9IE:5L;4$_P#_V:5:&R Z;_.H]&M@HHU.$#3WVWUR2\W+$T_TZQR:
M:_B,X9#YLCJ+#XI%>F-L0<5%&>G=U>4*PG2)A(X*!(S[ 7:WNEHN_7P\*6BI
M4OJDB[I4K_?$8Y+)8=++'.6E4?.XHB=>E]D-;A87\*+]\V3$=;1O>8CYDC__
M@ZXTIUJTW;F-PH';8:6!3-$55G1TK6)]$,MH093W*_.(<Z:-YS2JZ8Z9]G(7
M@]_6ER.R7!,=\P:*;[X.$WR$9[D0Y7VJC5^CN6$2SU/8G$ N-QX;(VY9*T=5
M'.1._<E3D9K\M8@5(Z_>_H3UIJ&L?D#74 !?!)X$-G[>LEAJ@&P*JN]V(/FT
M*JG97JJ^V-8G4;/]UNGWZ+0J>9?#PRQ])57YFT?=EV8VV6-;Q0[G"SHL3*Y_
M"^8)4]:1)Q)?J/J$7B/)*$_PN$H>NKOUHEWTF4<O9_>SWAF4"PY@^OYP#0>@
M;'$ /PX8$Q*(/*AED-K>7D#ZM+U?'#@O^4@<,<'UAHTC:U+642!]15.MMRG%
MIII#Y9Y\XYU2)(.RSS>%(WH)O@O"_:F\VWA3@VG$]">" P@<4 %NG?IP%&Q'
M0:M%5?ZKG9LI-3F\[:LG4QKI]M#@^(C&4\NMMB54EH&L,$:2X_.HSJ<;Q83F
ME\H3U;]X=!PM2'B%EL#M'0@R_*ORH-Z.8NA\H]KK$RJ[\,9KQ]EV.& 1L:,$
M+;-]BP,B:R^G?:F.3./K*](4Y^YG3MIP5H8O+,%:RVY+GJ-E""AU,^&>QY[E
M^L[4A!Z?F1TEV(9B.G+; FSJ%+""<%,#<!/UYD63J>P6=E/>E27.R%O.1B,B
MT7A[0UB'%BQI#B8$5)3D!F*''=8:^<=<H23_GVR-!]0N:F>Y&W#^OWUX=EFE
MC\23\H+K5.TNY/G+RGR-?<\.(\%IC&89!3EZ%]U5P<WKDKAZ<EGB')@:UI4V
MNCA+4DG#SV]-9NO#FBD\I8:^U<4G4TX;=_7J)BZV*:%W=7E-3.G;WE5(7Z?8
M<??"WD\?\#>QUK"HY//)\LQWE+1#3/15895 5U@XX@.+HYAD)8_-9SHK#DEE
MQN/78=.M7MX#72ZWK,[Y[\41E"92B+^H0[>6+I2^L>'_U!='BW<3@YZ-[,SR
MOLZ8G9DJ[Q+>8)JG.IEZN+*?=[1GBT8@1=#X]:$J\VC8;/*K>2O7R&XRYLCG
M[KF:](Z><_7Y BY<(9?3R(.[FCCHO)PG=T37=8LL+'D?61I'G6/U-'9V\1]$
MS[_#I%N4IU=DB$X$M&S/^B;U"7K;P,IP0"SQ9\42[$-K!3=8O"AWM>SSBV0Q
MR 7.OI[#@]RI)RN.W\X3[I]W>)(S"L%LVV9Q%78K:REM-Q%X&%)X2"V$86QD
M/J9:["5HNZ0&3^+'M^T?Y;GQUN" #L3LA7L3,'0BEE0T?*9]EO(.S'/H*0Z
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M*']).L-!;>S:66 E\>( ;Q)[-CUR!EYZ.G()/A>NYXH(]_6@DA'F"Y%]7E?
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MB,L<S0LF["/! GK<3UVTVK1;%&3C"I.^8$KG^K9L$7'P!;FC-K"MKLW'JN*
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MU4 ^89>.BYC%>>W<(8QK_E6KMC<7'GA=;T)P#[ZCCBF8\<!5#>R-)@3VJ(Z
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MOS6;IB#20[&<5)-!7F*+B>? 2J?GCC7,J1B#^PGWDV1$F'2*N+3664LII19
MID#=+4I3E6\&WRXF_[^G2XJF$#F-UGA_O@UV7W!G3,E*3F=+$CO])F.B]?>:
MA.K \KH-CKPS]UZ8Z6'L7];-L-C2YLS\IB9WG.:C4#$TBCHF8%]O<5?Y&FAZ
M)DL7LN1=Q,,1,KNL""%,*KM@0_XCW;(XLS,G'8,08@7LI1$)R7J2O$+7"<N?
MJ#-%TE(!3IFO-FD!MCRDL,--P=HKQT^T2\H_*#U\^]A$0LH/K#\5/Y4!O&AC
M:?;U3388ZR!;4PH&(!@$0T3G.U7PA$Q':&AF: <>:',DJ82DOJG;)'5ME0/;
M3BDD2<&H'MS$W'VM]N)SFJZM]0GG E4.6"'@ >G@HMF[!X/%/U_0 M&O5,X%
MK*Z8WW:VT-9^MO[20VNYTC%<)]B$2<'L;NRU%/.@>2.R5Y#[2YFRK3(]>HG7
M=IYYS^BJ2G U'H!_(HE#1&BOF$MO$]J*QNPP\T-2!<G"^9S/O'5XMU<_>V:W
M6\H7/YDJC"\3F&7D5TA!QO@N@R$/#<N]21S14CT-?1WP$?4QZ9CEXO6/@*4K
MU5 4:ZW.C4=9Q"Y5M#\M0Q>$>6SSS=5=G%VDP<[?]UWU]RM)3Z?2K1SC@UP^
M*PA]-/-9Z#[=@T#P@*$_?Y?>"3!+@-W]!$7P..3V7P-B_X?H8P!Y0Y2F2;9J
MB4&?F\:WR9GAR=B!Z9$7'7+$TJLA1&#$B]]9]AP'1"D7F?S"A\/69XRE@0$2
M"=[0$/G>Y:]?US_JT+RT)T\Q+)3LO]IM*R)! K#$22?7&!(%E-W] F7"T"L7
MI,VO<8_)#[R$#ZA+=:]P9-D]TBGQBYP!&^FY=4J9SJK?20[C$=%3^+5<)T"B
MKD=C,F2,$.UN[K.G6G!Y8:M A(R3QSH&B'+,])K<4$]<29*\*O/Z>C% ])4=
M(*X>)J!5WGK1(\/XO$O63Z8WS4A/J6S9-^<.<474L_V72B2%;8S-OF";5:@3
MU#U08F2Z-43.!Z4/7R3<X;BDI3 A62\TS0.1#: 7JO;SZ&"1?>9<^IE$XK:1
MSS:-(F']E_3 EDCJ9*MGMH_Y-*-)#5 !;IS7O9!3)#<_-V$=1=K,U8?X!WYT
M,<&G"H.*2>3]3/M;>C*T"MXT2VDT )EO+^\D9ST(Y"],,>2S#4T>V(>.J$OV
M/1&BW='QN[N?28J\1L:U9#?K-[#OATQ&^_:H,7TIG4.^JZ]#)S2J)<F;^(;H
MFH&YW%_"P0@&HL:BGU4_2[D[]R6"\FE49ABLB>#*BM#2TJ[X<D^=LLTJ"S-5
M;U*!9WY'2WR#+D*LP1@V%84SKXITR'?:<L"4_9(HYX:@ _'E=(:VK;1WS^36
M06+^]CD":"/.H$*1U&DR4,!XI97CBI@":S$!'A@,!I!4%"5Z<HP!#S8?DI5T
MOFIM&@=U^'^YU%OZAQ-T?HW,3@3!]73&JE""@5@]^'<>3>NOQ3A)GOFOQ9[A
MSX#K;M!A[GGET72FT]D\^!"+;4[6>ANUQU0.56,6ZFT.<3RW8H%S M=E?9%\
M>0@TXOJC)#_=7TNXSDW7SZ]K]$1Z4EUEZ)&1+V@>7:^\3A_D0%(8OBG\VBC\
M%RMC/^6CT*1;RQF&C9'=3UT6;<3N^G'NPLT]AZWG_&Z1'-G8X?1C^6/Z5E*)
M-7^H2\))0X\?/PJ^W'ZU0Z"I[G5L1RJG3S<%R(VNGS/ &JW,7F- ,1[X$,Z]
MSI:<F#N26Z>W&W^V]ADKGC_KX*]5TY#$[WQB)9YP>9)=DW2? NL^4[=!E&F'
M.[Y(4H[DQ\#/T7H?0H2LU-:FS34DY]CN=DQ0T4LB%$LC(G1&RT,+'ANQ6;SD
MG+5/S.(PFIT*@.(!#H*3-26+,^SMW;]C#KWOX2&O +(:E"&ZIF8=X?9JKQZ3
ML2P:LUYBOO0A66_LQLOW3FPOV1*&F +M]RU3@BJRPQ4B-9J2R-?SEM[.*RW=
MI0T'Z!#W.;("OET6/Z*-P /KG5L$1R[^6/\\- _V3>EOS.,R-.MR1_U3:W7*
MT#AYT$>MHWXMY^\KX4H1+[/BOX=(ME<%$K2-$K/5,0.L,WX;1$MP<<(0N$N@
MO7+MR((&@(4RP3.!5H'H7(A6% \0, FF/X_2:EH)1' <K^1B*2&+&O_6^?J?
M_1FB_EXM?Q#V"W*^[T#\[B\5C"P6S6[?%KUEO/T^26"H^0U4+FO!MR+@;Y6=
M"O<VN'OOOX) 9P,H@>G_&"C_]^B3'(9N1O5&=_>;98OAL/[>H-N3F^^+D3=V
M:NK&F"BX=V[HDJ_7 H_C'U4G>-[J1D:]S<2\(%]Y1:L(+K PTH-RW&P)]1#P
M1,<W!<3K/UK?F\P>BN9%F_?S+6T/+:_;SL;8YI'$=5[D)FC+<7Y--5Y%=5W2
M/4%#=^[+^$? ZE9V0DH^L^27,G4?<E^;RQ0*06H4)=--ZSMNE8,MI?*D8NY)
MBD+EE1';VUUE.K+PR*5I8VLR$O?KWK<UZFO5<2SC.;0")PTTU]F[N")4QT)D
MOO_Z@=EN"&NIG3TS9\^?.*54#7+@T:*>(.)U+NY5"5<*P=S4';Q37?4\1LG&
MQ):N6IJZ :0,QGQL&A7]Q5,7QOK^%?=9(HUVN#E=<I8W'C@D&-)//W?^2)A7
MCJZ1&UG4)"M4^:G'?,3C$=UL4Q7&J=DNJ'C)'KX83?[+-DMF-9_%T)Z4!C@X
M8OBA(%S8?UW@;MY=\H<-7KSK"KZS#B0&;,U.)85QK 9&(2%GNC[).=);':57
M,+V*CG&YA2J%D:347$8S@ ?-I/D"S2T/_Y7)@[.MP[PKJGD?"PCZZI\F5E/U
MZG'F>\HKH<X9-VLDS)0OMTLZE?S*SUQR&74:?'-R-E_+64A\WHXSR-V8S@&3
M*!*]6C(/[6<'8S!YE,,EVJ_4ENWL 6E/..C<GV]BE>#3^WISU^&&_!^'C%=(
M:=7JI<5VN>W$Y29\XE=NX<W.1X.6E2EGXD]5G^R["H3ULF"+%,YAIP>R'WJ.
M6Q($.LZ&^WXIU>1.,^?.@=+^C*<1AS1!)'$RP'))DD>]P4N4R!SXY^Y8VFDF
M'1\R?;*)?\@=#H98OFW_)TU@SY.Z,]/AYC9QMWX?3US=-#*#O_/E@_RP':_S
MG"_"?6W!;6#A%\$FT//1D_C?>92Y,W(H-$;N_-"")E3ARX^^<<V1CKTKUX\8
MD_]>I[R<8\1,V#[N 9%X8N@VP;A&">01_T]3,D/- V+;K9/1^,IU;36 3ZD]
MF^44Y_6?%_XKB?3^?Q(,_^-_ 5!+ P04    " !YA*E8@S(#_ZE<  "/<
M#0   &EM86=E7S P,BYJ<&?LNV5875NR+CQQAT!P#Q)DX>Z6X,'=W8,[!$V
MX [!W2VXNT-P#2X!@KO+NF3WWGUV]SG=?>ZYWX][GZ\G3_U8-6O4'%6CJF:]
M8TS \^ UX(64F*08  $! >@__P'@1> -  \+"P<+ P\'!X>  (^(C(F"C(2$
MC(?Q$@V3")^$F B?D)"4@H&*E(R.G)"0FI.&CHF9C8V-A(J;GXN%CX&5C>67
M$@AX! 1D)&1<%!1<EE>$KUC^MR]P!X .#Y$!:0<%009 HD- H4. >P 2 ("
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MZ3#OYC K[25S<9&H6.?O69BFW/]2 BJMYP77L1!1.-9F_1/E=-D'YHW5 S"
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MYR7R\KDLA-3\G^GX,Y>6PIWH#;2NSP(8V%>J9KQ6>KH37!="RTY*\FG*N)X
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M_/\(P)1G$OD]3O4W*P >%O5[*I!?G )Q+@!]FD4UC>M#WF7GVZ/'!>C?<\[
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M+3(P,C0P,S,Q7VQA8BYX;6Q02P$"% ,4    " !YA*E8(NYZ-F<N  !!^0(
M%0              @ %3;@  879X;"TR,#(T,#,S,5]P<F4N>&UL4$L! A0#
M%     @ >82I6-$C%__S,@$ AG(*  T              ( ![9P  &4U-C0T
M7S$P<2YH=&U02P$"% ,4    " !YA*E8*&.+)C0'   G'P  $
M    @ $+T $ 934V-#1?97@S,2TQ+FAT;5!+ 0(4 Q0    ( 'F$J5A';CU+
M*P<   $?   0              "  6W7 0!E-38T-%]E>#,Q+3(N:'1M4$L!
M A0#%     @ >82I6&TT@J/@!0  <!8  !               ( !QMX! &4U
M-C0T7V5X,S(M,2YH=&U02P$"% ,4    " !YA*E8]5X];I-=   X;   #0
M            @ '4Y $ :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( 'F$J5B#
M,@/_J5P  (]P   -              "  9)" @!I;6%G95\P,#(N:G!G4$L%
3!@     +  L M@(  &:? @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>e5644_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20240331"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20240331.xsd" xlink:type="simple"/>
    <context id="From2023-10-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ShareProceedsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:ShareProceedsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_MichaelJFoxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012021-09-30_custom_AnavexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:AnavexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="AsOf2023-02-03_custom_ThirdPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">avxl:ThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-03</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012022-09-30_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-012023-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-10-01to2024-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-10-01to2024-03-31" id="Fact000004">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-10-01to2024-03-31" id="Fact000005">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-10-01to2024-03-31" id="Fact000006">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-10-01to2024-03-31" id="Fact000007">0001314052</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0077"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0246"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2023-10-01to2024-03-31"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesValue
      contextRef="From2022-10-012023-03-31"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_ShareProceedsReceivableMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-10-01to2024-03-31" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-10-01to2024-03-31" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-10-01to2024-03-31" id="Fact000015">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-10-01to2024-03-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-10-01to2024-03-31" id="Fact000017">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-10-01to2024-03-31" id="Fact000018">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-10-01to2024-03-31" id="Fact000019">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-10-01to2024-03-31" id="Fact000020">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-10-01to2024-03-31" id="Fact000021">630 5th Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-10-01to2024-03-31" id="Fact000022">20th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-10-01to2024-03-31" id="Fact000023">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-10-01to2024-03-31" id="Fact000024">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2023-10-01to2024-03-31" id="Fact000025">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2023-10-01to2024-03-31" id="Fact000026">10111</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-10-01to2024-03-31" id="Fact000027">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-10-01to2024-03-31" id="Fact000028">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-10-01to2024-03-31" id="Fact000029">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-10-01to2024-03-31" id="Fact000030">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-10-01to2024-03-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-10-01to2024-03-31" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-10-01to2024-03-31" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-10-01to2024-03-31" id="Fact000034">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-10-01to2024-03-31" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-10-01to2024-03-31" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-10-01to2024-03-31" id="Fact000038">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-05-09"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">84641537</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">139386000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000048"
      unitRef="USD">151024000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">3785000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000051"
      unitRef="USD">2709000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">1345000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">653000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">144516000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">154386000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000065"
      unitRef="USD">3726000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">4322000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">4915000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000069"
      unitRef="USD">7295000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">917000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000072"
      unitRef="USD">917000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">9558000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">12534000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000080"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000082"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000084"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000086"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000092"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000094"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000096"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000098"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000100"
      unitRef="Shares">83616218</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000102"
      unitRef="Shares">83616218</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000104"
      unitRef="Shares">82066511</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000106"
      unitRef="Shares">82066511</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">84000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000110"
      unitRef="USD">82000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">447345000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">434839000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <avxl:ShareProceedsReceivable
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">-234000</avxl:ShareProceedsReceivable>
    <avxl:ShareProceedsReceivable
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">0</avxl:ShareProceedsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">-312237000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">-293069000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">134958000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">141852000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">144516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">154386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">2790000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">2883000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">5399000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">6200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">9729000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">11307000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">18413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">23373000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">12519000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">14190000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">23812000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">29573000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">-12519000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">-14190000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">-23812000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">-29573000</us-gaap:OperatingIncomeLoss>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000157"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrants>
    <avxl:NonOperatingIncomeFromGrants
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrants>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000162"
      unitRef="USD">472000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">750000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">1064000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">1483000</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">1756000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">1465000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000169"
      unitRef="USD">3764000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">2733000</us-gaap:InterestIncomeExpenseNet>
    <avxl:OtherFinancingExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000172"
      unitRef="USD">-0</avxl:OtherFinancingExpense>
    <avxl:OtherFinancingExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">964000</avxl:OtherFinancingExpense>
    <avxl:OtherFinancingExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">-0</avxl:OtherFinancingExpense>
    <avxl:OtherFinancingExpense
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">964000</avxl:OtherFinancingExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">-150000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">-118000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">7000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000180"
      unitRef="USD">247000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">2078000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">1133000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000184"
      unitRef="USD">4835000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">3524000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000187"
      unitRef="USD">-10441000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000188"
      unitRef="USD">-13057000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000189"
      unitRef="USD">-18977000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">-26049000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">105000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">50000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">191000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000195"
      unitRef="USD">30000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">-10546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">-13107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-26079000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000207"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000209"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000211"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000213"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000215"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000217"
      unitRef="USDPShares">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000219"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000221"
      unitRef="USDPShares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">82464226</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-03-31"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">82464226</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">78304363</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-03-31"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">78304363</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000236"
      unitRef="Shares">82269965</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000238"
      unitRef="Shares">82269965</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">78138940</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000242"
      unitRef="Shares">78138940</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">82086511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">437184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">-301691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">135575000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">7410000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-01-012024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">-234000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">7178000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <avxl:CommitmentSharesShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000272"
      unitRef="Shares">3707</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">26000</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">99000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">99000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">2652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">2652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">-10546000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-10546000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000300"
      unitRef="Shares">83616218</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">447345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">-312237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">134958000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">78032135</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">393582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">-258536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000306"
      unitRef="USD">135124000</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000322"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">844000</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">844000</avxl:InitialCommitmentShares>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">2075000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">18151000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">18153000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <avxl:CommitmentSharesShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000338"
      unitRef="Shares">9080</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">44183</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">181000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">181000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">3970000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">3970000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000357"
      unitRef="USD">-13107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">-13107000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">80235398</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">416728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">-271643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">145165000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000374"
      unitRef="Shares">82066511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">434839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">-293069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">141852000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000388"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">7410000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-10-012024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">-234000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">7178000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <avxl:CommitmentSharesShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000396"
      unitRef="Shares">3707</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2023-10-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000404"
      unitRef="Shares">46000</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">158000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000402"
      unitRef="USD">158000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000407"
      unitRef="USD">4938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000410"
      unitRef="USD">4938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000424"
      unitRef="Shares">83616218</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000418"
      unitRef="USD">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">447345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_ShareProceedsReceivableMember"
      decimals="-3"
      id="Fact000420"
      unitRef="USD">-234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">-312237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000422"
      unitRef="USD">134958000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000432"
      unitRef="Shares">77942815</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000426"
      unitRef="USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000427"
      unitRef="USD">387977000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000429"
      unitRef="USD">-245564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">142491000</us-gaap:StockholdersEquity>
    <avxl:InitialCommitmentSharesShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000446"
      unitRef="Shares">75000</avxl:InitialCommitmentSharesShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">844000</avxl:InitialCommitmentShares>
    <avxl:InitialCommitmentShares
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">844000</avxl:InitialCommitmentShares>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000454"
      unitRef="Shares">2075000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">18151000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">18153000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <avxl:CommitmentSharesShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000462"
      unitRef="Shares">9080</avxl:CommitmentSharesShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares
      contextRef="From2022-10-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000470"
      unitRef="Shares">133503</avxl:SharesIssuedPursuantToExerciseOfStockOptionsShares>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">439000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <avxl:SharesIssuedPursuantToExerciseOfStockOptions
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">439000</avxl:SharesIssuedPursuantToExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">9317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">9317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">-26079000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000482"
      unitRef="USD">-26079000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000490"
      unitRef="Shares">80235398</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">416728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">-271643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000488"
      unitRef="USD">145165000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">-19168000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000496"
      unitRef="USD">-26079000</us-gaap:NetIncomeLoss>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">0</avxl:NoncashFinancingRelatedCharges>
    <avxl:NoncashFinancingRelatedCharges
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000502"
      unitRef="USD">845000</avxl:NoncashFinancingRelatedCharges>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">4938000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">9317000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">1076000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">1545000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">692000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">628000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-596000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">2456000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">-2380000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000520"
      unitRef="USD">878000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">0</avxl:IncreaseDecreaseInDeferredGrantIncome>
    <avxl:IncreaseDecreaseInDeferredGrantIncome
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">473000</avxl:IncreaseDecreaseInDeferredGrantIncome>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">-18974000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000526"
      unitRef="USD">-14283000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">7178000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">18153000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">158000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">439000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">7336000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">18592000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">-11638000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">4309000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">151024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">149158000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">139386000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">153467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000552"
      unitRef="USD">220000</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <avxl:CashPaidForStateAndLocalMinimumIncomeTaxes
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000553"
      unitRef="USD">140000</avxl:CashPaidForStateAndLocalMinimumIncomeTaxes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000555">&lt;p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zVquyOVOCMle" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;Note 1 &lt;span id="xdx_827_zKA3th0VVxZe"&gt;Business Description&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Anavex Life Sciences Corp. (&#x201c;Anavex&#x201d; or
the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex analyzes genomic data
from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative
and neurodevelopmental diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73
is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene,
methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2023-10-01to2024-03-31" id="Fact000557">&lt;p id="xdx_808_eus-gaap--BasisOfAccounting_zV3AqSQEUKT" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Note 2 &lt;span id="xdx_82F_zgsJzL5IulI5"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zknPsUIJItp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zbqgpltKOaMa"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2023 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2023 filed with the SEC on November 27, 2023.
The Company follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the six months ended March 31,
2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--LliquidityPolicyTextBlock_zFI9bTi0SREa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zJ6zC46Uj13i"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zfYWLHu7rmYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zGiShBljRHFi"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zM8b8w3vfKTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zWNRr0rCht8a"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGfnrupflT7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zmgNY1Eiqs2e"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024 and September 30, 2023, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_z9PrflCYqYf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zVkpoaKUryQa"&gt;Basic
and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024 loss per share excludes &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240331_zmV3jqXp2BU8" title="Loss per share for potentially dilutive common shares"&gt;15,755,114&lt;/span&gt;
(March 31, 2023: &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_zMzVmxJcFosj" title="Loss per share for potentially dilutive common shares"&gt;15,001,613&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3VLPMGUVod6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zOOQVnB9Xcnf"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2023, the Financial
Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable
Segment Disclosures.&#x201d; This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30,
2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000559">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zknPsUIJItp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zbqgpltKOaMa"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed consolidated
interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly,
certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed
or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information
presented not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These accompanying unaudited condensed consolidated
interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are
necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2023 was derived
from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto
included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2023 filed with the SEC on November 27, 2023.
The Company follows the same accounting policies in the preparation of interim reports.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Operating results for the six months ended March 31,
2024 are not necessarily indicative of the results that may be expected for the year ending September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <avxl:LliquidityPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000561">&lt;p id="xdx_845_ecustom--LliquidityPolicyTextBlock_zFI9bTi0SREa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zJ6zC46Uj13i"&gt;Liquidity&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the Company&#x2019;s potential drug compounds
are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or,
if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash
flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the current working capital
position will be sufficient to meet the Company&#x2019;s working capital requirements beyond the next 12 months after the date that these
condensed consolidated interim financial statements are issued. The process of drug development can be costly, and the timing and outcomes
of clinical trials are uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may
be subject to change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including
but not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based
on the timing of future clinical trials.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other than our rights related to the 2023 Purchase
Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if
available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on
a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</avxl:LliquidityPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-10-01to2024-03-31" id="Fact000567">&lt;p id="xdx_84B_eus-gaap--UseOfEstimates_zfYWLHu7rmYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zGiShBljRHFi"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates
estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability
of deferred tax assets, share based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts,
historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not
readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will
be affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000569">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zM8b8w3vfKTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zWNRr0rCht8a"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These consolidated financial statements include the
accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (&#x201c;Anavex Australia&#x201d;),
a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex
Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have
been eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000571">&lt;p id="xdx_848_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zGfnrupflT7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zmgNY1Eiqs2e"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value hierarchy under GAAP is based on three
levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which
are the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - 	quoted prices (unadjusted) in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - observable inputs other than Level 1, quoted
prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - 	assets and liabilities whose significant
value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024 and September 30, 2023, the Company
did not have any Level 3 assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000577">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_z9PrflCYqYf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zVkpoaKUryQa"&gt;Basic
and Diluted Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic income/(loss) per common share is computed by
dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period.
Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the
weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and
warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted
net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted
net loss per share because their effect would be anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2024 loss per share excludes &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20231001__20240331_zmV3jqXp2BU8" title="Loss per share for potentially dilutive common shares"&gt;15,755,114&lt;/span&gt;
(March 31, 2023: &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_zMzVmxJcFosj" title="Loss per share for potentially dilutive common shares"&gt;15,001,613&lt;/span&gt;) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000579"
      unitRef="Shares">15755114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000581"
      unitRef="Shares">15001613</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000583">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3VLPMGUVod6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zOOQVnB9Xcnf"&gt;Recently Adopted Accounting
Pronouncements&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In November 2023, the Financial
Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, &#x201c;Segment Reporting: Improvements to Reportable
Segment Disclosures.&#x201d; This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending September 30, 2025 and our interim periods within the fiscal year ending September 30,
2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;In December 2023, the FASB
issued ASU No. 2023-09, &#x201c;Income Taxes:&#160;Improvements to Income Tax Disclosures.&#x201d; This guidance requires consistent categories
and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment
is effective for our fiscal year ending September 30, 2026. The Company is currently assessing the impact of this guidance on its disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000585">&lt;p id="xdx_80F_ecustom--OtherIncomeDisclosureTextBlock_zvmiBt2Zlx2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 3 &lt;span id="xdx_821_z4Y8u21B1Jze"&gt;Other Income&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Grant Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of March 31, 2024, the
Company had received a $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn6n6_c20231001__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxMember_zsmz6Bl0U3oi" title="Research and development incentive income"&gt;1&lt;/span&gt;.0 million research grant awarded by the Michael J. Fox Foundation for Parkinson&#x2019;s Research. The grant
will be used to fund a clinical trial of the Company&#x2019;s lead compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 related to Parkinson&#x2019;s disease.
Of the total, $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230930__dei--LegalEntityAxis__custom--AnavexMember_zRZcbkW30ybd" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year ended September 30, 2023 and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20201001__20210930__dei--LegalEntityAxis__custom--AnavexMember_zKF1xeSKuROa" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million was received during the year ended September
30, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The grant income has been
deferred when received and is being amortized to other income as the related research and development expenditures are incurred. During
the three and six months ended March 31, 2024, the Company recognized $&lt;span id="xdx_90B_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20240101__20240331_zm0vCSbixRlb" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90C_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20230101__20230331_zilKPRJs5am2" title="Grant income"&gt;0&lt;/span&gt;, respectively (2023: $&lt;span id="xdx_903_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20231001__20240331_zj4ml7dPpc14" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20221001__20230331_zNxL1TSSSlTf" title="Grant income"&gt;25,000&lt;/span&gt;, respectively) of
this grant on its statements of operations as grant income. At March 31, 2024, an amount of $&lt;span id="xdx_90F_ecustom--DeferredGrantIncome_iI_pn5n6_c20240331_zS9bCKblcLnd" title="Grant income, amount"&gt;0.9&lt;/span&gt; million (September 30, 2023: $&lt;span id="xdx_900_ecustom--DeferredGrantIncome_iI_pn5n6_c20230930_zWmqrVziV2Fl" title="Grant income, amount"&gt;0.9&lt;/span&gt; million)
of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been recognized to other income.
The Company will recognize this income on its statement of operations as the relating expenditures are incurred to offset the income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Research and development
incentive income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Research and development
incentive income represents the income earned by Anavex Australia of the Australia R&amp;amp;D credit. This cash incentive is received by
Anavex Australia, upon filing of a claim in connection with Anavex Australia&#x2019;s annual income tax return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;During the three and six
months ended March 31, 2024 the Company recorded research and development incentive income of $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331_zsebmwizv1O9" title="Research and development incentive income"&gt;0.5&lt;/span&gt; million (AUD &lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20240101__20240331__srt--CurrencyAxis__currency--AUD_zJZVATdDd8K8" title="Research and development incentive income"&gt;0.7&lt;/span&gt; million) and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331_zjbVDKCe0PG7" title="Research and development incentive income"&gt;1.1&lt;/span&gt;
million (AUD &lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20231001__20240331__srt--CurrencyAxis__currency--AUD_zEk8YwYeUUT6" title="Research and development incentive income"&gt;1.6&lt;/span&gt; million), respectively (2023: $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20230101__20230331_zWbCpJDkCst7" title="Research and development incentive income"&gt;0.7&lt;/span&gt; million (AUD &lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20230101__20230331__srt--CurrencyAxis__currency--AUD_zDKAtpjC7tWg" title="Research and development incentive income"&gt;1.1&lt;/span&gt; million) and $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230331_zYeKdO54Nf54" title="Research and development incentive income"&gt;1.5&lt;/span&gt; million (AUD &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pn5n6_c20221001__20230331__srt--CurrencyAxis__currency--AUD_zfKLNjxF0Alk" title="Research and development incentive income"&gt;2.2&lt;/span&gt; million), respectively) in respect
of the Australia R&amp;amp;D credit for eligible research and development expenses incurred during the period. This amount is included within
Other income on the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;At March 31, 2024, Incentive
and tax receivables includes $&lt;span id="xdx_900_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20240331_z0d5HKF0mQLj" title="Incentive and tax receivables"&gt;3.6&lt;/span&gt; million (AUD &lt;span id="xdx_905_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20240331__srt--CurrencyAxis__currency--AUD_z0z1LyJnfe3c" title="Incentive and tax receivables"&gt;5.6&lt;/span&gt; million) (September 30, 2023: $&lt;span id="xdx_902_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20230930_zocYaQ40iKN9" title="Incentive and tax receivables"&gt;2.5&lt;/span&gt; million (AUD &lt;span id="xdx_903_ecustom--IncentiveAndTaxReceivables_iI_pn5n6_c20230930__srt--CurrencyAxis__currency--AUD_z7eQB3U7epX3" title="Incentive and tax receivables"&gt;3.9&lt;/span&gt; million)) relating to Australia
R&amp;amp;D credits earned during the year that are expected to be reimbursed upon filing of the Company&#x2019;s annual claim under this program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;The Australia R&amp;amp;D credit
program is a self-assess program whereby the Company must assess its eligibility each year to determine (i) if the entity is eligible
(ii) if the specific R&amp;amp;D activities are eligible and (iii) if the individual R&amp;amp;D expenditures have nexus to such R&amp;amp;D activities.
The Company evaluates its eligibility under the tax incentive program as of each balance sheet date based on the most current and relevant
data available. Anavex Australia is able to continue to claim the R&amp;amp;D tax incentive for as long as it remains eligible and continues
to incur eligible research and development expenditures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Although the Company believes
that it has complied with all the relevant conditions of eligibility under the program for all periods claimed, the Australian Tax Office
(ATO) has the right to review the Company&#x2019;s qualifying programs and related expenditures for a period of four years. If such a review
were to occur, the ATO may have different interpretations of certain eligibility requirements. If the ATO disagreed with the Company&#x2019;s
assessments and any related subsequent appeals, it could require adjustment to and repayment of current or previous years&#x2019; claims
already received. Additionally, if the Company was unable to demonstrate a reasonably arguable position taken on such claims, the ATO
could also assess penalties and interest on such adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;Currently, the Company&#x2019;s
tax incentive claims from 2020 to 2023 are open to potential review by the ATO. Additionally, the period open for review is indefinite
if the ATO suspects fraud. The Company has not provided any allowance for any such potential adjustments, should they occur in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-03-31_custom_MichaelJFoxMember"
      decimals="-6"
      id="Fact000587"
      unitRef="USD">1000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-09-30_custom_AnavexMember"
      decimals="-5"
      id="Fact000589"
      unitRef="USD">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012021-09-30_custom_AnavexMember"
      decimals="-5"
      id="Fact000591"
      unitRef="USD">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000595"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="Fact000597"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2022-10-012023-03-31"
      decimals="0"
      id="Fact000599"
      unitRef="USD">25000</avxl:NonOperatingIncomeFromGrant>
    <avxl:DeferredGrantIncome
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000601"
      unitRef="USD">900000</avxl:DeferredGrantIncome>
    <avxl:DeferredGrantIncome
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000603"
      unitRef="USD">900000</avxl:DeferredGrantIncome>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-01-012024-03-31"
      decimals="-5"
      id="Fact000609"
      unitRef="USD">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2024-01-012024-03-31_currency_AUD"
      decimals="-5"
      id="Fact000611"
      unitRef="USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-01to2024-03-31"
      decimals="-5"
      id="Fact000613"
      unitRef="USD">1100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-10-012024-03-31_currency_AUD"
      decimals="-5"
      id="Fact000615"
      unitRef="USD">1600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-01-012023-03-31"
      decimals="-5"
      id="Fact000617"
      unitRef="USD">700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2023-01-012023-03-31_currency_AUD"
      decimals="-5"
      id="Fact000619"
      unitRef="USD">1100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-03-31"
      decimals="-5"
      id="Fact000621"
      unitRef="USD">1500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2022-10-012023-03-31_currency_AUD"
      decimals="-5"
      id="Fact000623"
      unitRef="USD">2200000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:IncentiveAndTaxReceivables
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000625"
      unitRef="USD">3600000</avxl:IncentiveAndTaxReceivables>
    <avxl:IncentiveAndTaxReceivables
      contextRef="AsOf2024-03-31_currency_AUD"
      decimals="-5"
      id="Fact000627"
      unitRef="USD">5600000</avxl:IncentiveAndTaxReceivables>
    <avxl:IncentiveAndTaxReceivables
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000629"
      unitRef="USD">2500000</avxl:IncentiveAndTaxReceivables>
    <avxl:IncentiveAndTaxReceivables
      contextRef="AsOf2023-09-30_currency_AUD"
      decimals="-5"
      id="Fact000631"
      unitRef="USD">3900000</avxl:IncentiveAndTaxReceivables>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000633">&lt;p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z25cOZabHba5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 4 &lt;span id="xdx_82F_zNErAYmm0mE9"&gt;Accrued Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The principal components of accrued liabilities consist of (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zSGkyYREISz3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_znUspmfuqmK8" style="display: none"&gt;Schedule of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331_zH4vQ2fKHKya" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20230930_z5BB6nvxccth" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_zZZ4U4JI5Dq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,209&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_zwgKvz2P2Wn" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,360&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FixedContractAccruals_iI_d0_zDUEVfdSER3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--MilestoneBasedContractAccruals_iI_zvpBTkrgDnRl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_z6cK2UgVFNlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_zv6wgtlCC3b5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;4,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;7,295&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000635">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_pn3n3_zSGkyYREISz3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_znUspmfuqmK8" style="display: none"&gt;Schedule of accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331_zH4vQ2fKHKya" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20230930_z5BB6nvxccth" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--AccruedClinicalSiteAndPatientVisitsCosts_iI_zZZ4U4JI5Dq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued clinical site and patient visits costs&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,209&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,006&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AccruedBonusesCurrent_iI_zwgKvz2P2Wn" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued compensation and benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;630&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,360&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--FixedContractAccruals_iI_d0_zDUEVfdSER3l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--MilestoneBasedContractAccruals_iI_zvpBTkrgDnRl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Milestone based contract accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_z6cK2UgVFNlb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;All other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,531&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,624&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_zv6wgtlCC3b5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total accrued liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;4,915&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;7,295&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">1209000</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <avxl:AccruedClinicalSiteAndPatientVisitsCosts
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000638"
      unitRef="USD">2006000</avxl:AccruedClinicalSiteAndPatientVisitsCosts>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000640"
      unitRef="USD">630000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">1360000</us-gaap:AccruedBonusesCurrent>
    <avxl:FixedContractAccruals
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">0</avxl:FixedContractAccruals>
    <avxl:FixedContractAccruals
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">38000</avxl:FixedContractAccruals>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">1545000</avxl:MilestoneBasedContractAccruals>
    <avxl:MilestoneBasedContractAccruals
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">1267000</avxl:MilestoneBasedContractAccruals>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000649"
      unitRef="USD">1531000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">2624000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000652"
      unitRef="USD">4915000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">7295000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000655">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5CX69JGah6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 5 &lt;span id="xdx_82A_zniqpAzbEhib"&gt;Equity Offerings&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Common shares are voting and are entitled to dividends
as declared at the discretion of the Board of Directors (the &#x201c;Board&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s Board&#160;has the authority to
issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting
any series or the designation of the series.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sales Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into a Controlled Equity Offering
Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp;
Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company may offer and sell shares of common stock
(&#x201c;Shares&#x201d;) registered under an effective registration statement from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon delivery of a placement notice based on the Company&#x2019;s
instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the Shares by methods deemed to
be an &#x201c;at the market&#x201d; offering, in negotiated transactions at market prices prevailing at the time of sale or at prices related
to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written
consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents
may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. The Sales Agents will act
as agent on a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and
federal law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has agreed to pay the Sales Agents commissions
for their services of up to &lt;span id="xdx_902_ecustom--PercentageOfGrossProceedsFromSales_pip0_dp_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zj0WvIOGuUH" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed
to provide the Sales Agents with customary indemnification and contribution rights. During the six months ended March 31, 2024 and 2023,
&lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pip0_do_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zf8fqSiXeIgh" title="Number of common stock sold"&gt;&lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pip0_do_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember_zJjHSi1hAHQc" title="Number of common stock sold"&gt;no&lt;/span&gt;&lt;/span&gt; shares were sold pursuant to the Offering. At March 31, 2024, an amount of $&lt;span id="xdx_90D_ecustom--SalesOfAgreementAmount_iI_pn5n6_c20240331_z5CDZKyLNVb3" title="Sales of agreement amount"&gt;142.4&lt;/span&gt; million (September 30, 2023: $&lt;span id="xdx_90F_ecustom--SalesOfAgreementAmount_iI_pn5n6_c20230930_zzwlZekMwnB7" title="Sales of agreement amount"&gt;142.4&lt;/span&gt; million) was
registered pursuant to an effective registration statement. The Company currently is unable to sell shares of common stock under the Sales
Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2023 Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 3, 2023, the Company entered into a $150.0
million purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;),
pursuant to which the Company has the right to sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $150.0
&lt;span id="xdx_900_ecustom--ValueOfSharesObligatedToPurchase_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zm8Wb6FXHw0b" style="display: none" title="Obligated to purchase"&gt;150,000,000&lt;/span&gt; million in value of its shares of common stock from time to time over a three-year period until February 3, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for entering into the 2023 Purchase
Agreement, the Company issued to Lincoln Park &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsFctYHz57Oj" title="Share issued for offering, shares"&gt;75,000&lt;/span&gt; shares of common stock as a commitment fee (the &#x201c;initial commitment shares&#x201d;)
and agreed to issue up to an additional &lt;span id="xdx_90C_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_pip0_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zRJ3av2M90ae" title="Pro rata basic number of shares obligated to purchase"&gt;75,000&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased, at the Company&#x2019;s discretion,
the $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230202__20230203__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zgw04c5tAbig" title="Proceeds from Issuance or sale of equity"&gt;150&lt;/span&gt;.0 million aggregate commitment. The Company determined the fair value of the initial commitment shares was $&lt;span id="xdx_90F_ecustom--FairValueOfInitialCommitment_iI_pn5n6_c20230203_z9NL5K1Nnqbg" title="Fair value of the initial commitment"&gt;0.8&lt;/span&gt; million with
reference to the closing price of the Company&#x2019;s shares on the Purchase Agreement date. In addition, the Company incurred third party
expenses of $&lt;span id="xdx_901_ecustom--IncurredExpenses_iI_pn5n6_c20230203__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--ThirdPartyMember_zWlzfXwTrJGl" title="Incurred expenses"&gt;0.1&lt;/span&gt; million in connection with entering into the Purchase Agreement. These amounts were expensed to other financing expense
on the statements of operations during the year ended September 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the six months ended March 31, 2024, the
Company issued to Lincoln Park an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zur39g0wxaI7" title="Share issued for aggregate, shares"&gt;1,503,707&lt;/span&gt;
shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesOther_pip0_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zZ4kEPrn6j2h" title="Shares issued under Sales Agreement, net of shares issue costs, shares"&gt;1,500,000&lt;/span&gt;
shares of common stock for an aggregate purchase price of $&lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLpsrPXdc0n9" title="Number of shares issued for aggregate purchase price, value"&gt;7.4&lt;/span&gt;
million and &lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8qptIcZR6A1" title="Number of shares issued for commitment"&gt;3,707&lt;/span&gt;
commitment shares. During the six months ended March 31, 2023, the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_ztWKjRFDF5O" title="Share issued for aggregate, shares"&gt;2,159,080&lt;/span&gt;
shares of common stock under the 2023 Purchase Agreement, including &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zeubRkKj97Jb" title="Shares issued under Sales Agreement, net of shares issue costs, shares"&gt;2,075,000&lt;/span&gt;
shares of common stock for an aggregate purchase price of $&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsT072V4HN1e" title="Number of shares issued for aggregate purchase price, value"&gt;18.2&lt;/span&gt;
million, and &lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zox0kdhE8In5" title="Number of shares issued for commitment"&gt;9,080&lt;/span&gt;
commitment shares and the &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20221001__20230331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBGq1od83j7j" title="Number of shares issued for initial commitment shares"&gt;75,000&lt;/span&gt;
initial commitment shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024, an amount of $&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues1_pn5n6_c20231001__20240331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement2023Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zsfm5ireHVoc" title="Amount of shares remain available"&gt;114.7&lt;/span&gt; million remained
available under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      id="Fact000661"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember"
      decimals="INF"
      id="Fact000663"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember"
      decimals="INF"
      id="Fact000665"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avxl:SalesOfAgreementAmount
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000667"
      unitRef="USD">142400000</avxl:SalesOfAgreementAmount>
    <avxl:SalesOfAgreementAmount
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="Fact000669"
      unitRef="USD">142400000</avxl:SalesOfAgreementAmount>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      id="Fact000671"
      unitRef="USD">150000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000673"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">75000</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-02-022023-02-03_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-6"
      id="Fact000677"
      unitRef="USD">150000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <avxl:FairValueOfInitialCommitment
      contextRef="AsOf2023-02-03"
      decimals="-5"
      id="Fact000679"
      unitRef="USD">800000</avxl:FairValueOfInitialCommitment>
    <avxl:IncurredExpenses
      contextRef="AsOf2023-02-03_custom_ThirdPartyMember"
      decimals="-5"
      id="Fact000681"
      unitRef="USD">100000</avxl:IncurredExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012024-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      id="Fact000683"
      unitRef="Shares">1503707</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000685"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000687"
      unitRef="USD">7400000</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <avxl:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000689"
      unitRef="Shares">3707</avxl:StockIssuedDuringPeriodSharesNewIssues1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-03-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      id="Fact000691"
      unitRef="Shares">2159080</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">2075000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000695"
      unitRef="USD">18200000</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <avxl:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">9080</avxl:StockIssuedDuringPeriodSharesNewIssues1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-012023-03-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      id="Fact000699"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-10-012024-03-31_custom_PurchaseAgreement2023Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="-5"
      id="Fact000701"
      unitRef="USD">114700000</avxl:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000707">&lt;p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMQ2X78MFb9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Note 6 &lt;span id="xdx_826_zg5Tma7oaSq5"&gt;Commitments and Contingencies&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;Leases
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;The
Company leases office space under an operating lease with an initial term of 12 months or less. Under the terms of the office lease,
the Company is required to pay its proportionate share of operating costs. &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i style="font-style: normal; font-weight: normal"&gt;During
the three and six months ended March 31, 2024 and 2023, operating lease costs were as follows (in thousands):&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--LeaseCostTableTextBlock_pn3n3_zqOM4eN6D917" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zaj01Oaq5Qt7" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20240101__20240331_zE1SniLqyBm" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20230101__20230331_zhMPspwmi48j" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20231001__20240331_z0qJ2X64ggg8" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20221001__20230331_zA16A6W3XB05" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseCost_zhX6UbDxgG1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Employee 401(k) Benefit Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based employees.
United States based employees eligible to participate in the plan may contribute up to the current statutory limits under the Internal
Revenue Service regulations. The 401(k) plan permits the Company to make additional matching contributions on behalf of contributing employees.
&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="color: Black"&gt;During the three and six
months ended March 31, 2024 and 2023, the Company &lt;i style="font-style: normal; font-weight: normal"&gt;made matching contributions under the 401(k) plan as follows (in thousands):&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zrHn2iRJnYo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zgww5hPqb2C6" style="display: none"&gt;Schedule of contribution plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240101__20240331_z5TNiEfCDPY" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20230101__20230331_zxrisPNYSTZd" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20231001__20240331_zkhkfeeHy9s6" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20221001__20230331_zsyisF7uzy66" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PensionContributions_zBm7syOCfnae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt; color: gray"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font-style: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;The Company is subject
to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be
no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will
not have a material adverse effect upon the Company&#x2019;s consolidated financial statements. The Company does not believe that any of
such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
The complaint is captioned Blum v. Anavex Life Sciences, Corp. et al., case number 1:24-cv-01910, and names the Company and Christopher
Missling as Defendants. The complaint alleges violations of the Securities and Exchange Act of 1934 resulting from disclosures and statements
made about certain clinical trials for ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73. The Company believes the complaint is without merit. The Company is
vigorously pursuing its defenses and a potential dismissal of all claims asserted in the lawsuit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;Share Purchase Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2024 and September 30, 2023, the Company
had &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20240331_zmu0kXb8hTc" title="Warrants outstanding"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pip0_c20230930_zjNWFQrDzou7" title="Warrants outstanding"&gt;160,000&lt;/span&gt;&lt;/span&gt; warrants outstanding at a weighted average exercise price of $&lt;span id="xdx_909_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20240331_za276aAeuKc5" title="Warrants outstanding weighted average exercise"&gt;&lt;span id="xdx_901_ecustom--WarrantsOutstandingWeightedAverageExercise_iI_pip0_c20230930_zZA5R009xQBj" title="Warrants outstanding weighted average exercise"&gt;3.72&lt;/span&gt;&lt;/span&gt; as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvZm3K3TZexk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zx3ZHkyRjUcf" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zWSYRfqFOdKh" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number of shares outstanding"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zGSRuTAaP0ff" style="width: 20%; text-align: right" title="Exercise price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 40%"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgtDAwaSlgS7" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zElcoj0Dihmi" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zUe4YIaE1AX9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zwFJWe3l5PA8" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331_zEn37jqZ4UA3" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="color: Black"&gt;&lt;b&gt;&lt;i&gt;Stock&#x2013;based
Compensation Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2015 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 18, 2015, the Company&#x2019;s Board approved
a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of stock options and restricted stock awards
to directors, officers, employees and consultants of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHLRjapMAs3l" title="Common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2019 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 15, 2019, the Board approved the 2019 Omnibus
Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors,
officers, employees, consultants and advisors of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The maximum number of our common shares reserved for
issue under the plan was &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20231001__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zg0JjM2GgeE9" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; shares, subject to adjustment in the event of a change of the Company&#x2019;s capitalization.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended September 30, 2022, &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20211001__20220930__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zO46bnH4wQee" title="Option granted"&gt;406,453&lt;/span&gt;
options previously available under the 2019 Plan and the 2015 Plan became available under the 2022 Plan (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2022 Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 25, 2022, the Board approved the 2022 Omnibus
Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan was approved by stockholders on May 24, 2022. Under the terms of the 2022
Plan, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20231001__20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zMhNmYAtQYp9" title="Additional shares of common stock available for issuance"&gt;10,000,000&lt;/span&gt; additional shares of Common Stock will be available for issuance under the plan, in addition to the shares available
under the 2019 Plan and the 2015 Plan. Any awards outstanding under a previous stock option plan will remain subject to and be paid under
such plan, and any shares subject to outstanding awards under a previous plan that subsequently cease to be subject to such awards (other
than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2022 Plan provides that it may be administered
by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the Board at the
time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then
the exercise price shall not be less than 110% of fair market value of the Company&#x2019;s shares of common stock on the grant date. Stock
options may be granted under the 2022 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser
periods as may be determined by the Board, subject to earlier termination in accordance with the terms of the 2022 Plan. At March 31,
2024, &lt;span id="xdx_903_ecustom--OptionIssued_c20231001__20240331_zean1FrsW2qh" title="Option issued"&gt;5,452,500&lt;/span&gt; options had been issued under the 2022 Plan and &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20240331__us-gaap--PlanNameAxis__custom--StockOptionPlan2022Member_zhhdn5dWG0Gj" title="Option available issuance"&gt;5,132,202&lt;/span&gt; options were available for issue under the 2022 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock option
activity during the year ended September 30, 2023 and six months ended March 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;











&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zdqrhYa4Z913" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B6_zuodOXuWWejh" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zudUh9AjlTIj" style="width: 12%; text-align: right" title="Number of Options Outstanding at Beginning"&gt;13,169,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4Lr5W19egq4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning"&gt;6.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWhbMTK8qji8" style="width: 12%; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning"&gt;4.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1scUMGyvzAd" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning"&gt;62,267,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6vd6iqeiDVa" style="text-align: right" title="Number of Options, Granted"&gt;1,959,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW92rvDzJI7f" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;9.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6SLOJMNHF6k" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmCBVuk8B2i" style="text-align: right" title="Number of Options, Exercised"&gt;(759,753&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzHlDzpeTqBh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsMLjQtayyJc" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFTsyDzPzgb5" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"&gt;4,629,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxn4PGvtKn7b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(257,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT9j4Pj89de6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5NKIXLSYrZk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;6.74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA7gZ28dyHS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding at Beginning"&gt;14,111,780&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVo7tvcbg5Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning"&gt;7.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zab2kuyfpI58" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning"&gt;5.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWsYgff63quk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning"&gt;22,290,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxIjNofDpIf7" style="text-align: right" title="Number of Options, Granted"&gt;1,750,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKNPTQUPuSf9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;5.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zy3Dj2ufvAwg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;3.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK7fnGAHBdV6" style="text-align: right" title="Number of Options, Exercised"&gt;(46,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0fFTEoAfV8l" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK59nm7ZftMj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;2.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmRxtyTRQ3N4" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"&gt;125,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXgP0dfwMfs5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(221,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7UDJrqOjmue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;13.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU1Bq6dHfVDf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;9.06&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0sCPx3LQrf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding at Ending"&gt;15,595,114&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8dL4cyfH4ci" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at Ending"&gt;6.85&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz5Hif7OJH9f" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding at Ending"&gt;12,480,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXas9bb6sXCh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable"&gt;9,955,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6HigpdS0Ute" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_pp0p0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zentbb8GD9Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;12,440,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AD_zQVPwiZPcXG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following summarizes information about stock options
at March 31, 2024 by a range of exercise prices:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z89dJq6hkTUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B2_zagP1ilq69O4" style="display: none"&gt;Schedule of summarized information about stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;contractual life (in&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znDHNvPCxSt1" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTehO74UuMje" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1i890sMCEV5" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,243,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTEg961l1fI2" title="Weighted average remaining contractual life (in years)"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zwbcJTV4Qr9" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zi4r5sCwSmP7" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,243,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNAssKYlvRs7" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIRzOQARwmd7" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zkfE6UeN4yYb" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zbOpFnkyPHPh" style="text-align: right" title="Number of outstanding options"&gt;2,167,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKGJe864X377" title="Weighted average remaining contractual life (in years)"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhO09CvJojAf" style="text-align: right" title="Weighted average exercise price"&gt;3.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z3MocNbcufs4" style="text-align: right" title="Number of vested options"&gt;2,017,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhtu2jEuHUBg" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zcYeQbB8m9Rj" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zZghSEregeG7" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zQ0jdn6lHQTc" style="text-align: right" title="Number of outstanding options"&gt;6,790,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaGTU4v6tpod" title="Weighted average remaining contractual life (in years)"&gt;6.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUwJseYVxZN1" style="text-align: right" title="Weighted average exercise price"&gt;6.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zT78gGUGMv8g" style="text-align: right" title="Number of vested options"&gt;3,436,472&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zLJGcSSyfLt4" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zklt3QYYxEPg" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zXiY0TCzby0c" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zxrVhlD46LD5" style="text-align: right" title="Number of outstanding options"&gt;1,894,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFfVC65BXJIk" title="Weighted average remaining contractual life (in years)"&gt;7.85&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zK3oIuxtPuGf" style="text-align: right" title="Weighted average exercise price"&gt;10.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1fGjgeRm0Bl" style="text-align: right" title="Number of vested options"&gt;705,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZ4IKKHZoNY9" style="text-align: right" title="Weighted average exercise price options vested"&gt;11.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRekty1ejdIl" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zQkzNKWyTdU6" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zI0eUAto7LPb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zdD4YUAXKXTb" title="Weighted average remaining contractual life (in years)"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_ziZbjP9be7rb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zIqHQBA0cp4e" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;552,917&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zw9eNEK5jUZ4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.28&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSbBoqJORJR" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;15,595,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvOy2O8iPLS2" title="Weighted average remaining contractual life (in years)"&gt;5.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjVuMsabsk1d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price"&gt;6.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUpuUf0ADDih" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;9,955,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlK1IRYcEKV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested"&gt;5.38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zFoZmvHm8sK5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average grant date fair value of options
vested at March 31, 2024 was $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zb4MFttPh8Cg" title="Weighted average grant date fair value of options vested"&gt;4.07&lt;/span&gt; (September 30, 2023: $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zgMPztwOY1La" title="Weighted average grant date fair value of options vested"&gt;3.94&lt;/span&gt;). At March 31, 2024, the weighted average contractual life of options outstanding
was &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zwopy4gLxEXl" title="Weighted average contractual life of options outstanding"&gt;6.0&lt;/span&gt; years (September 30, 2023: &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zdcJ6sVyEGpb" title="Weighted average contractual life of options outstanding"&gt;6.0&lt;/span&gt; years) and for options exercisable was &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20231001__20240331__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zdre5HMajH2f" title="Weighted average contractual life of options exercisable"&gt;4.5&lt;/span&gt; years (September 30, 2023: &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20221001__20230930__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_z8xpHfOElB82" title="Weighted average contractual life of options exercisable"&gt;4.75&lt;/span&gt; years).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value is calculated as the
difference between the exercise price of the underlying awards and the quoted market price of the Company&#x2019;s stock for the options
that were in-the-money at March 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three and six months ended March 31, 2024,
the Company recognized stock-based compensation expense of $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20240331_ztXnwKYdSy4d" title="Share based compensation expense"&gt;2.7&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20231001__20240331_z1GK3PdAaolb" title="Share based compensation expense"&gt;4.9&lt;/span&gt; million, respectively (2023: $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20230331_zpo6SSSDR9hl" title="Share based compensation expense"&gt;4.0&lt;/span&gt; million and $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20221001__20230331_zmei0KGW2tpc" title="Share based compensation expense"&gt;9.3&lt;/span&gt; million,
respectively) in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have
been included in general and 	administrative expenses and research and development expenses on the Company&#x2019;s condensed consolidated
interim statement of 	operations as follows (in thousands):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zjfULGHAAg1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B8_zEyalFhs0NGe" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbQM9WQCcnqc" style="width: 10%; text-align: right" title="Total share based compensation"&gt;979&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsmkmRN7mck8" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoaLPorJWvth" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZmYjr638CYb" style="width: 10%; text-align: right" title="Total share based compensation"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zApFxNZu1MFa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVMKRxNA2Vr7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,713&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGtnsPcJVGoc" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,033&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTb2U5FQMJ8h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;6,317&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zWxedXQ3tb5h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,652&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zz4oAfX0nB5d" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,970&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zTWoC4nlDv1k" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;4,938&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331_zt5KH4EvvwP6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,317&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A0_zzrtn8q8zyp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;An amount of approximately $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20240331_zLbcl4JeuA75" title="Remaining stock based compensation"&gt;14.5&lt;/span&gt; million in stock-based
compensation is expected to be recorded over the remaining term 	of such options through fiscal 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;The fair value of each option award
granted during the three and six months ended March 31, 2024 and 2023 is estimated on the date of grant using the Black Scholes option
pricing model based on the following weighted average assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zFfKx8VBGcsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_znw7mXYVD7Hb" style="display: none"&gt;Schedule of weighted average
assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_zIdZZtnEjvgi" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230331_zJz8uKzViwV5" title="Risk-free interest rate"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfBVqffNbQsi" title="Expected life of options (years)"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zHhXrgY0mwO7" title="Expected life of options (years)"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z9hrgRugBlr3" title="Annualized volatility"&gt;84.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230331_z6RKz6vN7yse" title="Annualized volatility"&gt;85.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zuMquOHDfWc7" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230331_zBEZtTrN3E21" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A9_zNyYOjBEuvH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock compensation charges recognized
during the three and six months ended March 31, 2024 and 2023 was determined with reference to the quoted market price of the Company&#x2019;s
shares on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000709">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--LeaseCostTableTextBlock_pn3n3_zqOM4eN6D917" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zaj01Oaq5Qt7" style="display: none"&gt;Schedule of operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20240101__20240331_zE1SniLqyBm" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20230101__20230331_zhMPspwmi48j" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20231001__20240331_z0qJ2X64ggg8" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20221001__20230331_zA16A6W3XB05" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseCost_zhX6UbDxgG1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000711"
      unitRef="USD">31000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">30000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000713"
      unitRef="USD">61000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000714"
      unitRef="USD">60000</us-gaap:OperatingLeaseCost>
    <us-gaap:DefinedContributionPlanDisclosuresTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000716">&lt;table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--DefinedContributionPlanDisclosuresTableTextBlock_pn3n3_zrHn2iRJnYo6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zgww5hPqb2C6" style="display: none"&gt;Schedule of contribution plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20240101__20240331_z5TNiEfCDPY" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20230101__20230331_zxrisPNYSTZd" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20231001__20240331_zkhkfeeHy9s6" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20221001__20230331_zsyisF7uzy66" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PensionContributions_zBm7syOCfnae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Contributions to 401(k) plan&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DefinedContributionPlanDisclosuresTableTextBlock>
    <us-gaap:PensionContributions
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">94000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000719"
      unitRef="USD">56000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000720"
      unitRef="USD">167000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">100000</us-gaap:PensionContributions>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000723"
      unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">160000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000727"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:WarrantsOutstandingWeightedAverageExercise
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="Fact000729"
      unitRef="USDPShares">3.72</avxl:WarrantsOutstandingWeightedAverageExercise>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000735">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zvZm3K3TZexk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zx3ZHkyRjUcf" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zWSYRfqFOdKh" style="padding: 0pt 0pt 0pt 10pt; width: 20%; text-align: right; text-indent: -10pt" title="Number of shares outstanding"&gt;150,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zGSRuTAaP0ff" style="width: 20%; text-align: right" title="Exercise price"&gt;3.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 40%"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgtDAwaSlgS7" title="Expiry Date"&gt;May 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zElcoj0Dihmi" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zUe4YIaE1AX9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise price"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20240331__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zwFJWe3l5PA8" title="Expiry Date"&gt;April 21, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pip0_c20240331_zEn37jqZ4UA3" style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: right; text-indent: -10pt" title="Number of shares outstanding"&gt;160,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-03-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      id="Fact000739"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-03-31_custom_PurchaseWarrantsMember"
      id="Fact000741">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-03-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      id="Fact000745"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-03-31_custom_PurchaseWarrants1Member"
      id="Fact000747">2026-04-21</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000749"
      unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      id="Fact000751"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2023-10-012024-03-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      id="Fact000753"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-10-012022-09-30_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000755"
      unitRef="Shares">406453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2023-10-012024-03-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000757"
      unitRef="Shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <avxl:OptionIssued
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">5452500</avxl:OptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31_custom_StockOptionPlan2022Member"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">5132202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000767">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zdqrhYa4Z913" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B6_zuodOXuWWejh" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;($)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 30%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zudUh9AjlTIj" style="width: 12%; text-align: right" title="Number of Options Outstanding at Beginning"&gt;13,169,616&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z4Lr5W19egq4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning"&gt;6.61&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWhbMTK8qji8" style="width: 12%; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning"&gt;4.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1scUMGyvzAd" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning"&gt;62,267,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6vd6iqeiDVa" style="text-align: right" title="Number of Options, Granted"&gt;1,959,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zW92rvDzJI7f" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;9.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6SLOJMNHF6k" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;6.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zOmCBVuk8B2i" style="text-align: right" title="Number of Options, Exercised"&gt;(759,753&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zzHlDzpeTqBh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zsMLjQtayyJc" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zFTsyDzPzgb5" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"&gt;4,629,026&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxn4PGvtKn7b" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(257,083&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT9j4Pj89de6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;12.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20221001__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5NKIXLSYrZk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;6.74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zA7gZ28dyHS8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding at Beginning"&gt;14,111,780&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVo7tvcbg5Nj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at Beginning"&gt;7.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zab2kuyfpI58" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value at Beginning"&gt;5.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWsYgff63quk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding at Beginning"&gt;22,290,069&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxIjNofDpIf7" style="text-align: right" title="Number of Options, Granted"&gt;1,750,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKNPTQUPuSf9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;5.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zy3Dj2ufvAwg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;3.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK7fnGAHBdV6" style="text-align: right" title="Number of Options, Exercised"&gt;(46,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0fFTEoAfV8l" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;3.43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zK59nm7ZftMj" style="text-align: right" title="Weighted Average Grant Date Fair Value, Exercised"&gt;2.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmRxtyTRQ3N4" style="text-align: right" title="Aggregate Intrinsic Value, Exercised"&gt;125,170&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXgP0dfwMfs5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited"&gt;(221,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z7UDJrqOjmue" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;13.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zU1Bq6dHfVDf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;9.06&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zm0sCPx3LQrf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding at Ending"&gt;15,595,114&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z8dL4cyfH4ci" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at Ending"&gt;6.85&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz5Hif7OJH9f" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value Outstanding at Ending"&gt;12,480,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXas9bb6sXCh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Exercisable"&gt;9,955,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6HigpdS0Ute" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;5.38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_pp0p0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zentbb8GD9Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable"&gt;12,440,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">13169616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000771"
      unitRef="USDPShares">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000773"
      unitRef="USDPShares">4.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000775"
      unitRef="USD">62267309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000777"
      unitRef="Shares">1959000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000779"
      unitRef="USDPShares">9.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000781"
      unitRef="USDPShares">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">759753</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000785"
      unitRef="USDPShares">2.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000787"
      unitRef="USDPShares">0.95</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">4629026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">257083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2022-10-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000795"
      unitRef="USDPShares">6.74</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Shares">14111780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000799"
      unitRef="USDPShares">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000801"
      unitRef="USDPShares">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-09-30_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000803"
      unitRef="USD">22290069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">1750500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000807"
      unitRef="USDPShares">5.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000809"
      unitRef="USDPShares">3.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Shares">46000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000813"
      unitRef="USDPShares">3.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000815"
      unitRef="USDPShares">2.60</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000817"
      unitRef="USD">125170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Shares">221166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000821"
      unitRef="USDPShares">13.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000823"
      unitRef="USDPShares">9.06</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">15595114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000827"
      unitRef="USDPShares">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000829"
      unitRef="USD">12480916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000831"
      unitRef="Shares">9955616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000833"
      unitRef="USDPShares">5.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact000835"
      unitRef="USD">12440416</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000837">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z89dJq6hkTUa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span id="xdx_8B2_zagP1ilq69O4" style="display: none"&gt;Schedule of summarized information about stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="7" style="text-align: center"&gt;Range of exercises prices&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted average&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;contractual life (in&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted average&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number of&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 11pt; text-align: center"&gt;&lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;From&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;To&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;exercise price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_znDHNvPCxSt1" style="width: 11%; text-align: right" title="Range of exercise prices, lower range limit"&gt;0.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTehO74UuMje" style="width: 11%; text-align: right" title="Range of exercise prices, upper range limit"&gt;3.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_z1i890sMCEV5" style="width: 11%; text-align: right" title="Number of outstanding options"&gt;3,243,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zTEg961l1fI2" title="Weighted average remaining contractual life (in years)"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zwbcJTV4Qr9" style="width: 10%; text-align: right" title="Weighted average exercise price"&gt;2.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zi4r5sCwSmP7" style="width: 10%; text-align: right" title="Number of vested options"&gt;3,243,060&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zNAssKYlvRs7" style="width: 10%; text-align: right" title="Weighted average exercise price options vested"&gt;2.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zIRzOQARwmd7" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zkfE6UeN4yYb" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zbOpFnkyPHPh" style="text-align: right" title="Number of outstanding options"&gt;2,167,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zKGJe864X377" title="Weighted average remaining contractual life (in years)"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhO09CvJojAf" style="text-align: right" title="Weighted average exercise price"&gt;3.39&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z3MocNbcufs4" style="text-align: right" title="Number of vested options"&gt;2,017,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_zhtu2jEuHUBg" style="text-align: right" title="Weighted average exercise price options vested"&gt;3.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zcYeQbB8m9Rj" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;5.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zZghSEregeG7" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;9.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zQ0jdn6lHQTc" style="text-align: right" title="Number of outstanding options"&gt;6,790,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zaGTU4v6tpod" title="Weighted average remaining contractual life (in years)"&gt;6.62&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zUwJseYVxZN1" style="text-align: right" title="Weighted average exercise price"&gt;6.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zT78gGUGMv8g" style="text-align: right" title="Number of vested options"&gt;3,436,472&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zLJGcSSyfLt4" style="text-align: right" title="Weighted average exercise price options vested"&gt;6.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zklt3QYYxEPg" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;9.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zXiY0TCzby0c" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;13.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zxrVhlD46LD5" style="text-align: right" title="Number of outstanding options"&gt;1,894,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zFfVC65BXJIk" title="Weighted average remaining contractual life (in years)"&gt;7.85&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zK3oIuxtPuGf" style="text-align: right" title="Weighted average exercise price"&gt;10.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_z1fGjgeRm0Bl" style="text-align: right" title="Number of vested options"&gt;705,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zZ4IKKHZoNY9" style="text-align: right" title="Weighted average exercise price options vested"&gt;11.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zRekty1ejdIl" style="text-align: right" title="Range of exercise prices, lower range limit"&gt;13.01&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zQkzNKWyTdU6" style="text-align: right" title="Range of exercise prices, upper range limit"&gt;25.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zI0eUAto7LPb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of outstanding options"&gt;1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zdD4YUAXKXTb" title="Weighted average remaining contractual life (in years)"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_ziZbjP9be7rb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price"&gt;18.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zIqHQBA0cp4e" style="border-bottom: Black 1pt solid; text-align: right" title="Number of vested options"&gt;552,917&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zw9eNEK5jUZ4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price options vested"&gt;18.28&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSbBoqJORJR" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of outstanding options"&gt;15,595,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zvOy2O8iPLS2" title="Weighted average remaining contractual life (in years)"&gt;5.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjVuMsabsk1d" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price"&gt;6.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pip0_c20231001__20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUpuUf0ADDih" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of vested options"&gt;9,955,616&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pip0_c20240331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlK1IRYcEKV8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options vested"&gt;5.38&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000839"
      unitRef="USDPShares">0.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000841"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000843"
      unitRef="Shares">3243060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      id="Fact000845">P4Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000847"
      unitRef="USDPShares">2.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000849"
      unitRef="Shares">3243060</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice1Member"
      decimals="INF"
      id="Fact000851"
      unitRef="USDPShares">2.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000853"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000857"
      unitRef="Shares">2167500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      id="Fact000859">P4Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000861"
      unitRef="USDPShares">3.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000863"
      unitRef="Shares">2017500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice2Member"
      decimals="INF"
      id="Fact000865"
      unitRef="USDPShares">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000867"
      unitRef="USDPShares">5.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000869"
      unitRef="USDPShares">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">6790554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      id="Fact000873">P6Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000875"
      unitRef="USDPShares">6.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000877"
      unitRef="Shares">3436472</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice3Member"
      decimals="INF"
      id="Fact000879"
      unitRef="USDPShares">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000881"
      unitRef="USDPShares">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000883"
      unitRef="USDPShares">13.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000885"
      unitRef="Shares">1894000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      id="Fact000887">P7Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000889"
      unitRef="USDPShares">10.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000891"
      unitRef="Shares">705667</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice4Member"
      decimals="INF"
      id="Fact000893"
      unitRef="USDPShares">11.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000895"
      unitRef="USDPShares">13.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000897"
      unitRef="USDPShares">25.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000899"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      id="Fact000901">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000903"
      unitRef="USDPShares">18.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000905"
      unitRef="Shares">552917</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember_custom_OptionPrice5Member"
      decimals="INF"
      id="Fact000907"
      unitRef="USDPShares">18.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000909"
      unitRef="Shares">15595114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      id="Fact000911">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000913"
      unitRef="USDPShares">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-10-012024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000915"
      unitRef="Shares">9955616</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000917"
      unitRef="USDPShares">5.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-012024-03-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000919"
      unitRef="USDPShares">4.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-012023-09-30_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000921"
      unitRef="USDPShares">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-012024-03-31_us-gaap_OptionMember"
      id="Fact000923">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-10-012023-09-30_us-gaap_OptionMember"
      id="Fact000925">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-10-012024-03-31_us-gaap_OptionMember"
      id="Fact000927">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-10-012023-09-30_us-gaap_OptionMember"
      id="Fact000929">P4Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-03-31"
      decimals="-5"
      id="Fact000931"
      unitRef="USD">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-5"
      id="Fact000933"
      unitRef="USD">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-03-31"
      decimals="-5"
      id="Fact000935"
      unitRef="USD">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-012023-03-31"
      decimals="-5"
      id="Fact000937"
      unitRef="USD">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000939">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_pn3n3_zjfULGHAAg1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B8_zEyalFhs0NGe" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Six months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zbQM9WQCcnqc" style="width: 10%; text-align: right" title="Total share based compensation"&gt;979&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zsmkmRN7mck8" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoaLPorJWvth" style="width: 10%; text-align: right" title="Total share based compensation"&gt;1,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZmYjr638CYb" style="width: 10%; text-align: right" title="Total share based compensation"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zApFxNZu1MFa" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;1,673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zVMKRxNA2Vr7" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,713&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGtnsPcJVGoc" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,033&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTb2U5FQMJ8h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;6,317&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20240331_zWxedXQ3tb5h" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,652&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensation_pn3n3_c20230101__20230331_zz4oAfX0nB5d" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,970&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pn3n3_c20231001__20240331_zTWoC4nlDv1k" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;4,938&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20221001__20230331_zt5KH4EvvwP6" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;9,317&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000941"
      unitRef="USD">979000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000943"
      unitRef="USD">1257000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000945"
      unitRef="USD">1905000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-03-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000947"
      unitRef="USD">3000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">1673000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000951"
      unitRef="USD">2713000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-012024-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000953"
      unitRef="USD">3033000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-03-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000955"
      unitRef="USD">6317000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000957"
      unitRef="USD">2652000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000959"
      unitRef="USD">3970000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-03-31"
      decimals="-3"
      id="Fact000961"
      unitRef="USD">4938000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-012023-03-31"
      decimals="-3"
      id="Fact000963"
      unitRef="USD">9317000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000969"
      unitRef="USD">14500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-10-01to2024-03-31" id="Fact000971">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zFfKx8VBGcsd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 6)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_znw7mXYVD7Hb" style="display: none"&gt;Schedule of weighted average
assumptions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20231001__20240331_zIdZZtnEjvgi" title="Risk-free interest rate"&gt;4.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20221001__20230331_zJz8uKzViwV5" title="Risk-free interest rate"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20240331_zfBVqffNbQsi" title="Expected life of options (years)"&gt;5.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221001__20230331_zHhXrgY0mwO7" title="Expected life of options (years)"&gt;5.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20231001__20240331_z9hrgRugBlr3" title="Annualized volatility"&gt;84.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20221001__20230331_z6RKz6vN7yse" title="Annualized volatility"&gt;85.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20231001__20240331_zuMquOHDfWc7" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20221001__20230331_zBEZtTrN3E21" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000973"
      unitRef="Pure">0.0428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000975"
      unitRef="Pure">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-10-01to2024-03-31" id="Fact000977">P5Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-10-012023-03-31" id="Fact000979">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000981"
      unitRef="Pure">0.8484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000983"
      unitRef="Pure">0.8528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="Fact000985"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-012023-03-31"
      decimals="INF"
      id="Fact000987"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-01-012024-03-31" id="Fact000988">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-01-012024-03-31" id="Fact000989">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-01-012024-03-31" id="Fact000990">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-01-012024-03-31" id="Fact000991">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
